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APPLICATION OF Pd CATALYZED ALKYLATION: SYNTHESIS OF 
BICYCLIC FURANS, ISOXAZOLINES AND CYCLOPENTANE AMINO ACID 
ANALOGS 
 
Pasha M Khan 
 
ABSTRACT 
Palladium is probably the most useful metal in organic syntheses. It has shown great 
utility in various reactions such as C-C, C-N, C-O bond formation under mild conditions. 
The presence of abundant amount of palladium-chemistry related literature in the form of 
books, reviews emphasizes the growing importance of these reagents. Nowadays 
organopalladium chemistry is being used in various fields such as new methodology 
development, natural product synthesis, synthesis of polymers. Regio- and 
stereoselectivity is another facet of Pd catalyzed methodologies which has been 
extensively utilized in the last decade to obtain enantiopure compounds. The main 
emphasis of this work is to utilize Pd catalyzed allylic alkylation to synthesize new 
heterocycles including furans, isoxazolines and new cyclopentane amino-acid analogs in 
an enantioselective manner. The stereochemical outcome of these reactions is influenced 
by desymmetrization catalyzed by hydrolytic enzymes namely lipases.  
           Chapter 1 reviews the recent advances in the field of palladium catalyzed synthesis 
of bicyclic furan analogs and provides a mechanistic explanation for these processes.  
xix 
 
 Chapter 2 describes synthesis of new optically pure isoxazoline-2-oxide and furan 
analogs using Pd(0) catalyzed intramolecular cyclizations. Starting from a meso-diol, 
optically pure compounds were prepared without utilizing chiral ligands at any stage of 
the synthesis. The stereochemical outcome of the product (>99 % ee) was influenced by 
desymmetrization catalyzed by Pseudomonas cepacia lipase and the stereoselective 
nature of the palladium catalyzed transformations. 
Chapter 3 describes Pd(0) catalyzed allylic alkylation of allylic esters using  
various 10, 20 nitroalkanes. This reaction resulted in the formation of nitro substituted 
aldehydes and ketones via an isomerization-alkylation step. The effect of various 
solvents, catalyst-ligand systems and bases was also studied. The presence of versatile 
nitro group in these compounds which can be easily converted to a ketone, reduced to 
amine or transformed into carboxyl group, imines, hydroxylamines, makes them an 
attractive starting material for various other synthetic compounds. 
Chapter 4 describes the chemoenzymatic synthesis of L-carbafuranomycin and 
related cyclopentane amino acids analogs. The synthesis utilizes the hydrolytic enzymes 
to induce enantioselectivity in the whole process. Out of all the peptidomimetics and 
related compounds, unnatural amino acids such as bicyclic and carbocyclic amino acids 
are of valuable  interest as they have provided new building blocks for large number of 
potential drug candidates. The work presented here provides a more general and  efficient 
route to these class of unnatural amino acids. 
Chapter  1 
INTRODUCTION AND BACKGROUND 
 
1.1 General Introduction 
Palladium is probably the most useful metal in organic syntheses. It has shown great 
utility in various reactions such as C-C, C-N, C-O bond formation under mild 
conditions.1 The presence of abundant amount of palladium chemistry related literature in 
the form of books2 and reviews3 emphasizes the growing importance of these reagents. 
Nowadays organopalladium chemistry is being used across the spectrum of organic 
syntheses, from synthesis of complex natural products to synthesis of polymers. Apart 
from carbon-carbon bond formation, palladium can also catalyze carbon-heteroatom bond 
formation resulting in various O, N, and S heterocycles under very mild conditions (Fig 
1-1).1e,f,g  
 
Fig 1-1 Use of palladium in heterocyclic chemistry 
    1 
 
    2 
 
Regio- and stereoselectivity is another facet of Pd catalyzed methodologies which has 
been extensively utilized in the last decade to obtain enantiopure heterocycles. The last 
two decades have witnessed a huge growth in the use of  Pd catalyst in synthetic organic 
chemistry including natural product syntheses2s and methodology developments. A large 
number of Pd catalyzed cross coupling reactions like Negishi coupling,  Suzuki coupling,  
Stille coupling, Kumada coupling, Sonogashira coupling, Heck reaction and Tsuji-Trost 
coupling  have been extensively utilized in heterocyclic chemistry.1f  
 Recently, we have reported chemoenzymatic synthesis of furan and isoxazoline 
derivatives via Pd catalyzed allylic alkylation and cyclizations starting from a meso-diol.3 
This methodology provided a new route to bicyclic furan compounds using Pd(0) 
catalysis and the stereochemical outcome of the products was decided by enzymatic 
desymmetrization of meso starting materials. Furan derivatives are widely distributed in 
large number of natural products,4 pharmaceuticals,5 agrochemicals6 and perfumes6. 
Fused bicyclic tetrahydrofuran compounds also provide important structural units to 
many bioactive natural products, lignans, macrodiolides, nucleosides and avermectins.44 
A large number of anthelmintics belonging  to the avermectin or milbemycin families 
also contain fused bicylic tetrahydrofuran ring systems (fig 1-2).48 The remarkable 
activity and safety of the avermectins and milbemycins have made them key drugs in 
animal and human health and crop protection. The avermectins are structurally similar to 
the anti-bacterial macrolides. 
 
  
Fig 1-2 Anti-helmintic compounds containing bicyclic furan ring system 
 
Seeds of the Indian neem tree Azadirachta indica, used as insecticide preparations 
for ornamentals and food crops, are rich in  bicyclic furanoids (fig 1-3).49 The advantages 
offered by  neem-bicylic furanoids is specificity and slow activity as an insect antifeedant 
and growth regulator.50 
 
 
Fig 1-3 Structure of azadirachtin related limonoids found in neem extract  
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The bicylic furanoids are also found as an active component in large number of perfumes 
and odorants,51 e.g., Ambrox® bearing an ambery smell is an active ingredient of Drakkar 
Noir fragrance (fig 1-4).  
 
 
Fig 1-4 Tetrahydrofuran containing various odorants  
 
The vast abundance of these novel ring systems has resulted in new methods for 
their synthesis. Pd catalyzed methodologies have been leader in this field due to easy 
handling, functional group tolerance and high stereo and regioselectivities.2p,7 In this 
chapter we have focused on the advances made in the last fifteen years in Pd catalyzed 
synthesis of bicyclic furanoids and a mechanistic explanation of these new processes 
wherever applicable. The main purpose of this chapter is to summarize the new methods 
discovered for synthesis of bicycle furan ring systems and analogs. Also, the chapter 
introduces the reader to the mechanistic explanation and experimental evaluation of these 
Pd catalyzed processes. Since Pd catalysis can be applied to a variety of substrates in 
order to obtain bicyclic heterocycles, hence this chapter is broadly divided on the basis of 
the substrates involved in synthesis of  bicyclic O-heterocycles. 
 1.2 Cyclization of γ-hydroxy cyclic alkenes 
Pd catalyzed cyclization of γ-hydroxy alkenes was first reported by Semmelhack et al 8f 
where γ-hydroxy alkenes were treated with catalytic amount of PdCl2 and 3 equiv CuCl2 
under CO atmosphere in methanol to yield tetrahydrofurans (Scheme 1-1, eq 1). Similar 
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transformations were applied towards synthesis of several natural products as 
tetronomycin and goniothalesidol8g,h containing a tetrahydrofuran or tetrahydropyran 
core. Even though this methodology provided an easy access to bicyclic furan ring 
systems but still suffered from some major drawbacks. The diastereoselectivity of this Pd 
(II) catalyzed synthesis of O- heterocycles was low, specially for the substrates with no 
substitution at the allylic position. Also this methodology is limited to installation of ester 
functionality at C-1’(scheme 1-1) position. Recently Wolfe et al 8a-e tried to overcome the 
abovementioned shortcomings by carrying the cyclizations of various γ-hydroxy cyclic 
(eq 3, scheme 1-1) and acyclic (eq 2, scheme 1-1) alkenes with various aryl and alkenyl 
bromides in the presence of palladium catalyst generated in situ. Various γ-hydroxy 
acyclic and cyclic alkenes can be converted to furan 10 and bicyclic furan 11 analogs in 
good yields with moderate to high diastereoselectivity using Pd0/phosphane complex.  
 
Scheme 1-1 Pd(II) catalyzed intramolecular cyclization of cyclic alkenols 
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The authors demonstrated that Pd catalyzed reaction of aryl or vinyl bromides and γ-
hydroxy alkenes can be used to synthesize various tetrahydrofuran analogs through 
formation of a C-C and C-O bond along with establishment of two new stereocenters.8 
Table 1-1 shows the application of this strategy on cyclic γ-hydroxy alkenes to yield 
bicyclic furan analogs in high yields and diastereoselectivity. As discussed in the latter 
section, an extensive mechanistic studies conducted by Wolfe et al indicated an 
involvement of syn addition of the aryl group and the oxygen atom across the olefin both 
in cyclic and acyclic internal alkene substrates.  
Table 1-1 Cyclization of γ-hydroxy cyclic alkenesa 
 
Entry Alcohol R-Br Product dr Yieldc 
1a  
 
 
 O
    6 
 
HH
OMe  
>20:1 69% 
(ref 8c) 
2a 
 
 
>20:1 53% 
(ref 8c) 
3a,e 
 
 
 
>20:1 78% 
(ref 8c) 
4b 
 
 
 
>20:1 53% 
(ref 8b) 
5b 
 
 
 
- 0%d
(ref 8b) 
 
6b 
 
 
 
 
  
10:1 60% 
(ref 8b) 
 
7b HO
 
 
>20:1 70% 
(ref 8b) 
 
8a 
 
 
 
>20:1 66% 
(ref 8b) 
a Conditions: 1.0 equiv of alcohol, 2.0 equiv of ArBr, 2.0 equiv of NaOtBu, 2.5mol%of 
Pd2(dba)3, 10 mol% of P(o-tol)3, toluene(0.125M), 110oC.  b Conditions: 1.0 equiv of 
alcohol, 2.0 equiv of ArBr, 2.0 equiv of NaOtBu, 1mol%of Pd2(dba)3, 2 mol% of dpe-
phos, THF(0.13-0.25M), 65oC. c Yields represent average isolated yields for two or more 
experiments. d oxidation of the alcohol substrate to 2-allylcyclopentanone was observed. e 
Xantphos (5 mol%) was used. 
The proposed catalytic cycle for cyclization of γ-hydroxy cyclic alkenes or 
“carboetherification” is shown in scheme 1.2 and begins with oxidative addition of aryl 
bromide to the Pd/phosphine complex followed by reaction with the alcohol 13 in the 
    7 
 
    8 
 
presence of a base to give complex 14.8d The complex 14 undergoes a syn-oxypalladation 
process which is rare in both catalytic and stoichiometric reactions of palladium 
alkoxides to yield new complex 15 which after a reductive elimination results in the 
desired product 16 and regeneration of Pd(0) catalyst.8b,d In case of α-susbstituted 
cyclopentanol substrates (table 1.1  entry 4,5) the outcome of the reaction depended on 
stereochemistry of the starting material. Pd catalyzed reaction of cis alcohol (Table 1.1, 
entry 4) gave the desired product in 53% yield and >20:1 de but the reaction of analogous 
trans substrate (Table 1.1, entry 5) did not yield the desired bicyclic product but resulted 
in 2-allylcyclopentanone. The rate of the reaction also depends on the ring size as Pd 
catalyzed cylization of cyclohexene substrates (table 1.1, entry 6,7) was faster than 
corresponding cyclopentene analogs. For example the coupling of 4-bromo anisole with 
cyclopentene alcohol substrate  (table 1.1, entry 1) required two days to reach completion 
whereas the six member analog was consumed within two hours (table 1.1, entry 8). 
Wolfe et al 8b also observed that the cyclic substrates (table 1.1) resulted in products with 
higher diastereoselectivity (> 20:1) as compared to their acyclic analogs (3-5:1) (scheme 
1.3b). This observation was explained by conducting deuterium labeling experiments on 
the γ-hydroxy alkene substrates and comparing the intermediates involved in cyclic and 
acyclic substrates as shown in scheme 1.3.  
LnPd0
LnPd
Ar
Br
R2
HO
R1
O
Pd
Ar
Ln
H
R2
R1H
O
Pd
Ar
Ln
H
R2
R1H
O
R1
H
H
R2
Ar
Ar-Br
12
1314
15
16
NaOtBu
 
Scheme 1-2: Catalytic cycle for Pd(II) catalyzed intramolecular cyclization of γ-hydroxy 
alkenes  
In general, it was also pointed out that the high diastereoselectivity in case of 
cyclic γ-hydroxy alkenes arises from the lack of σ-bond rotation and inability of 
reversible β-H elimination in these substrates as explained below. Pd aryl alkoxide  
complex 17 obtained from the cyclic alkenol (table 1.1, entry1-3) can result in complex 
18 by intramolecular insertion of the cycloalkene in Pd-O bond of complex 17.8 Complex 
18 can directly break down (fast) to yield the desired product 19 or can undergo β-
hydride elimination (slow), utilizing one β-H atom syn to the palladium atom to yield 
complex 20. As  shown in scheme 1-3 the Pd(Ar)(H) complex in 20 cannot be transferred 
to opposite face of alkene yielding 22 due to inability to form any σ-alkylpalladium 
complex and no C-C bond rotation in internal alkene. However, in principle, if complex 
20 is formed it will readily collapse to give alkene 21 and Pd(Ar)(H) complex which will 
undergo a unimolecular C-H bond forming reductive elimination faster than regenerating 
the Pd complex 22 via a bimolecular alkene coordination and insertion into Pd-H bond. 
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Hence in the case of cyclic substrates, the Pd catalyzed cyclization gave products with 
higher diatereoselectivity as the side reactions are minimized.  Also, the same mechanism 
when applied to the acyclic substrate 23 can be used to explain the moderate 
diatereoselectivity. Treatment of the acyclic substrate (scheme 1-3c) with Pd(0) catalyst, 
aryl bromide and NaOtBu can result in the palladium aryl alkoxide complex 24, similar to 
the cyclic substrate (complex 17).9  Syn insertion of the alkene into Pd-O bond will result 
in intermediate 25 10 which can undergo reductive elimination to give the major 
diastereomer 26. Intermediate 25 can also undergo C-C bond rotation about C1’-C2 σ-
bond followed by syn β-hydride elimination to yield complex 27 which can be converted 
into complex 28 via reinsertion of alkene into the Pd-H bond with opposite 
regiochemistry.10,11 Palladium complex 28 has much more flexibility in terms of C-C 
bond rotation and can undergo rotation to 28’. Complexes 28 and 28’ can result in 
compounds 30 and 29 respectively via aseries of re-insertion and reductive elimination. 
Hence in aliphatic substrates the diasteromeric ratio is reduced due to more flexibility of 
the substrates in terms of C-C bond rotation. 
 1-3a: Mechanistic explanation for higher diastereoselectivity for cyclic substrates 
+ Ar-Br Ar
OHO
cat. Pd2(dba)3
cat.P(o-tol)3
NaOtBu,Toluene
110o C
R1
R2
R1
R2
OOO
Ph
H H H
From E-alkene
73% 5:1 dr
From Z-alkene
71% 5:1 dr
From E-alkene
55% 5:1 dr
Ph t-Bu
 
1-3b: Pd(0) catalyzed cyclization of γ-hydroxy acyclic alkenes 
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1-3c: Mechanistic explanation for lower diastereoselectivity for acyclic substrates 
Scheme 1-3: (a) Mechanistic explanation for higher diastereoselectivity for cyclic 
substrates (b) Pd(0) catalyzed cyclization of γ-hydroxy acyclic alkenes (c) Mechanistic 
explanation for lower diastereoselectivity for acyclic substrates 
1.3 Carbonylation-cyclization of alkynes 
Pd catalyzed carbonylation of alkynes has been extensively used for synthesis of 
benzofurans and other compounds as acetylene carboxylates, and γ-lactones.13a-c  For 
example Yamamoto et al13d utilized Pd(OAc)2 catalyzed reaction of carbon tethered 
acetylenic aldehydes with various aliphatic alcohols (MeOH, EtOH) to obtain five and 
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six membered  ketals (scheme 1-4, eq 1). Also recently Gabriele et al13e reported Pd 
catalyzed cyclization of 4-yn-1-ols to yield a furan ring system containing an acrylate 
group along with a mixture of acetal in the presence of PdI2/KI at high temperature and 
pressure (scheme 1-4, eq 2).  
Scheme 1-4: Pd catalyzed carbonylation-cyclization of alkynes. 
Kato et al 12 further optimized this Pd catalyzed carbonylation-cyclization of alkynes 
utilizing a Pd(0)/benzoquinone catalytic system to synthesize various furan ring systems 
(Scheme 1-4, eq 3). The formation of acetals as by-product of the reaction (scheme 1-4, 
eq 1,2 ) was circumvented by trapping the acid produced during the catalytic cycle 
(scheme 1-9) using p-benzoquinone. Benzoquinone also acts as an oxidizing agent to 
convert Pd(0) to Pd(II) in the catalytic cycle (scheme 1-9). This method is also applicable 
to acyclic substrates which gave rise to a furan nucleus (scheme 1-5). Five different 
catalysts were studied by the authors in this oxidative cyclization and palladium(II) 
chloride and bis(acetonitrile)-dichloropalladium (II) gave superior results. Also 
preliminary studies showed that the presence of a free hydroxyl group in the substrate is 
indispensable for initiating the reaction. The substrates which had no free hydroxyl group 
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(R3≠H) did not react and the starting material was recovered in quantitative yield (scheme 
1-5). Pd catalyzed carbonylation-cyclization approach was also applied to acyclic 
substrates to obtain saturated furan compounds containing an acrylate side chain (scheme 
1-5). 
 
Scheme 1-5 Pd catalyzed carbonylation-cyclization of alkynes in cyclic substrates. 
Kato et al also further extended Pd catalyzed carbonylation-cyclization approach to 
cyclic-2-methyl-2-propargyl-1,3-diols to obtain bicyclic furan ring systems in an 
asymmetric fashion by using various chiral bisoxazoline ligands(fig  1-5).12  
 
Scheme 1-6 Pd catalyzed carbonylation-cyclization of cyclic-2-methyl-2-propargyl-1,3-
diols. Conditions used: Pd(CH3CN)2Cl2 (5 mol%)/p-benzoquinone (1.1 eq), CO balloon 
MeOH. 
Seven different substrates including a six and a five membered cyclic-2-methyl-2-
propargyl-1,3-diols were examined for asymmetric carbonylation-cyclization (scheme 1-
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6). All the substrates (scheme 1-6) were treated with bis(acetonitrile)-dichloro-
palladium(II)/benzoquinone in methanol at 00C under CO atmosphere. In the case of 
meso-cyclopentane derivative 35e the authors reported no reaction and the starting 
material was recovered. In case of other meso diols 35b, c, f the formation of desired 
product is reported at low temperatures (-45OC). In case of diols 35d, g which have a 1,3 
trans relationship only the hydroxy group cis to the propargyl  group reacted to yield the 
desired product. This also explains the non-reactivity of 35e due to absence of a hydroxy 
group cis to the propargyl group. The ee of the reaction depends on temperature, catalyst, 
solvent, ligands used and even on the structure of substrate. Kato et al used 35a as the 
model system to study the effect of ligands. The ee of the reaction decreased from 65% 
(98% yield) to 57% (90% yield) when the temperature was increased from -30OC to 0OC 
(ligand A, fig 1-5). The absence of a chiral ligand did produce the desired product as a 
racemic mixture in 85% yield. Although Pd(CF3CO2)2 was used as the catalyst for the 
most of the reactions but other catalysts as Pd(CH3CN)4(BF4)2 was also employed giving 
a lower ee (ligand A, fig 1-5). Seven chiral ligands (figure 1-5) were utilized for this Pd 
catalyzed carbonylation-cyclization. Ligand E14 gave a moderate ee (56%) and other 
ligands B,16 C,15 F 15 G15 did yield the product but in low ee’s. The reactions conducted in 
presence of ligands D16and H16 proceeded in extremely poor yields and no ee’s. The 
authors also observed good yields and moderate enantioselectivity by addition of solvents 
like CH2Cl2, iPrOH.  Changing the solvent system to THF:MeOH=10:1 resulted in 
slower rates and low yields and ee’s. 
 Fig 1-5 Chiral bisoxazoline ligands used in Pd catalyzed carbonylation-cyclization of 
cyclic-2-methyl-2-propargyl-1,3-diols.  
The structure of the substrate also affected the yields and enantioselectivity 
(Scheme 1-7). It is also reported that when meso-diols 35a,b,f were subjected to 
asymmetric Pd catalyzed carbonylation-cyclization, the enantioselectivities obtained were 
highly substrate dependent. Substrate 35a yielded product 36a in relatively high ee (65%) 
as compared to the racemic product obtained in the 35 b, f. This trend suggested that the 
presence of equatorial substituents (shown in blue in scheme 1-7) is an important factor 
which influences the ee’s of the products. 
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 Scheme 1-7  \Effect of equatorial substituents on ee of the products obtained by Pd 
catalyzed carbonylation-cyclization of cyclic-2-methyl-2-propargyl-1,3-diols 
The Pd(II) mediated cyclization-carbonylation strategy was also extended to 4-yn-1-ones 
by Kato et al 12b as shown in scheme 1.8. Different open-chain and cyclic substrates (fig 
1.6) were subjected to a (CH3CN)2PdCl2/p-benzoquinone system in methanol at room 
temperature under a carbon monoxide atmosphere. Cyclic substrates resulted in the 
formation of the corresponding   bicyclic furan analogs 38 along with methoxy acrylates 
39. 
 
Scheme 1-8 Pd(II) mediated cyclization-carbonylation of 4-yn-1-ones 
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Fig 1-6 Various acyclic and cyclic 4-yn-1-ones subjected to Pd(II) mediated cyclization-
carbonylation 
  The authors also proposed a mechanism explaining the formation of the products 
38, 39. Pd(II) initially coordinates to the alkyne which is induced by attack of the 
carbonyl oxygen to alkyne from the side opposite to palladium to form intermediate A. A 
nucleophilic attack of MeOH on the carbon atom of the cationic carbonyl group from the 
side opposite the methyl ester group results in intermediate B. Intermediate B undergoes 
CO insertion (intermediate C) and subsequent reaction with MeOH, can yield the acetal 
products and generates Pd(0) (path I). Also Pd(0) gets reoxidized to Pd(II) using p-
benzoquinone. On the other hand, the formation of methoxyacrylate can be explained by 
the attack of MeOH (path II) on the olefinic carbon of the vinyl palladium intermediate A 
followed by CO insertion and subsequent reaction with MeOH. 
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 Scheme 1-9 Mechanism for Pd(II) mediated cyclization-carbonylation  
1.4  Alkylation of allylic meso-diesters and dicarbonates using soft nucleophiles 
Pd catalyzed allylic alkylation has been extensively used in natural product synthesis and 
bicyclic furan ring compounds are no exception.2s Bicyclic furan skeleton can also be 
constructed by Pd catalyzed allylic alkylation. Recently, our group has reported a 
chemoenzymatic synthesis of bicyclic furan ring systems.3 The synthesis involved lipase 
catalyzed desymmetrization as the key step for enantioinduction without the use of chiral 
ligands. Also, Tanimori et al 17,18 have studied Pd catalyzed allylic alkylation to obtain 
various cyclopentafuran analogs (scheme 1.10) by carrying out sequential C-C and C-O 
bond formation utilizing 1mol% [Pd(η3-C3H5)Cl]2 and dppf 
(diphenylphosphinoferrocene) on diacetates and dicarbonates. The dicarbonates reacted 
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in base-free conditions due to generation of base (alkoxide) during the catalytic cycle 
whereas DBU was employed as a base  in case of diacetates. 
 
Scheme 1-10 Pd catalyzed synthesis of cyclopenta(b)furan analogs. 
The authors also observed  that a variety of β-keto esters including aromatics and 
heteroaromatics, terminal alkenes, bulky and free hydroxyl substituted were all suitable 
substrates for this methodology. Table 1.2 shows various 2-substituted 4,6a-Dihydro-
3aH-cyclopenta[b]furan-3-carboxylates obtained by Tanimori et al. The non-reactivity of 
41f is explained on the basis of steric hindrance due to bulky tert-butyl group. This 
method gives an easy access to 2-substituted bicyclic furan analogs. The process also 
shows tolerance to functionalities as alkenes, alkynes, hetroaromatics and even free 
hydroxyl group. 
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Table 1-2 Synthesis of 2-substituted 4,6a-Dihydro-3aH-cyclopenta[b]furan-3-
carboxylates 
 
Entry R1 R2 Product %Yield
41a  Me 
 
52 
41b Me 
 
58 
41c CH3(CH2)9 Me 
 
59 
41d PhCH(OH)CH2- Me 
O
COOMeH
H
Ph
HO  
71a 
41e S
 
Et 
 
43 
41f t-Bu Me 
 
(expected) 
0 
a Obtained as an inseparable 1:1 mixture of diastereomers 
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1-5  Heck reaction of 2,3-unsaturated glycosides 
Intramolecular Heck reaction on carbohydrate templates has been utilized to obtain 
bicylic furan analogs.19-21 Carbohydrates are easily available and provide an easy route to 
optically active compounds with a variety of functional groups and stereochemical 
features. Sinou et al synthesized synthesized enantiopure bicyclic O-heterocycles using 
Pd catalyzed cyclization of appropriate glycals and pseudoglycals. 
Sinou et al utilized palladium catalyzed Heck reaction on erythro or threo aryl 2,3-
unsaturated glycosides to obtain the corresponding bicyclic derivatives via β-
alcoxyelimination by (scheme 1.11).19 Treatment of erythro carbohydrate derivatives 43 
with Pd(OAc)2, PPh3, Et3N in the presence of tetrabutyl-ammonium sulfate gave the 
bicylic derivatives 44in moderate to good yields. Utilizing the same reaction conditions 
the threo derivatives 45 gave the corresponding tetrahydrofuran derivatives 46 (Scheme 
1.11). The yield of the reaction depended on the nature of the leaving group. A better 
leaving group as OEt resulted in a higher yield as compared to the substrates bearing an 
aryl ether substituent. 
O
TBDMSO
O OR
Br
cat Pd(OAc)2,/PPh3, 
 Bu4NHSO4, Et3N
   
MeCN/H2O
23-72%
O
O
TBDMSO
43 44
O
OTBDMS
O
R
Br
cat Pd(OAc)2,/PPh3, 
Bu4NHSO4, Et3N
   
MeCN/H2O
30-51%
O
O
OTBDMS
45 46
(a) R= H, (b) R= C2H5,(c) R= p-t-BuC6H4, (d )R= p-NO2C6H4
OH
O
TBDMSO
44'
OR
OH
O
OTBDMS
46'
OR
 (a) R= C2H5, (b) R= p-t-BuC6H4, (c )R= p-NO2C6H4
 
Scheme 1-11: Heck-type cyclization of 2,3-unsaturated glycosides 
Table 1.3 shows  the bicyclic tetrahydrofuran compound 44a-c obtained via a Heck 
cyclization of unsaturated carbohydrates 43, 45. The products were obtained in 23-72%  
yield depending on the nature of the anomeric subsituent (entries 1,3,5, table 1.3). The 
authors also mentioned that for substrates 43b, c the reaction was conducted at lower 
temperatures since the substrates underwent degradation at 80oC. Also changing the 
solvent from CH3CN-H2O to DMF resulted in formation of bicyclic product 44 along 
with tetrahydrofuran compound 44’ in 50% and 20% yield respectively (entry 2, table 
1.3). Compound 44 can be explained by cleavage of the C-O bond of the ring. However 
under same conditions substrate 43b resulted only in the bicyclic product 44 and can be 
explained on the basis of the fact that O-C6H4-pBut (43b) is a better leaving group than 
OEt (43a).  
 
 
    23 
 
    24 
 
Table 1.3  Pd(0) catalyzed cyclization of unsaturated carbohydrates 43 and 45 (ref 19)a 
Entry Starting 
material 
T 0C/Time 
(h) 
Solvent Products(yield) 
1 43a 80/10 CH3CN-H2O(5:1) 44 (72%) 
2 43a 80/24 DMF 44 (50%) + 44’(20%) 
3 43b 50/30 CH3CN-H2O(5:1) 44 (32%) 
4 43b 80/24 DMF 44 (70%) 
5 43c 40/27 CH3CN-H2O(5:1) 44 (23%) 
6 45a 50/17 ,, 46 (51%) 
7 45b 80/10 ,, 46’ (57%) 
8 45c 50/53 ,, 46 (32%) 
9 45d 40/29 ,, 46 (30%) 
aRatio of reactants 43or 45:Et3N:Bu4NHSO4:Pd(OAc)2:PPh3=10:25:10:1:2 
bIsolated yields after column chromatography on silica gel. 
Treatment of dihydropyran 45a with catalytic amount of Pd(OAc)2 in the presence of 
Bu4NHSO4 and Et3N resulted in the bicyclic tetrahydrofuran product 46a in 51% yield 
(entry 6, table 1.3) via a classical Heck-type cyclization. Also the unsaturated threo 
derivative 45b  resulted in the tetrahydrofuran structure 46’ (57% yield) due to cleavage 
of the cyclic C-O bond.20-21 On the other hand the substrates 45c,d resulted in the bicyclic 
product 46c,d due to fragmentation of the aglycon moiety in 32 and 30% yield (entries 
8,9, table 1.3). Sinou et al have also utilized Pd catalyzed cylization of carbohydrate 
templates to obtain other enantiopure bi and tricyclic compounds. 
O
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Scheme 1-12: Mechanism for Pd catalyzed Heck-type cyclization of 2,3-unsaturated glycosides 
Sinou et al also proposed the mechanism of these Pd catalyzed cyclizations of 
carbohydrate templates to involve a σ-vinyl palladium intermediate A (scheme 1.12) 
formed via an oxidative addition.20,21 Complex A undergoes association-insertion process 
utilizing the unsaturation in the pyranose ring system to yield complex B. It was also 
proposed that the oxygen atom of the aglycon is coordinated to the metal center based on 
the reports of Jeffrey22 and Cacchi23 et al. Intermediate B undergoes deoxypalladation to 
give ionic complex C which loses Pd(0)  and ROBr to yield the final product 46. The 
authors also mentioned that only few examples of dehydroxypalladation are known in 
literature, including σ-bonded palladium(II) intermediates of tetrahydrofurans and only 
few cases of β-alkoxyelimination  processes.24,25 Use of chelating diphosphines resulted 
in poor yields again by preventing the complexation of the aglycon oxygen atom to 
palladium.  
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1.6 Pd(0) catalyzed  intramolecular addition of vinyl bromides to vinyl sulfones 
O
SO2Ph
cat Pd(PPh3)4, Et3N
CH3CN/THF, refluxR
Br
O
SO2Ph
R
n
n
0-73%
47
48a n=2; R=H   (73%)
48b n=2; R=Me (No Reaction)
48c n=1; R=H   (58%)   
Scheme 1-13: Pd(0) catalyzed cyclization of vinylic bromides 
Pd catalyzed cyclization of vinyl bromides 47(R=H) has also been utilized to obtain cis–
fused bicyclic ethers (Scheme 1.13).26 The  reaction was dependent on the nature of 
substituents on the double bond. The presence of any substituents such as methyl resulted 
in no cyclization and starting material was recovered in 75% yield. Also in order to 
promote the cyclization of vinyl bromide 48b, 5 equivalents of AgNO3 was added to the 
reaction mixture, however no desired product was obtained.27 
1-7 Pd catalyzed  intramolecular 1,4 addition to conjugated dienes 
Palladium(II) catalyzed cyclization of 1,3-dienes has proven to be an important tool in 
organic synthesis.28-32 The first report of Pd(II) promoted cyclization of 1,3-dienes was 
reported by Izumi and Kasahara in 1975.28 Later on Backvall and Andersson et al utilized 
this methodology to conduct 1,4-dialkoxylation of 1,3-dienes in an alcoholic solvent with 
catalytic amount of acid.29  In general there are three different types of intramolecular 
1,4-dialkoxylation depending on the position of alcohol side chain (Scheme 1.14). 
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Scheme 1-14: Different types of intramolecular 1,4-dialkoxylation 
Recently Andersson et al30 utilized the type I intramolecular cyclzation of 1,3-dienes in 
the presence of CO and an amine to synthesize amide containing ethers (Scheme 1.15). 
The reaction proceeds via an intramolecular nucleophilic addition on the diene to give an 
intermediate π-allyl palladium complex which is subsequently carbonylated to give either 
a overall 1,2- or 1,4-addition over the diene. The ratio of the 1,4 addition product 50a and 
1,2 addition product 50b can be altered by varying the CO pressure and choice of the 
solvent. 
OH Pd(OAc)2, Et2NH
CO (1 atm), THF
O
H2N
O
O
O NH2
49 50a 50b  
Scheme 1-15 Pd(II) catalyzed synthesis of amide-containing ethers via cyclization-
carbonylation of 1,3-dienes  
Bäckvall et al31 have utilized type II and III Pd(II) catalyzed 1,4 dialkoxylation of 1,3 
dienes to synthesize various spiro and bicyclic oxygen heterocycles in a stereocontrolled 
manner (scheme 1.16). The diene alcohol 51 was cyclized to yield a cis product in the 
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presence of 5 mol% Pd(OAc)2, 10 mol% MeSO3H, and 2 equivalents of p-benzoquinone 
in MeOH at room temperature.29h  By changing the solvent to EtOH and BnOH the 
corresponding  ethyl and benzyl ethers were obtained, repectively. Authors also reported 
the synthesis of  trans acetoxy product 53 by carrying the reaction in the presence of 
LiOAc in AcOH. Palladium catalyzed cyclization of six membered diene alcohol 54 
(n=1) with benzoquinone as oxidant was problematic due to competing aromatization and 
Diels-Alder addition of diene. This problem was overcome by slow addition of the diene 
to the reaction mixture to obtain the spiro-furan compounds 52,53.  
cat Pd(OAc)2,cat MeSO3H, 
Benzoquinone, ROH
51a
OH
O
RO
R= Me(>97% cis)
R= Et  (>97% cis)
R= Bn (>97% cis)
52
51a,b
OH cat Pd(OAc)2,Li2CO3, 
Benzoquinone, AcOH
Acetone
O
AcO
9 examples with 40-86% yields
n n
n= 1, 2 n= 1, 2
53
 
Scheme 1-16 Pd(II) catalyzed oxaspirocyclization of 1,3 dienes  
Bäckvall et al have also conducted an extensive study on palladium catalyzed oxidation 
of diene alcohols to yield tetrahydrofurans and tetrahydropyrans via an intramolecular 
1,4-addition to the conjugated diene.29e The reactions are usually carried in acetone-acetic 
acid (4:1) mixture or an alcoholic solvent utilizing palladium acetate as the catalyst and 
benzoquinone as the oxidant. Depending on the attacking species a 1,4-oxyacetylation 
(acetate) or 1,4-oxychlorination (chloride)  or 1,4-oxyalkoxylation (alcohol) can be 
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obtained. In general these reactions involve electrophilic addition of the alcohol and the 
palladium(II) catalyst to the diene to produce a π-allyl intermediate which subsequently 
undergoes stereoselective substitution(scheme 1.18, 1.20). The stereochemistry of the 
products in the case of 1,4-oxyacetylation depends on the presence or absence of LiCl 
(Scheme 1.17).29e,i  
cat Pd(OAc)2, LiCl, AcOH
p-Benzoquinone
HO
cat Pd(OAc)2, AcOH
p-Benzoquinone
OAcO
OAcO
n
n=0,1,3,5
n
n
> 98% cis
> 98% trans
55
56
54
 
Scheme 1-17 Effect of addition of LiCl on Pd (II) catalyzed intramolecular 1,4 
dialkoxylation  
The effect of LiCl (chloride ion) on these Pd(II) catalyzed reactions can be explained on 
the basis of the fact that in the presence of LiCl, after an initial trans acetoxypalladation 
of one of the double bonds an external trans attack by acetate on the intermediate 
palladium complex results in a final cis product. Whereas, in the absence of LiCl the 
acetate attached to palladium metal inserts in cis fashion resulting in an overall trans 
product (Scheme 1.18).  
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Cl -
Cl - free
Pd
Cl
O
O
Pd
AcO
O
O
trans attack 
by acetate
cis insertion
OAc
OAc
OAc
OAc
AcO
AcO
57
59-cis
59-trans
58a
58b
 
Scheme 1-18 Mechanistic explanation for the effect of Cl- ion on Pd catalyzed 1,4-
Diacetoxylation of 1,3-Dienes 
 
1.7.1  1,4-oxyacetoxylation of conjugated dienes 
The dienol 60, 61 when subjected to the palladium catalyzed oxyacetoxylation in the 
presence of acetic acid. The authors conducted the reaction under three different 
conditions: A (no LiCl), B (0.2 eq LiCl), C (2eq LiCl). As explained in scheme 1.23 the 
absence of LiCl (method A, table 1.4) resulted in trans oxyacetoxylation, 0.2 eq of LiCl 
(method B, table 1.4) gave an overall cis oxyacetoxylation product. The use of 2 
equivalents of LiCl (method C) resulted in incorporation of chloride and an overall cis-
1,4 oxychlorination (table 1.5). 
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Table 1-4  Pd(0) catalyzed stereocontrolled cis 1,4-oxyacetoxylation of dienols (ref 29e)a 
Entry Dienol Method Product %yieldb Stereochemc 
 
 
1 
 
 
 
OH
60  
 
 
A 
O
AcO
H
H
66-trans
 
87 
 
>98%trans 
 
 
2 
 
 
B O
AcO
H
H
66-cis
 
82 
 
cis:trans=91:9 
 
 
3 
 
 
 
HO
61  
 
A 
O
AcO
H
H
67-trans
 
87 
 
>98%trans 
 
 
4 
 
B 
O
AcO
H
H
67-cis
 
78 
 
cis:trans=91:9 
 
 
5 
 
 
 
OH
62  
 
A 
O
AcO
H
H
68-trans
 
85 
 
>98%trans 
 
 
6 
 
B 
O
AcO
H
H
68-cis
 
86 
 
cis:trans=91:9 
 
 
7 OH
63  
 
A 
O
AcO
H
Me
69
 
65 
 
>98%trans 
 
 
8 
 
 
 
 
A 
O
H
H
AcO
70-trans
 
90 
 
>98%trans 
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9 
OH
64  
 
B 
O
H
H
AcO
70-cis
 
81 
 
>98%cis 
 
 
10 
 
 
HO
65  
 
A 
O
AcO H
H
71-trans
 
86 
 
cis:trans=25:75 
 
 
11 
 
B 
O
AcO H
H
71-cis
 
84 
 
>98%cis 
a All reactions were performed in acetone-acetic acid (4:1) using 5 mol% Pd(OAc)2 and 2 eq 
benzoquinone, Method A: Absence of LiCl, Method B: 0.2 equiv LiCl. b Isolated yields. c 
Refers to the addition across the diene sytem. 
 
1.7.2  1,4-oxychlorination of conjugated dienes 
 Bäckvall et al29e also conducted 1,4 oxychlorination of conjugated dienes and reported 
that  the use of 2 equivalents of LiCl resulted in an overall 1,4-oxychlorination (table 1-
5). Also in few cases of oxychlorination and oxyacetoxylation the effect of substituents 
on the side chain of the dienol was also studied and it was concluded that the presence of 
substituents on the side chain do not effect the rate of the reaction. For example, 
α,α−dimethyl alcohol 75 (entries 5,6, table 1-4 and entry 3 table 1-5)  gave the 
corresponding products in good yields. However, substitution at the 4-position of the 
diene decreases the rate of  the reaction (entry 7, table 1.4 and entry 4 table 1-5) but the 
stereoselectivity for these two reactions was still >98%. 
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Table 1-5  Pd(0) catalyzed stereocontrolled cis 1,4-oxychlorination of dienolsa 
Entry Dienol Reaction 
timeb 
Product %yieldc Stereochemd 
 
1 OH
60  
 
12+0 
O
Cl
H
H
72
 
91 
 
>98%cis 
 
2 
HO
61  
 
12+12 
O
Cl
H
H
73
 
89 
 
>98%cis 
 
3 
OH
62  
 
12+24 
O
Cl
H
H
74
 
90 
 
>98%cis 
 
4 OH
63  
 
12+24 
O
Cl
H
Me
75
 
72 
 
>98%cis 
 
5 OH
64  
 
12+0 
O
H
H
Cl
76
 
88 
 
>98%cis 
 
6 
HO
65  
 
12+12 
O
Cl H
H
77
 
81 
 
>98%cis 
a All reactions were performed as in table 1.4 but in presence of 2 eq of LiCl b In all the 
substrates the addition time of the diene was 12h. The second figure refers to the reaction time 
after completed addition. c Isolated yields. d Refers to the addition across the diene sytem. 
It was also pointed out that this Pd catalyzed oxychlorination and oxyacetoxylation works 
well for six and seven membered dienes with two and three carbon chains. Hence this 
method can be applied to synthesize fused [6,5], [6,6], [7,5],[7,6] tetrahydrofuran and 
tetrahydropyran systems But when this methodology was extended to synthesize an 
annulated oxetane system from alcohol 78 or a seven membered oxygen containing ring 
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system , no cyclized product was obtained (scheme 1.19). In case of the alcohols 78, 79 a 
complex mixture of isomers was obtained when they were subjected to Pd catalyzed 1,4 
oxychlorination. 
78
OH
HO
79
no cyclized product
no cyclized product
 
Scheme 1-19 Non-reactivity of dienols 78, 79 towards Pd catalyzed 1,4- oxychlorination 
1.7.3  1,4-oxyalkoxylation of conjugated dienes 
Bäckvall et al also converted diene alcohols 60-65 to the oxygen heterocycles via a Pd(II) 
catalyzed diacetoxylation (table 1.6).29eThe reaction was carried out in the presence of 5 
mol% Pd(OAc)2, 10 mol% MeSO3H and 2 equivalent p-benzoquinone in various 
alcoholic solvents. The addition of catalytic amount of methanesulfonic acid  increases 
the reactivity of the intermediate (π−allyl) palladium complex. In all the cases the 
reaction was highly stereoselective. Three different alcohols MeOH, EtOH, BnOH were 
investigated during this study and the products were obtained in 55-87% yield. 
Table 1-6 Pd catalyzed intramolecular 1,4-Dialkoxylation of 1,3 cylohexadienesa 
Entry Dienol Solvent Product %yieldb Stereochemc 
 
 
1 
 
MeOH 
O
MeO
H
H
80  
75 cis:trans=91:9 
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2 
 
OH
60  
 
EtOH 
O
EtO
H
H
81  
85 cis:trans=90:10 
 
 
3 
BnOH 
O
BnO
H
H
82  
75 cis:trans=90:10 
 
 
4 HO
61  
EtOH 
O
EtO
H
H
83  
86 >98%cis 
 
 
5 OH
62  
EtOH 
O
EtO
H
H
84  
83 cis:trans=91:9 
 
 
6 OH
63  
EtOH 
O
EtO
H
Me
85  
55 cis:trans=87:13 
 
 
7 
 
 
OH
64  
 
MeOH 
O
H
H
MeO
86  
74 >98%cis 
 
 
8 
EtOH 
O
H
H
EtO
87  
87 >98%cis 
 
 
9 
BnOH 
O
H
H
BnO
88  
85 >98%cis 
 
 
10 HO
65  
EtOH 
O
EtO H
H
89  
85 >98%cis 
a The reactions were performed in the appropriate alcohol (5mL/mmol) using 5mol% Pd(OAc)2, 
10 mol% MeSO3H  and 2 equiv of p-benzoquinone. b Isolated yields. c Refers to the addition 
across the diene sytem. 
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The catalytic cycle for these intermolecular 1,4-oxidations is shown in scheme 1.20 and 
involves a (π−allyl) palladium complex. An intermolecular attack by the alcohol on the 
initially formed (η4−diene) palladium complex results in the formation of the 
tetrahydrofuran or tetrahydropyran ring systems. These type of reactions of alcohols with 
dienes coordinated to palladium are well precendented in literature.31 The oxypalladation 
proceeds with trans stereochemistry. The role of benzoquinone is to coordinate 32  to the 
(π−allyl) palladium complex and thereby inducing the nucleophilic attack (B). During 
later steps in the catalytic process Pd(0)-benzoquinone complex(C)  may be formed 
which would disproportionate to the hydroquinone and palladium(II) upon reacting with 
the acid.33-34 
 
Scheme 1-20  Mechanism for Pd catalyzed  intramolecular 1,4 addition to conjugated 
dienes 
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1.8 Oxidative cyclization of heteroatom nucleophile with unactivated olefins  
Pd can act both as a nucleophile in the form of Pd(0) and as an electrophile as in Pd(II) 
and this versatile property has been utilized in development of oxidative cyclization of 
alcohols to result in various O-heterocycles.35b-j Recently Stoltz et al 35a studied the 
oxidative cyclization of alcohols and phenols using Pd(II) catalysts and molecular O2 as 
the oxidant. The importance of this process lies in the fact that it avoids the use of co-
catalysts, organic oxidants (like benzoquinone), donating solvents as DMSO which ahs 
been used in previous work on similar reactions.35b-j Stoltz work is based on a previous 
reacemic Pd(II) catalyzed oxidation of alcohols by Uemura et al which involved Pd(II) 
catalyzed oxidation of alcohols.36 
Stoltz et al 35a conducted oxidative cyclizations of various heteroatom 
nucleophiles with unactivated olefins using Pd(II) catalysts in pyridine using molecular 
oxygen as the only oxidant in a non-polar solvent as toluene. Five different type of 
nucleophiles: primary alcohols, phenols, carboxylic acids, vinylogous acid, amines were 
utilized in this process. Electron rich phenols proved to be excellent substrates for this 
oxidation resulting in oxidative cyclization products smoothly. Primary alcohols can 
resulted in both fused or spiro ring systems depending on the position of alcohol group 
with respect to the tethered alcohol. The mechanistic studies conducted with 
stereospecifically deuterium labeled alcohols indicated a syn oxypalladation mechanism 
rather than a trans oxypalladation in the case of both mono and bi-dentate ligands. 
In order to optimize the reaction conditions the authors conducted aerobic oxidation of 2-
(1,2-dimethyl-1-propenyl)phenol in the presence of various Pd(II) salts, O2, pyridine and 
MS 3Å in toluene at 80o C (Table 1-7). These conditions were chosen on the basis of 
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Uemura’s alcohol oxidation conditions. 36 Some of the effective catalysts used in kinetic 
resolution chemistry such as Pd(nbd)Cl2 proved to be ineffective for this cyclization.37 
After scanning a large number of Pd catalysts the authors concluded that electron 
deficient Pd(II) catalyst Pd(TFA)2 is the most effective catalyst for this cyclization. Out 
of all the exogenous bases used, sodium carbonate resulted in 95% yield in 30 minutes. 
Pd(0) catalysts were found to be poor catalyst for this oxidative cyclization resulting in 
product in trace amounts or no reaction. The authors also tried oxidative cyclization in 
the presence  of elemental Hg which resulted in slower reaction rate but did not prevent 
the reaction contraindicating the fact that Pd or Pd nanoparticles are involved as the 
catalytic species. 38 
Table 1-7 Optimization of reaction conditions for Pd(II) catalyzed oxidative cyclization 
Entry Pd source Additive Time Yielda 
1 Pd(nbd)Cl2 none 24h 7% 
2 PdCl2 none 24h 27% 
3 Pd(OAc)2 none 24h 76% 
4 Pd(TFA)2 none 60 min 87% 
5 Pd(TFA)2 Na2CO3 20 min 95% 
6 Pd2(dba)3 None 24h 25% 
7 Pd black None 24h Nr 
8 none None 24h Nr 
9 Pd(TFA)2 None, no O2 24h 24% 
10b Pd(TFA)2 Na2CO3,Hg0 5 h 84% 
a Isolated yields. b With 5 mol% of (pyridine)2Pd(TFA)2, 10 mol% of 
pyridine, 2 equiv Na2CO3, 30 equiv Hg0. 
Various pyridine based ligands were also scanned during the optimization conditions 
(table 1.8).39 Authors also found out that substituted pyridyls which are less coordinating 
than pyridine resulted in precipitation of Pd black due to electronic and steric reasons. 
Also bidentate ligands such as 2,2’-dipyridyl (table 1-8, entry 6), 4,7-dimethyl-1,10-
phenanthroline(table 1-8, entry 7), TMEDA(table 1.8, entry 10), or TMPDA(table 1-8, 
entry 11) resulted in slower reaction rates. Weak alkylamine donors also resulted in 
precipitation of Pd black (table 1-8, entries 8,9,11). On the other hand nicotinate 
derivatives (table 1-8, entries 4 and 5) resulted in some rate enhancement. Out of all the 
ligands used pyridine offered the best combination of reactivity, catalyst stability and 
availability. 
Table 1-8  Pd(II) catalyzed oxidative cyclization using various substituted pyridyl and 
alkyl amine ligands a 
Entry
b 
Ligand No 
Additive 
40% 
ligand 
40% ligand+40% 
Na2CO3 
 
1 
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N
 
98% 
1h 
99% 
1h 
99% 
15min 
 
2 
 
85% 
2.5h 
96% 
9h 
99% 
2h 
 
3  
50% 
24hc 
68% 
24h 
91% 
5h 
 
4 
 
84% 
8hc 
99% 
40min 
96% 
15min 
 
5 
 
70% 
30minc 
99% 
30min 
99% 
5min 
 
6 
 
92% 
18h 
97% 
5h 
93% 
5h 
    40 
 
N
 
7 
N  
94% 
8h 
96% 
24h 
99% 
24h 
 
8 N
 
82% 
20hc 
90% 
5hc 
92% 
5hc 
 
9  
15% 
24hc 
15% 
24hc 
10% 
24hc 
 
10 
 
73% 
12h 
97% 
8h 
99% 
8h 
 
11  
34% 
20 hc 
54% 
20hc 
76% 
11hc 
aReaction carried out with 5 mol% LnPd(TFA)2, 500mg/mmol of MS3Å, 1 atm O2, toluene (0.1M), 800C. b 
conversion determined by GC.c Pd black precipitate was observed in the reaction mixture. d For entries 
6,7,10 and 11, 20 mol% of excess ligand was used. 
Authors also cyclized various aliphatic alcohols using this oxidative cyclization protocol 
(table 1.9). In all the cases, the corresponding heterocyclic compounds were obtained 
with little or no oxidation to aldehydes. The reaction pathway-cyclization versus 
oxidation to aldehydes depends not only on the nature of the alcohol but also the nature 
of palladium source.36 In order to conduct mechanistic studies, Stoltz et al36,37synthesized 
stereospecifically deuterium labeled substrates (Scheme  1.21) and explained the 
formation  of the specific products on the basis of one of the three basic mechanisms 
involving Pd(II) catalyzed cyclizations (Scheme 1.22). As shown in scheme 1.21 
treatment of trans-98 with 10 mol% of (pyridine)2Pd-(TFA)2, 20 mol% pyridine, 2 equiv 
Na2CO3, 1 atm  O2 and 500mg/mmol of MS3Å in toluene at 800C for 3h provided 99d 
and 100d in a 4:1 ratio and 91% yield . Similarly, the reaction of cis substrate yielded 99 
and 101 in a ratio of 1:0.7 and almost quantitative yield. 
 
Table 1-9  Pd(II) catalyzed oxidative cyclization of primary alcohols a 
Entry Substrate Product Time yield 
 
1b 
OH
90
O
94
 
3h 
 
87% 
 
2 OH91  
O
95  
10h 93%c 
 
3 
OH
92  O
96  
7.5h 69%d 
 
4 
OH
93  O97  
20h 60%e 
a With 5 mol% of Pd(TFA)2, 20 mol% pyridine, 2 equiv Na2CO3, 
500mg/mmol of MS3Å, 1 atm O2, toluene (0.1M), 80oC. b mixture of E and 
Z olefins was used. c isolated with 7% of aldehyde. d isolated with 7% of 
olefin isomer. e Isolated as a 5:2.3:1 mixture of product:olefin isomer: 
aldehyde. 
OH
O
CO2Et
D
EtO2C CO2Et
CO2EtD
O
CO2Et
CO2EtD
OH
CO2Et
D
EtO2C
O
CO2Et
CO2EtH
O
CO2Et
CO2Et
D
4.5h
91% yield
3h
99% yield
trans-98
cis-98
99d 100
99 101
4   :  1
1   : 0.7
N Pd(TFA)2
n
(10 mol%)
pyridine(30 mol%)
Na2CO3 (2 equiv), MS3
toluene, O2, 800C
Å
 
Scheme 1-21 Oxidative cyclization of deuterium labeled primary alcohols with pyridine as a 
ligand. 
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 The mechanistic explanation for the products obtained from 98 is explained in scheme 
1.22 using the cis substrate as the model. As stated earlier the authors compared all the 
three possible pathways for Pd (II) catalyzed oxidative cyclization. According to path A, 
Pd coordinated olefin  is attacked by the pendant alcohol or alkoxide in an anti fashion. 
This is followed by β-H elimination to give deuterium labeled product 99d which is not 
formed, hence ruling out this mechanism. According t path B oxypalladation occurs 
resulting in C-H(D) activation and subsequent reductive elimination upon formation of 
new C-O bond. Since for a Pd(II)-π-allyl electrophile, a primary alcohol (alkoxide) comes 
under a soft nucleophile category, hence the reductive elimination will be anti. Also, 
unless selective C-D activation occurs (less probability), a mixture of labeled (99-d) and 
non-labeled (99) compounds should be observed but a single product was obtained. Also, 
this pathway does not explain the formation of the minor product 101. The last pathway 
(C) involves syn oxypalladation involving Pd-alkoxide followed by syn β-D elimination 
to yield the major product 99. The formation of the minor product 101 can be explained 
by re-insertion of Pd-D intermediate to the product double bond. Since the Pd(0) 
intermediate in path B does not account for the formation of olefin isomer 101, hence the 
authors favored syn oxypalladation path C. 
E D
E
cis-98
99
101
OH
OH
E
E
D
H
{PdII}
O
E
E D
H
{PdII}
O
E
D
E
O
E
ED
path A
path B
OH
E
E
{PdII}
H(D)
-H(D)X
O
E
H(D)
E
{Pd0}
O
E
D
E
{PdII} H
-allylπ O
E
H(D)
O
E
E(D)HE
path C
O
E
D
H
[Pd]
E O
E
E D
H
{Pd} O
E
H
E {Pd} D
O
E
E {Pd}
H
D
O
E
H
E
O
E
E D
{Pd} H
O
E
EH
O
E
EH
D
 99-d
not 
observed
E= CO2Et
 
Scheme 1-22 Pathways for Pd(II) catalyzed oxidative cyclization of deuterium labeled 
primary alcohols  
 
 Authors also used both monodentate and bidentate ligand for this Pd(II) catalyzed 
oxidative cyclization.37 But these two type of ligands show considerable difference in 
reaction rates. This difference can be explained on the basis of degree of stabilization of 
the intermediates by the two ligands. As shown in scheme 1.23,  a neutral monodentate 
ligand such as pyridine can dissociate to provide  free coordination site  while remaining 
in a neutral state. Whereas, in the case of a bidentate ligand like dipyridyl, dissociation of 
a neutral ligand is difficult due to chelation, hence an anionic ligand should dissociate 
resulting in a charged intermediate. These type of charged intermediates are high in 
energy resulting in lower reactivity. 
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Scheme 1-23 Reaction pathways for Pd(II) oxidative cyclization using A:monodentate, 
B: bidentate ligands. 
 
1.9 Cyclization and cross-coupling reaction of acetylenic alkoxides 
Palladium catalyzed cyclization of acetylenic alcohols has been used extensively to 
obtain mono and bicycle O-hetercycles.40b-e Luo et al synthesized stereodefined 2-
alkylidenetetrahydrofurans by treating alkyl/aryl acetylenic alcohols with n-BuLi 
followed by addition of 10 mol% Pd(OAc)2 or PdCl2 and 1 equivalent of organic halide 
(Scheme 1-24).40a 
n
1. BuLi,THF
2. cat. Pd(II), PPh3
3.R'X
n= 1,2
R= H, n-Bu, Ph
R'=Ph, Me,Bn, 2-thienyl
110 111
O
R
R'OH
R
 
Scheme 1-24 Pd(II) catalyzed cyclization and cross-coupling reaction of acetylenic 
alkoxides 
  According to this report40a both acetylenic aryl and alkyl alkoxides underwent 
cyclization and cross-coupling to yield five and six membered rings with high regio- and 
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stereoselectivities. Apart from Pd(OAc)2 and PdCl2 other Pd catalysts such as Pd(dba)2 
and PdCl2(PPh3)2 gave lower yields. It was also discovered that surprisingly use of bases 
such as NaHCO3, MeONa resulted in no detectable amount of the desired products.  
OH
OH
OH
OH
O
Ph
O
Ph
O
Ph
no reaction
Reaction conditions: (1)  BuLi, THF, (2) Pd(II) cat., PPh3, (3) PhI
(60%)
(47%)
(54%)
110a
110b
111d
111c
111a
110d
110c
 
Scheme 1-25 Pd(II) catalyzed cyclization and cross-coupling reaction of acetylenic 
alkoxides  
Scheme 1-25 shows various five and six membered acetylenic alcohols subjected 
to Pd catalyzed intramolecular cyclization and cross coupling to yield bicyclic furan 
analogs by Luo et al. Compound 110b (trans-2-(2-propynyl)cyclopentanol) did not result 
in any cyclized product (scheme 1-25). 40 In order to explain the formation of the products 
the authors proposed an initial proton abstraction from the alcohol followed by 
complexation of the oxidative Pd(II) adduct with the triple bond to be involved in this 
one pot Pd catalyzed process. The complex undergoes trans-oxypalladation to give 
intermediate B which undergoes reductive elimination to yield the product and regenerate 
Pd catalyst (Scheme 1-26). 
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Scheme 1-26  Mechanism for Pd(II) catalyzed cyclization and cross-coupling reaction of 
acetylenic alkoxides  
1.10 Pd catalyzed intramolecular cyclization of 7-Hydroxy-1,3-diene with aryl 
bromides 
Recently, Yeh et al 41 studied palladium catalyzed intramolecular reaction of 7-Hydroxy-
1,3-diene with various aryl bromides to obtain bicyclic furan analogs (Scheme 1.27). 
Various acyclic and cyclic substrates were subjected to this palladium catalyzed 
alkoxyarylation of 7-Hydroxy-1,3-dienes and depending on the structure of the starting 
dienols, different types of products were obtained. In case of cyclic 7-Hydroxy-1,3-
dienes, a 1,4-alkoxyarylation product was obtained via a η1- η3- η1 allylic rearrangement, 
whereas in the case of acyclic substrates a 1,2 alkoxyarylation product was obtained.41 
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ArBr
Pd(PPh3)4 (2mol%)
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THF,   2h
O
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Ar
15 examples
36-84% yield
112-114 115-125  
Scheme 1-27 Pd catalyzed intramolecular alkoxyarylation of 7-Hydroxy-1,3-dienes 
The bicyclic tetrahydrofuran analogs were obtained in high diastereoselectivity via this 
Pd catalyzed intramolecular alkoxyarylation of 7-Hydroxy-1,3-dienes which can be 
explained on the basis of the proposed mechanism shown in scheme 1.28. The high 
diastereoselectivity indicates involvement of the Pd(Ar)-(OR)-olefin intermediate 126 
which is derived from chelation/direction by the substrate as also proposed by Wolfe et 
al.8a,b Intermediate 126 can result in insertion of olefin into the Pd-O bond to give η1 –
allylpalladium intermediate 129 which may undergo η1- η3- η1 allylic rearrangement to 
yield η1–allylpalladium intermediate 130. Intermediate 130 can lead to reductive 
elimination to give 1,4 alkoxyarylation product 131 and 132 with simultaneous 
regeneration of Pd(0) catalyst or β-hydride elimination to provide compound 133. 
Another possibility for intermediate 126 is insertion of the olefin into the Pd-C bond of 
the intermediate 126 resulting in the metallobicyclic intermediate 127 via path B (scheme 
1.28). Later, intermediate 127 can led to 1,4-alkoxyarylation product 128 via reductive 
elimination. However compound 128 was not observed and hence this reaction is 
proposed to not follow path B. This observation can also be explained on the basis of the 
fact that sterically congested bicyclic intermediate 127 may undergo β−Ph elimination to 
regenerate 126 which will result in 1,4-alkoxyarylation product via path A (scheme 1.28). 
This β−Ph elimination can be considered as the reverse of the olefin insertion step in 
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Heck reaction. Also it should be noted that arylpalladation reactions are not reversible in 
most cases except where the (aryl)(alkyl)palladium intermediates do not have syn 
β−hydrogen atoms.42 Since intermediate 127 does not have any β−hydrogen atoms syn to 
palladium hence undergoing β−Ph elimination to give back intermediate 126 is favored. 
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Scheme 1-28  Possible mechanistic pathways for Pd catalyzed intramolecular 
alkoxyarylation of 7-Hydroxy-1,3-dienes 
It was also pointed out by the authors that the structure of the product and yields also 
depended on the nature of the aryl bromides employed. In case of electron rich aryl 
bromides (table 1.10, entries 1-4) the products obtained had the general structure with syn 
stereochemistry which also confirmed syn addition of the oxygen and the aryl group 
across the conjugated diene.  
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Table 1-10  Pd(II) catalyzed intramolecular alkoxyarylation of 7-Hydroxy-1,3-dienes  
Entry 1,3-diene alcohol aryl bromide Product yield
1  
OH
112  
 
O
115
 
55 
2 
 
O
116
62 
3 
OMeO
117
84 
4 Br
 
O
118  
56 
5 
 
OCl
119
54 
6 
 
O
Br
Br 120  
40 
7 Br
CF3
O
F3C 121  
36 
8 Br
O
122  
65 
9 
 
N O
123
48 
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O
Ph
Ph124  
65 
11 
 
O
Bn
Bn125  
58 
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    50 
 
BnBn
127
 
In case of electron-deficient aryl bromides (table 1.10, entries 5-9) a double bond 
migration product 119-123 was obtained. Also, increasing the bulk in the substrate also 
resulted in different products (table 1.10, entries 10-11). In case of alcohols with bulky 
dibenzyl and diphenyl groups at C-7, tetrahydrobenzofurans 124,125 were formed via a 
β-hyride limination from the intermediate 130.  
OH
2
OH
2
OH
134 136135  
Fig 1-7 Non-reactive 7 and 8-hydroxy 1,3-dienes under Pd catalyzed intramolecular 
alkoxyarylation 
Attempts to apply Pd catalyzed intramolecular alkoxyarylation of 7-Hydroxy-1,3-dienes 
by Yeh et al to larger ring systems were unsuccessful (fig 1-7). For example, 
intramolecular alkoxyarylation reaction of  8-hydroxy-1,3-dienes 134 and 135 resulted in 
the recovery of starting dienols. Also, the Pd-catalyzed reaction of the primary alcohol 
136 with bromobenzene did not result in tetrahydrofurans under the same reaction 
conditions albeit the corresponding aldehyde  was obtained resulting from oxidation of 
the starting dienol. 
 
1-11 Oxidative cylization of 2-[(E)-buten-2-yl-1]-2-carbomethoxycyclopentanol 
Pecanha et al43 utilized a palladium acetate/cupric acetate system to synthesize bicylic 
tetrahydrofuran ring systems in a diastereoselective manner (Scheme 1-29). 
Cyclopentanol 138 was synthesized from methyl-2-oxocyclopentanecarboxylate 137, in 
95-97% yield which was then subjected to Pd catalyzed cyclization. The general reaction 
conditions used by the authors involved 10 mol% palladium acetate, 100 mol% cupric 
acetate in methanol:water system (100:8).  
O
CO2Me
137
OH
CO2Me
Me
Pd(OAc)2 (0.1 eq)
Cu(OAc)2 (1 eq)
MeOH/H2O (100:8), rt
O
CO2Me
O
CO2Me
O
CO2Me
O
CO2Me
O
CO2Me
OMe OMe
138
139 140 141 142 143  
     product 
time 
139 140 141 142 143 
4ha 11% 31% 5% 0% 10% 
8ha 10% 21% 10% 0% 8% 
24ha 3% 0% 24% 13% 8% 
24hb 10% 42% 0% 0% 7% 
a solvent sytem MeOH:water(100:8) b solvent sytem 
isopropanol with water content (20%) 
Scheme 1-29 Pd(II) catalyzed oxidative cylization of 2-[(E)-buten-2-yl-1]-2-
carbomethoxycyclopentanol 
A time-study of the reaction was also conducted. After 4 hours at room temperature a 
mixture of 3α− and 3β-vinyl bicyclic derivatives 140, 139 in 1:3 diatereomeric ratio. 
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Apart from the desired bicyclic derivatives 139, 140 a cyclic ketal 141 was also obtained 
in 5% yield after 4 hours. Also when the reaction time was doubled to 8 hours the amount 
of ketal being formed also increased (Scheme 1.30). Extending the reaction time to 24 
hours resulted in bicyclic furan derivative in only 3% yield and the cyclic ketals 141 & 
142 in 24% and 13% yield respectively. The authors also tried to minimize the side 
reaction involving ketalization by changing the solvent system from methanol/water  to 
an isopropanol/water system. 
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O Me
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H O
Me
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D D'
O Me
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O
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139 140
Pd(OAc)2
O
CO2Me
PdOAc
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E E'
O
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MeOH O
CO2Me
PdOAc
B
O
CO2Me
OMe
141
MeOH
MeOH
O
CO2Me
C
O
CO2Me
143
protonation
MeOH
 
Scheme 1-30  Formation of various products via Pd(II) catalyzed oxidative cylization of 
cis-2-[(E)-buten-2-yl-1]-2-carbomethoxycyclopentanol 
 
Authors explained the formation of various products as shown in scheme 1.30. 
The formation of ketal 142  can result from the Wacker type “intermediate” A, followed 
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by ketalization with the solvent. Ketal 141 can be formed by nucleophilic attack by the 
solvent (MeOH) on the π−allyl intermediate B. Formation of compound 143 can be 
explained by isomerization of enol ether intermediate C (scheme 1-30). 
1-12 Conclusions 
In this chapter we have presented various useful Pd catalyzed methodologies to 
synthesize bicyclic furan ring systems. The last two decades have witnessed a huge influx 
of new Pd catalyzed reactions in synthesis of various heterocycles. Palladium offers 
many advantages as it is usually required in catalytic amounts and is known to tolerate a 
large number of functional groups thereby minimizing the use of protecting groups. 
Furan is one of the most commonly studied heterocyclic compound and is widely 
distributed in large number of natural products, pharmaceuticals, agrochemicals and 
perfumes. Due to the importance of these heterocycles, new and more efficient methods 
are required to synthesize them in higher yields in a stereoselective manner and Pd 
catalysis has been a leader in this field. This chapter also gives a mechanistic perspective 
for all the Pd catalyzed processes included, which will help the reader to understand the 
formation of different products and the diastereo- and enantioselectivities of the 
processes involved. 
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Chapter  2 
Pd(0) CATALYZED INTRAMOLECULAR ALLYLIC ALKYLATION: 
STEREOSELECTIVE SYNTHESIS OF FURAN AND ISOXAZOLINE-2-OXIDE 
ANALOGS 
 2.1 General introduction 
Palladium catalyzed nucleophilic substitution of allylic compounds, also 
known as Tsuji-Trost reaction has been extensively used for C-C bond formation in 
organic syntheses.1 Allylic acetates are the most common substrates used in this reaction 
along with various active methylene compounds as the nucleophile source. However 
other allylic substrates such as halides, carbonates, epoxides, sulfones have also been 
utilized which gives Tsuji-Trost reaction a broader scope.2 Hence, synthesis of a large 
number of natural product synthesis have been accomplished via utilization of Pd 
catalyzed allylic alkylation. 
 Pd catalysis has also been extensively utilized in synthesis of analogs of bioactive 
compounds and the inherent skeleton in an efficient manner. Various aspects of this 
reaction including mechanism, substrates, catalyst-ligand systems and nucleophiles have 
been studied and extensively reviewed.3 Over 100 different chiral ligands have been 
designed to induce excellent enantioselectivity by five different enantiodiscriminating 
events.3 The discovery of new chiral ligands has resulted in ability to conduct these Pd 
catalyzed alkylations in almost >99% ee, hence attracting more natural product syntheses. 
These methods have already been utilized to synthesize numerous biological targets such 
as aflatoxin B,4a aristeromycin,4b,c carbovir,4b,c cyclophellitol,4d ethambutol,4e 
galanthamine,4f mannostatin,4g neplanocin.4b,c 
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The work presented in this chapter extends the utilization of Pd catalysis 
towards synthesis of new bioactive furan and isoxazoline analogs which can further be 
modified into other biologically important compounds. One can find a large number of 
methods for synthesis of various furan5 and isoxazoline-2-oxide analogs6. The furan ring 
system can be obtained by  various synthetic methodologies such as iodocyclization of 2-
alkenyl-1,3-dicarbonyl compounds, selenium-induced electrophilic cyclizations or 
oxidative addition of enolizable carbonyl compounds to give alkenes promoted by one 
electron oxidants.6a Similarly, the general strategy for synthesis of the isoxazoline-2-
oxides (five membered nitronates) involves cyclization of γ-functionalized nitro 
compounds or [3+2] cycloaddition of nitrile oxides with olefins.6c  Unfortunately most of 
these methods involve use of stoichiometric amount of reagents making the process 
economically non-viable. Furthermore, these reactions also involve multiple steps and 
harsh reaction conditions to obtain the final products. In some methods such as synthesis 
of the isoxazoline-2-oxides (five membered nitronates) via cyclization of γ-functionalized 
nitro compounds the preparation of starting materials is itself tedious which makes the 
whole methodology less appealing to synthetic chemists. Also the nitrile oxides used in 
synthesis of isoxazoline-2-oxides have a tendency to undergo rapid dimerization to 
furoxan N-oxide, hence disfavoring this method for syntheses of the five membered N-
oxides.6d 
 Furthermore, till date none of the syntheses for the title compounds have 
involved the usage of enzymes to induce enantioselectivity hence making this work the 
first chemo-enzymatic syntheses of furan and isoxazoline-2-oxide analogs. This work 
also tries to minimize the use of any chiral ligands during the whole syntheses. Thirteen 
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new furan and isoxazoline-2-oxide analogs were obtained in high optical purity and high 
yields by utilizing lipases, a type of hydrolytic enzymes which are much milder and 
environment-friendly catalysts than all other organometallic catalysts used in previous 
synthesis to obtain high ee’s. The starting material for this methodology is a five 
membered meso-diacetate which can be easily obtained from commercially available 
dicylopentadiene. The meso-diacetate serves as a substrate for lipase catalyzed enzymatic 
desymmetrization which is the key step for the synthesis. The outcome of the reaction 
depends on the enantiopurity of the allylic acetate being used and is also controlled by the 
selectivity of the enzyme used. The enantiopure allylic acetate can also be converted to 
its enantiomer by a couple of protection/deprotection steps hence providing an easy route 
to the other enantiomer of these furan and isoxazoline analogs. The methodology 
presented here is highly versatile and presents a convenient and environment friendly 
route to obtain new furan and isoxazoline analogs in high yield and optical purity. The 
presence of functionalities as NO2, COOR, SO2Ph and alkenes gives a tool to modify 
these structure motifs to other biologically important systems. 
2.2 Introduction to furan and isoxazoline ring systems 
2.2.1 Furan ring systems in natural products and their bioactivity 
The furan moiety is found in many natural compounds (fig 2.1).7 Various polysubstituted 
furan compounds also serve as building blocks in synthetic organic chemistry. Furan 
derivatives are also widely distributed in biologically important compounds such as  
pharmaceuticals,8 agrochemicals,7 flavoring chemicals and perfumes.9  As shown in 
figure 2-1 furan moiety is found in large number of natural products as plagionicin A 
which belongs to a class of monotetrahydrofuran acetogenins and has exhibited a broad 
biological acivity including cytotoxicity in numerous tumor cell lines as well as 
antiparasitic, insecticidal, and immunosuppressive activities.10 Rubriflordilactone B is 
one of the two bisnortriterpenoids isolated from plants of genus Schisandra has shown 
cytotoxic activity against K562 cells and has anti HIV-activity.11 The tetrahydrofuran 
system is also found in some neurotoxic amino acids as Dysiherbaine which was isolated 
from a Micronesian sponge Dysidea herbacea. Dysiherbaine represents a new class of 
amino acids containing unique cis-fused tetrasubstituted hexahydrofuro[3,2-b]pyran.12 
This system is unusual and is only found in few compounds as halichondrins.12 
(CH2)11
O
OH OHOH
OH O
O
Plagionicin A-Cytotoxic Monotetrahydrofuran Acetogenins
O
O
NH2+CH3
OH
-OOC
NH3+-OOC
H
H
H
Dysiherbaine-neurotoxic amino acid
OO
O
O
H
H
H
H
H
O
O
H H
Rubriflordilactone B-anti HIV activity
O
OHO
O
Heliespirones B-lead compound for new agrochemicals
Halichondrin A
 
Figure 2-1 Furan ring system in bioactive natural products 
    64 
 
2.2.2 General methods for synthesis of furan ring systems 
 The presence of polysubstiuted furan ring systems in a large number of natural 
products  and their utility as building blocks in synthetic chemistry has attracted chemists 
to devise new methods for their synthesis. The synthesis has been extensively reviewed in 
literature.5  Recently, a large number of metal catalyzed reactions focusing on synthesis of 
furan and its analogs have been developed such as cyclization of 2-(1-alkynyl)-2-alken-1-
ones,13 allenyl ketones,14 3-alkyn-1-ones,15 (Z)-2-en-4-yn-1-ols,16 and, cycloisomerization 
of cyclopropyl and propenyl ketones.17 Recently Zhang et al utilized Pd(II) catalyzed 
three component coupling to obtain functionalized tetrasubstituted furans in moderate 
yields (Scheme 2-1).18  
Me
O
Ph
Ph
NuH R
R
R
X
 K2CO3  (4 equiv), CH3CN
[PdCl2(CH3CN)2] 
  (5 MOL%)
O
R
R
R
Nu
Ph
Me Ph
NuH =  MeOH, BnOH, PhOH, iPrOH
  X   = Cl
  R= H, Me, Ph, COOMe
42-89%
 
Scheme 2-1 Pd(II) catalyzed three component coupling of 2-(1-alkynyl)-2-alken-1-ones 
to afford tetrasubstituted furans  
Various cyclopentafuran compounds have been generated by Pd(II) catalyzed 
intramolecular cyclization of cyclic alkenols.19 By using molecular oxygen as reoxidant 
in the presence of  Pd(OAc)2 in DMSO/O2 various cyclic alkenols were converted to 
bicyclic cyclopentafuran 2 at room temperature(scheme 2-2).  
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 Scheme 2-2 Pd(II) catalyzed intramolecular cyclization of cyclic alkenols 
 Wolfe et al 20 have synthesized that various tetrahydrofuran analogs can be synthesized 
from aryl or vinyl bromides and γ-hydroxy alkenes. These  reactions led to formation of a 
C-C and C-O bond along with establishment of two new stereocenters in good to 
moderate stereoselectivity. Recently Tanimori et al 21 has utilized palladium catalyzed 
allylic alkylation to obtain furan analogs in low to moderate yields as a mixture of 
diastereomers. 
  All these processes emphasize the importance of Pd catalysis in  synthesis of 
these furan analogs. There is always a scope for modifying these methodologies to 
improve the yields and minimize the use of expensive and toxic chemicals to make the 
whole process more environment-friendly. Hence keeping all these factors in mind, this 
work tries to incorporate the use of hydrolytic enzymes (lipases) to influence the 
stereochemical outcome of the products.  
2.2.3 Isoxazoline ring systems in natural products and their bioactivity 
As shown in figure 2-2 isoxazolines and related ring systems are found in a large number 
of natural products and bioactive compounds.6-7 For example Calafianin, a bromotyrosine 
derivative was extracted from the mexican marine Sponge Aplysina gerardogreeni.22 
Bromotyrosine alkaloids (figure 2-2) containing an amino-imidazole system coupled to 
another aromatic system act as potent inhibitors of mycobacterial enzyme, mycothiol S-
conjugate amidase (MCA) which is found in Mycobacterium tuberculosis, the causative 
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agent of tuberculosis. Also some bicyclic isoxazolines (figure 2-2) have been used as 
mechanism-based inhibitors of human leukocyte elastase (HLE) and cathepsin G (Cath 
G) which are responsible for chronic inflammatory diseases such as pulmonary 
emphysema, cystic fibrosis, psoriasis  and rheumatoid arthritis.23 Apart from being found 
in large number of natural products isoxazolines have also been utilized in material 
science as nanoscale connectors in molecular electronic devices.24 
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Figure 2-2 Isoxazolines in natural products and other bioactive compounds 
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 2.2.4 Importance of isoxazolines in synthetic chemistry 
An isoxazoline ring system provides an attractive intermediate for syntheses of more 
complex systems and its analogs can be synthesized under mild conditions.6 The 
isoxazoline ring represents a fairly responsive heterocyclic system, for its treatment with 
the appropriate sort of reagent and can yield access to (a) γ-amino alcohols, (b) β-
hydroxy ketones (and thus α,β-unsaturated ketones, allylic alcohols, 1,3-diols, and 1,3-
dienes), (c) β-hydroxy nitriles, acids, and esters, and (d) α,β and β,γ-unsaturated oximes 
(Scheme 2-3). 
 
 
 
Scheme 2-3 Use of 2-isoxazolines as key intermediates in organic synthesis. 
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2.2.5 General method for the syntheses of isoxazoline-2-oxide and analogs  
The conventional strategy for the preparation of cyclic five- and six-membered nitronates 
(isoxazoline-2-oxides) involves intramolecular O-alkylation of properly functionalized 
aliphatic nitro compounds (Scheme 2-4, eq 1).6i, j Also, there is no general method for the 
synthesis of the these functionalized starting nitro compounds and each particular 
substrate requires special approach. Another route for syntheses of these compounds 
involve a [4 + 2] cycloaddition between conjugate nitro alkenes and olefins (Scheme 2-4, 
eq 2)6g,h.  Also these  isoxazoline-2-oxides 2 could be obtained by using nitrocarbenes as 
1,3-dipoles in a 1,3-dipolar cycloaddition (Scheme 2-4, eq 3).6a,b 
X NO2
n
N
O O
n
N
O-O N
O O-
N O-
O
N
O O
(1)
(2)
(3)
(ref 6 i,j)
(ref 6g,h)
(ref 6 a,b)
 
 
Scheme 2-4 General methods for synthesis of isoxazoline-2-oxides  
Recently Kunetsky et al utilized 1,3 dipolar addition on halonitro compounds to obtain 
isoxazoline-2-oxides in moderate yields after 2-7 days (scheme 2-5a).6a,b It was also 
found that the rate of cycloaddition increases in the order I < Cl ~ Br << F due to low 
activation energy6a in the case of F-analogs. This was also proved by the experimental 
conditions, for example the fluoro nitro compounds took 2 days at room temperature to 
yield the isoxazoline-2-oxides whereas the bromo analogs took 3-7 days. 
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 Scheme 2-5a Synthesis of isoxazoline-2-oxides from fluoronitro compoundsvia 
cycloaddition 
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Scheme 2-5b Tandem nitroaldol-ring closure of nitroacetic esters to synthesize 
isoxazoline-2-oxides 
Rosini et al have used a tandem nitroaldol–ring closure of ethyl nitroacetate with α–
bromo enones to obtain isoxazoline-2-oxides (scheme 2-5b).25 These reactions was tried 
under homogeneous as well as heterogeneous conditions giving similar results. The rate 
and the yield of the reaction depended on the degree of substitution of the enone β-
carbon.  
2.3 Pd catalyzed Syntheses of Furan and Isoxazoline-2-oxides 13 a-h 
The syntheses of furan and isoxazoline-2-oxide analogs (Scheme 2-6) were achieved by 
an intramolecular Pd(0) catalyzed cyclization and also involves enzymatic 
desymmetrization of meso starting materials. The synthetic approach described in this 
work brings the best of both (chemical and enzymatic) approaches in organic synthesis. 
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 Scheme 2-6 General procedure for syntheses of Isoxazoline-2-oxides and furan analogs 
via Pd catalyzed alkylation of allylic acetates 5, 9 and 10 
2.3.1 Synthesis of five membered cyclic allylic acetates 5, 9 and 10 
The syntheses begins with a retro Diels-Alder reaction where commercially available 
dicyclopentadiene was heated to 1700C to obtain the monomer cyclopentadiene (Scheme 
2-7). The momoner thus obtained was oxidized using peracetic acid to its monoepoxide 
(racemic).26 The monoepoxide was subsequently treated with acetic anhydride in the 
presence of Pd(PPh3)4 to obtain the meso-3,5-diacetoxycyclopentene (4). The 
desymmetrization of the meso diacetate (4) with lipase gave the (+)-monoacetate (5) 
which was the pivotal chiral induction reaction (Scheme 2-7). Unlike in resolution of a 
racemic substrate, in which the yield per enantiomer is limited to 50%, the 
desymmetrization of the meso diacetate allowed conversion of higher than 97% to the 
enantiomerically pure single enantiomer.27 A simple protection/deprotection strategy 
would enable access to the other enantiomer.  
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3
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Cyclopentadiene
(> 99%ee)  
Scheme 2-7 Synthesis of allylic monoacetate 5 via lipase catalyzed hydrolysis  
Enzymatic asymmetric induction is a powerful tool in developing elegant 
synthetic methodologies for natural products.28  A chemoenzymatic approach  to 
enantioselective synthesis of both (R and S) enantiomers of imperanene, a platelet 
aggregation inhibitor was recently reported from  our laboratories.29 Desymmetrization of 
meso compounds is an extremely important reaction and involves elimination of one or 
more symmetry elements in the substrate. A large number of compounds including 
alcohols, esters, anhydrides, nitriles have been subjected to enzymatic 
desymmetrizations.28c Hydrolases are the enzymes which have shown immense potential 
in carrying out these desymmetrizations. Out of all the hydrolases, lipases have been 
extensively used.28e For example, meso-2-Cycloalken-1,4-diols and diacetates have been 
subjected to enzymatic desymmetrizations utilizing lipase B from Candida antarctica 
(Novo SP-435) in organic and aqueous media.28e Of a number of different available 
lipases in our laboratories, the lipase from Pseudomonas cepacia (PS-30) was used to 
carry out hydrolytic desymmetrization of the diacetate.28 PS-30 catalyzed reaction of 
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meso-diacetate 4 produced monoacetate 5 in high enantiopurity (>97%) and 60% yield. 
The recovered diacetate was again subjected to hydrolysis with the recovered enzyme to 
obtain enantiopure monoacetate (5, [α]D20 (CHCl3) = +68.9; lit 27 [α]D20 (CHCl3) = +69.6) 
in total yield of 90%. The absolute stereochemistry of the monoacetate was established 
upon its comparison with the literature data27,28e as (+)-(1S, 4R)- 4-acetoxycylcopent-2-
en-1-ol. The enantiopurity of monoacetate 5 was confirmed by GC analyses of the 
racemic and enzymatically prepared monoacetate on a cylcodexB (30mX0.25mm, J&W 
scientific) chiral capillary column.  
HO OAc PCC
CH2Cl2
O OAc excess R3Li
Ether, -780C
HO OH
R3
Ac2O ,DMAP
THF
HO OAc
R3
5 6 7-8 9-10
7, 9 : R3 = Me 8, 10: R3 =; C C Ph  
Scheme 2-8 Syntheses of substituted tertiary allylic monoacetates 9-10 by addition of 
alkyl lithiums. 
In order to study the versatility of the palladium catalyzed methodology 
the monoacetate 5 was further modified by a series of transformations into other allylic 
monoacetated bearing a tertiary hydroxyl group. As shown in scheme 2-8 enantiopure 
monoacetate 5 was oxidized to ketone 6 using PCC (pyridinium chlorochromate) in the 
presence of sodium acetate in CH2Cl2 .30  The  α,β- unsaturated ketone 6 was treated with 
various alkyl lithiums to generate the cis-diols, 7 and 8  as the major product (>98%).  
Spectral data for compounds 7 was in complete agreement with 1H and 13C spectral data 
reported in the literature.31 Importantly, compound 8 produced colorless orthorhombic 
crystals and single crystal X-ray diffraction experiment confirmed that the two hydroxyl 
groups are on the same side of the cyclopentene ring thus confirming the cis relationship.  
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The ORTEP plot and the diffraction data is included in section 2.5.2. The absolute 
stereochemistry of the molecule was also established as (1S, 4R). This preference for the 
formation of syn isomer 7 and 8 can be explained on the basis of the steric and electronic 
factors. The acetoxy group in compounds 7 and 8 is in the beta face hence it directs the 
incoming nucleophile (alkyl lithium) from alpha phase due to steric factors giving a syn 
diol. Furthermore, the acetoxy group in the starting material when attacked by the alkyl 
lithium will form an alkoxide which will repel any nucleophile coming from the same 
(beta) face hence again favoring an alpha attack to give a syn product.  
The next step involved the synthesis of allylic acetates which would set up 
the stage for the first palladium catalyzed allylic alkylation. Hence, the diols 7 and 8 were 
treated with one mole of acetic anhydride and catalytic amount of DMAP to obtain the 
corresponding monoacetates 9 and 10 in quantitative yields (Scheme 2-8). 
2.3.2 Pd catalyzed allylic alkylation of cyclic acetates 5, 9 and 10 using soft 
nucleophiles 
The monoacetates were then subjected to palladium catalyzed allylic alkylation using 
various active methylene compounds (soft nucleophiles) as nitro and cyano esters, 
malonate diesters, sulphones (scheme 2-9).  Pd catalyzed alkylation could result in 
formation of a 1,2- or 1,4-adduct,32  but under the conditions studied the reaction proceeds 
with high regio- and stereo-selectivity to give the 1,4 adducts, 11a-i. The stereochemistry 
of the Pd-catalyzed alkylation has been studied extensively and is known to proceed with 
retention of configuration via double inversion.32 
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Scheme 2-9 Pd catalyzed allylic alkylation of acetates 5, 9, 10 using various active 
methylene compounds.  
 As shown in scheme 2-9 allylic acetates 5, 9, 10 were coupled  with various active 
methylene compounds using Pd (0) catalysis. Different bases such as NaH, potassium  
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tert-butoxide were used but potassium carbonate gave superior results and was used as 
the base for further investigations. Out of the various solvents used (CH2Cl2, diethyl 
ether) THF was chosen to carry out all the reactions due to ease of handling and superior 
results.  
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Scheme 2-10 General catalytic cycle for Pd (0) catalyzed allylic alkylation using active 
methylene compounds. 
As evident from the mechanism for these alkylations (Scheme 2-10) compound 11a-j 
would be a mixture of a pair of diastereomers at the site of the carbon-carbon bond 
formation (C6). The diastereomeric ratio of 11a-j determined from integral value of the 
H-6, H-2, and H-3 resonances in their 1H spectra was calculated to be ~ 1:1 (Table 2-1). 
These pairs of diastereomers were inseparable on a chromatographic column and 
appeared as a single spot on a TLC plate. As the diastereotopic center (C-6) is prone to 
racemization (because of its proximity to the electron withdrawing groups) and is 
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involved in generation of a carbanion in the following steps, no efforts were devoted to 
its resolution and the mixture was taken for further steps without separation.  
Table 2-1 Diastereomeric ratio & yields for Pd(0) catalyzed allylic alkylation of acetates 
5, 9 and 10 
 
Compound R1 R2 R3 Diastereomeric
Ratioa 
Yieldb
11a NO2 CO2Et H 1.07:1 62 
11b NO2 CO2Et Me 1.12:1 70
11c NO2 CO2Et C≡C-Ph 1.13:1 60
11d COMe CO2Et H 1.04:1 68
11e COMe CO2Et Me 1.28:1 65
11f COPh SO2Ph H 1.07:1 68
11g COPh SO2Ph Me 1.15:1 71
11h COPh SO2Ph C≡C-Ph 1.06:1 61
11i CN COOEt H 1.05:1 60
11j CN PhSO2 H 1.23:1 68
11k CO2Me CO2Me H - 73
a Diastereomeric ratio based on 1H-NMR analyses. b Isolated yields 
2.3.3 Pd(0) catalyzed intramolecular cyclization to synthesize furan and isoxazoline-
2-oxide analogs 
The alcohols 11a-k offer another allylic system which can be further utilized to carry an 
intramolecular Pd(0) catalyzed cyclization to give furan or iosxazoline-2-oxide systems. 
Hence, the allylic alcohols 11a-k were acetylated using acetic anhydride and catalytic 
amount of DMAP  in THF (scheme 2-11).  
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Scheme 2-11  Synthesis of acetates from allylic alcohols 11 a-k 
The secondary acetates 12 a, d, f, i-k were quite stable and were purified by column 
chromatography. Most tertiary acetates with  the exception of 12b were unstable and not 
amenable to purification on chromatographic columns and hence, were subjected to 
palladium catalyzed alkylation without any further purification. 
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 Scheme 2-12 Synthesis of bicyclic furan and isoxazoline-2-oxides via Pd(0) catalyzed 
intramolecular cyclization 
Allylic acetates 12 were subjected to palladium catalyzed intramolecular cyclization in 
the presence of K2CO3 and  Pd(PPh3)4 to yield bicyclic furan and isoxazoline-2-oxides 
(scheme 2-12). Nitro esters 12a-c resulted in the formation of optically pure isoxazoline-
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2-oxides. Keto-esters 12d-e and sulphones 12f-h resulted in the formation of  
cyclopentafuran compounds 13d-h (table 2-2). 
Table 2-2 Yields and optical rotation data for bicyclic furan and isoxazoline-2-oxide 
analogs 13a-h 
 
Compound R1 R2 R3 Yielda αD20 (CH2Cl2)
13a NO2 CO2Et H 85 -95.2 
13b NO2 CO2Et Me 64 -90.4 
13c NO2 CO2Et C≡C-Ph 63 -182.3 
13d Me CO2Et H 85 -77.8 
13e Me CO2Et Me 57 -146.1 
13f Ph SO2Ph H >98 -20.0 
13g Ph SO2Ph Me 59 -16.7 
13h Ph SO2Ph C≡C-Ph 65 -15.0 
13i CN COOEt H -b - 
13j CN SO2Ph H -b - 
aproduct isolated after column chromatography. bStarting material was recovered. 
 
 
It is noteworthy to mention that starting from a meso-diol, optically pure compounds 
were prepared without utilizing chiral ligands at any stage of the reaction. The 
stereochemical outcome of the product is solely influenced by the Pseudomonas cepacia 
lipase and the stereoselective nature of the palladium catalyzed transformations. 
Literature reports on synthesis of the furan derivatives have been catalyzed by 
palladium(0) in presence of chiral ligands leading to, at best, modest 
enantioenrichments.21,33 The cyclization reactions were also evaluated in presence of 
various bases, i.e., NaH, K2CO3, KtOBu (Scheme 2-12) in THF using catalytic amount of 
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Pd(0) catalysts. The yield of the reaction was independent of the base used. For all 
reactions recorded in table 2-2 reaction was performed using K2CO3 as the base. 
Pd(PPh3)4 and Pd2(dba)3 were the two Pd(0) catalysts evaluated in this reaction and 
identical results were obtained. Pd(II) catalysts like PdCl2 did not catalyze the cyclization. 
The cyclizations were also attempted in absence of base or catalyst and such variations 
did not give the desired product indicating that both base and the catalyst are vital for this 
cyclization.  
 
Scheme 2-13  Mechanism for formation of bicyclic furan and isoxazoline-2-oxides via 
Pd(0) catalyzed intramolecular cyclization 
Mechanism for formation of compound 13a-h is shown in Scheme 2-13, 
where the base deprotonates the methine proton between the two electron-withdrawing 
groups. The carbanion thus generated results in the formation of 13a-h via electron-flow 
through NO2 group (for isoxazoline-2-oxides) or enolate oxygen (for furan) (Scheme 2-
12). The stereochemical outcome of the reaction is the result of two sequential steps. First 
the formation of the Pd π-allyl complex occurs on the opposite side of the OAc leaving 
group because of steric control. In the second step, the attack of the nucleophile proceed 
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in an anti fashion with respect to metal resulting in a highly stereoselective reaction.34 
One of the isoxazoline-2-oxide, 13c produced colorless orthorhombic crystals. The single 
crystal X-ray diffraction experiment confirmed its structure (figure E2).  Unfortunately, 
the X-ray data could not establish the absolute stereochemistry of 13c but it is deduced 
through the stereochemistry of the monoacetate 5, as (1S,5S)-3-aza-4-(ethoxycarbonyl)-7-
phenylethynyl-2-oxabicyclo[3.3.0]oct-3,7-diene-3-oxide.   
Compounds 12i-j containing a cyano group, did not give the desired 
bicyclic system; starting material was always recovered and confirmed by 1H NMR. Even 
though compounds 12 i,j have an acidic proton which could be deprotonated by a base as 
shown in general mechanism (scheme 2-13) but the resultant bicyclic structure will have 
a highly strained aza-allene system, hence these two cyano esters did not cyclize when 
subjected to palladium catalysis in the presence of a base.  
In order to obtain the ee, compound 13a was treated with chiral shift-
reagent, Europium tris[3-(hepta-fluoropropylhydroxymethylene)-(+) -camphorate] and 1H 
NMR indicated enantiomeric excesses for compound 13a to be >97%. Figure 2-3 shows 
1H NMR comparison of racemic and enantioenriched 13a in presence (+)-Eu(hfc)3.  The 
H3 signals were used for calculation of % ee. The absence of doublet at 5.9 ppm in 
enantioenriched 13a indicated >97%ee. 
O
N O
COOEt
1
2 3
4
5 6
(b)
(a)
H-1
H-1 H-2
H-2
H-3
O
N O
COOEt
1
2 3
4
5 6
(-)
H-3
(-)
(-)
(+)
(±)
 
Figure 2-3 1H-NMR of compound 13a in the presence of (+)- Eu(hfc)3 (a) 
Enantioenriched (b) Racemic 
Interestingly, compound 12k led to an unusual product 13k containing an 
exocyclic double bond. The formation of this unusual product can be explained by the 
interconversion between the two π-allyl complexes I and II (Scheme 2-14).35 Recently 
Buono et al have studied Pd(0) catalyzed alkylation of a bicyclic allylic diacetate with 
stabilized nucleophiles such as malonates and have proposed the interconversion of π-
allyl complexes as the one shown in scheme 2-14.35 
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Scheme 2-14   Proposed mechanism for the formation of 13k from 12k via 
interconversion of the π-allyl complexes I and II 
2.4 Conclusion  
In summary, Pd catalyzed cyclization was utilized  to obtain optically pure furan 
and isoxazoline-2-oxide analogs in a practical manner utilizing mild reaction conditions. 
The method involves tandem use of the enzymatic and chemical catalysis. It is 
noteworthy to mention that starting from a meso-diol, optically pure compounds were 
prepared without utilizing chiral ligands at any stage of the reaction. The stereochemical 
outcome of the product is solely influenced by the Pseudomonas cepacia lipase and the 
stereoselective nature of the palladium catalyzed transformations. The key step is the 
desymmetrization of the meso diacetate (5) using commercially available Pseudomonas 
cepacia lipase (PS-30), in high ee.  Hence, this methodology tries to minimize the use of  
chiral ligands and again proves the importance and utility of enzymes in organic 
syntheses. The Pd(0) catalyzed cyclization is compatible with a wide spectrum of 
functional groups like NO2, COOR, COR, SO2R. This work provides a new pathway to 
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obtain optically pure furan and isoxazoline-2-oxide analogs which are rather difficult to 
obtain via previous strategies. 
2.5 Experimental 
2.5.1. General 
Lipase PS-30 was generous gifts from Amano Enzymes. 1H-NMR and 13C-NMR spectra 
were recorded on a Brucker 250 MHz and Varian 400, 500 MHz  spectrometer in CDCl3 
and acetone-d6 with TMS as the standard. Chemical shifts are reported in ppm, 
multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), p (quintet), h 
(sextet), m (multiplet) and bs (broad singlet). Optical rotations were measured with a 
Rudolph Research Analytical AutoPol IV Automatic polarimeter. Thin-Layer 
chromatography (TLC) was performed on glass plates coated with 0.25 mm thickness of 
silica-gel. All solvents were dried and distilled prior to use and organic solvent extracts 
were dried over Na2SO4. Mass measurements were carried out on an ESI LC MS system 
(Agilent Technologies). GC studies were carried out on Shimadzu gas chromatogram 
(Model 17A). A cyclodextrin column (30m X 0.25mm) from J&W Scientific was used 
for determining the ee of the monoacetate 5. 
2.5.2 X-Ray Crystallography 
Single-crystal X-ray diffraction data for the compounds 8 and 13c was collected on a 
Bruker SMART-APEX CCD Diffractometer with Kyroflex Low Temperature System 
using MoKα radiation (λ = 0.71073 Å), operating in the Ω and φ scan mode. Diffracted 
data were corrected for absorption using the SADABS program. Crystallographic data 
(excluding structure factors) for the structures in this paper have been deposited with the 
Cambridge Crystallographic Data Centre as supplementary publication numbers CCDC 
622489 and 622490. 
For the crystal of (1S, 4R)-1-Phenylethynyl-cyclopent-4-ene-1,4-diol, 4 molecules were 
found in each unit cell. The compound crystallized in a orthorhombic space group P2 (1), 
with cell dimensions a=5.3082(10) Ǻ, b=8.4869(16) Ǻ , c=17.005(3) Ǻ. A total of 5642 
unique reflection data were obtained to give a final R index [l>2σ(I)] of R1 = 0.0337, 
wR2 = 0.0894 and R indices (all data) R1 = 0.0365, wR2 = 0.0918. 
2.5.2.1  Crystallographic X-ray data for compounds 8 (1S, 4R)-1-Phenylethynyl-
cyclopent-4-ene-1,4-diol 
 
 
Figure E1. Ortep plot for X-ray structure of (1S, 4R)-1-Phenylethynyl-cyclopent-2-ene-
1,4-diol (8). 
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Table E1.  Crystal data and structure refinement for 8. 
 
Identification code  kb0725 
Empirical formula  C13H12O2 
Formula weight  200.23 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 6.2734(9) Å α= 90°. 
 b = 7.6864(11) Å β= 90°. 
 c = 22.307(3) Å γ = 90°. 
Volume 1075.6(3) Å3 
Z 4 
Density (calculated) 1.236 Mg/m3 
Absorption coefficient 0.083 mm-1 
F(000) 424 
Crystal size 0.30 x 0.20 x 0.12 mm3 
Theta range for data collection 1.83 to 25.10°. 
Index ranges -7<=h<=7, -9<=k<=7, -26<=l<=22 
Reflections collected 5642 
Independent reflections 1900 [R(int) = 0.0306] 
Completeness to theta = 25.10° 99.7 %  
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Absorption correction SADABS 
Max. and min. transmission 1.000 and 0.761 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1900 / 0 / 141 
Goodness-of-fit on F2 0.872 
Final R indices [I>2sigma(I)] R1 = 0.0337, wR2 = 0.0894 
R indices (all data) R1 = 0.0365, wR2 = 0.0918 
Absolute structure parameter -0.9(13) 
Largest diff. peak and hole 0.210 and -0.157 e.Å-3 
 
2.5.2.2 X-ray crystallographic data for (13c). 
For the crystal of 13c, 4 molecules were found in each unit cell. The compound 
crystallized in a orthorhombic space group P2(1)2(1)2(1), with cell dimensions 
a=6.630(4)Ǻ , b=10.067(6)Ǻ , c=21.631(11) Ǻ. A total of 3479 unique reflection data 
were obtained to give a final R index [l>2σ(I)] of R1 = 0.0626, wR2 = 0.1308  and R 
indices(all data) R1 = 0.0824, wR2 = 0.1444. 
 Figure E2. Ortep plot for X-ray structure of compound 13c 
Table E2.  Crystal data and structure refinement for 13c 
Identification code  kb0825 
Empirical formula  C17H15NO4 
Formula weight  297.30 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 6.630(4) Å α= 90°. 
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 b = 10.067(6) Å β= 90°. 
 c = 21.631(11) Å γ = 90°. 
Volume 1443.7(15) Å3 
Z 4 
Density (calculated) 1.368 Mg/m3 
Absorption coefficient 0.098 mm-1 
F(000) 624 
Crystal size 0.30 x 0.07 x 0.06 mm3 
Theta range for data collection 1.88 to 25.01°. 
Index ranges -7<=h<=6, -11<=k<=8, -14<=l<=20 
Reflections collected 3479 
Independent reflections 2176 [R(int) = 0.0437] 
Completeness to theta = 25.01° 87.8 %  
Absorption correction SADABS 
Max. and min. transmission 1.000 and 0.598 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2176 / 0 / 206 
Goodness-of-fit on F2 1.009 
Final R indices [I>2sigma(I)] R1 = 0.0626, wR2 = 0.1308 
R indices (all data) R1 = 0.0824, wR2 = 0.1444 
Absolute structure parameter 0(3) 
Largest diff. peak and hole 0.251 and -0.201 e.Å-3 
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2.5.3 Experimental procedure and characterization data  for compounds 5 and 6. 
2.5.3.1 (+)-(1S, 4R)- 4-acetoxylcylcopent-2-en-1-ol (5).26-28 
10g (0.054mol) of meso-diacetate 4,27, 28d was taken in a mixture of phosphate buffer (pH 
7.0; 75ml) and acetone (5ml) in a round bottom flask.  Lipase PS-30 (500mg) was added 
while maintaining the pH of the reaction mixture at 7.0 using 1N NaOH solution.  The 
reaction was stopped when no change in the pH of the reaction medium occurred.  The 
conversion at this point was estimated to be ~60 % by tlc.  The reaction mixture was 
extracted with ethyl acetate (3 x 200 mL). The organic layer was dried over Na2SO4 and 
concentrated by rotoevaporation.  The crude product was subjected to column 
chromatography over silica gel using ethylacetate: hexane (1:3) to isolate the 
monoacetate 5 as a white solid, mp 40-42 °C; αD20 (CHCl3) = +68.9; lit 27d αD20 (CHCl3) = 
+69.6); 1H NMR (CDCl3, 400 MHz): δ 1.60 (dt, 1H, J=14.8, 4.0 Hz), 2.01 (s, 3H), 2.76 
(p, 1H, J=7.2 Hz), 4.6 (m, 1H), 5.4 (m, 1H), 5.94 (d, 1H, J=4.0 Hz), 6.06 (m, 1H) ppm; 
13C NMR (CDCl3, 100 MHz): δ 20.5, 40.4, 74.6, 77.2, 132.3, 139.1, 171.3 ppm.  
2.5.3.2 (R)-4-Acetoxy-2-cyclopenten-1-one (6)30. viscous liquid; 1H NMR (CDCl3, 250 
MHz): δ 2.03(s, 3H), 2.22 (dt, 1H, J=18.7, 2.2 Hz), 2.73 (dt, 1H, J=19.0, 6.75 Hz), 5.78 
(m, 1H), 6.26 (d, 1H, J=5.7 Hz), 7.5 (m, 1H) ppm; 13C NMR (CDCl3, 62.5 MHz) δ: 20.8, 
40.9, 71.9, 136.9, 158.9, 170.4, 204.8  ppm.  
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2.5.4 General procedure for preparation of compounds 7 and 8. 
To a solution of (R)-4-Acetoxy-2-cyclopenten-1-one 6  (200 mg, 1.428 mmol) in freshly 
distilled ether (15 ml) at -78 °C was added 1.6 M solution of methyl lithium in ether (3.57 
ml, 5.712 mmol) under a nitrogen atmosphere. The reaction was allowed to stir for 1h 
and was quenched using NH4Cl solution. The product was purified by column 
chromatography using ethyl acetate: hexane (2:1) to afford 7 (150 mg, yield =92%) as a 
viscous liquid. 
2.5.4.1 (1S, 4R)-1-Methylcyclopent-2-ene-1,4-diol (7). viscous liquid; αD20(acetone) = 
+55.2 (c 0.02); 1H NMR (CDCl3, 250 MHz): δ 1.27(s, 3H, CH3), 1.71 (dd, 1H, J=14.5, 
2.7 Hz), 2.29 (dd, 1H, J=14.5, 7.2 Hz), 3.9 (bs, 2H), 4.58 (d, 1H, J=6.2 Hz), 5.79 (m, 2H) 
ppm; 13C NMR (CDCl3, 62.5 MHz) δ: 27.5, 49.5, 75.2, 81.2, 134.0, 141.0 ppm.  
HRESIMS calcd for C6H11O2 ([M+H]+): 115.0759; found: 115.0758 . 
2.5.4.2 (1S, 4R)-1-Phenylethynyl-cyclopent-4-ene-1,4-diol (8). White solid: mp=114-
116 °C; αD20 (acetone) = +330.5 (c 0.11); 1H NMR (CDCl3, 250 MHz) δ: 1.97(s, 1H, 
OH), 2.00 (s, 1H, OH), 2.04 (dd, 1H, J=14.0, 3.2 Hz), 2.82 (dd, 1H, J=14.0, 6.7 Hz), 4.78 
(dd, 1H, J=6.7, 3.2 Hz), 6.01 (s, 2H), 7.26-7.32 (m, 5H) ppm; 13C NMR ((CD3)2CO, 62.5 
MHz) δ: 52.4, 75.0, 76.2, 83.3, 93.3, 123.9, 129.1, 129.3, 132.2, 136.9, 137.7 ppm. 
HRESIMS calcd for C13H13O2 ([M+H]+): 201.0916; found: 201.0921. 
2.5.5 General procedure for preparation of compounds 9 and 10.  
To a solution of 7 (100 mg, 0.877 mmol) in dry THF (10 ml) at room temperature was 
added acetic anhydride (89 mg, 0.877 mmol), and catalytic amount of DMAP. The 
reaction was allowed to stir for 3h and then concentrated. The residue was taken in ethyl 
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acetate (40 ml) and was treated twice with saturated sodium bicarbonate solution (20 ml), 
followed by brine (10 ml). The organic layer was dried over sodium sulfate and the 
resulting product 9 was purified by column chromatography using ethyl acetate: hexane 
(1:2) (80.25 mg, yield= 58.77%). 
2.5.5.1 (1R, 4S)-4-Hydroxy-4-methyl-2-cyclopenten-1-yl Acetate (9): 1H NMR 
(CDCl3, 250 MHz) δ: 1.32 (s, 3H), 1.80 (dd, 1H, J=14.5, 3.5 Hz), 1.97 (s, 3H), 2.2 (bs, 
1H), 2.36 (dd, 1H, J=14.5, 7.5 Hz), 5.46 (m, 1H), 5.76 (d, 1H, J=5.5 Hz), 5.92 (d, 1H, 
J=5.5 Hz) ppm; 13C NMR (CDCl3, 62.5 MHz) δ: 21.2, 27.3, 46.7, 77.6, 80.9, 130.2, 
143.2, 170.8 ppm. HRESIMS calcd for C8H13O3 ([M+H]+): 157.0865; found: 157.0871. 
2.5.5.2 (1R, 4S)-4-Hydroxy-4-phenylethynyl-2-cyclopeneten-1-yl Acetate (10). 
viscous liquid; 1H NMR (CDCl3, 250 MHz) δ: 1.98 (s, 3H), 2.09 (dd, 1H, J=14.5, 3.7 
Hz), 2.82 (s, 1H), 2.91 (dd, 1H, J=14.5, 7.2 Hz), 5.6 (m, 1H), 5.92 (dd, 1H, J=5.5, 2.2 
Hz), 6.07 (d, 1H, J=5.5 Hz), 7.20-7.35 (m, 5H) ppm; 13C NMR (CDCl3, 62.5 MHz) δ: 
21.2, 47.8, 76.0, 77.1, 84.5, 90.2,122.2, 128.3, 128.6, 131.6, 132.0, 139.7, 170.9 ppm. 
HRESIMS calcd for C15H15O3 ([M+H]+): 243.1021; found: 243.1018. 
2.5.6 General procedure for preparation of compounds 11a-k (Scheme 2-9). 
To a solution of ethyl nitroacetate (100 mg, 0.752 mmol) in dry THF (10 ml) at room 
temperature was added potassium carbonate (110 mg, 0.800 mmol) under a nitrogen 
atmosphere. The reaction was allowed to stir for 20 minutes and Pd(PPh3)4 (43.4 mg, 
0.037 mmol), PPh3 (197 mg, 0.752 mmol), monoacetate 5 (106 mg, 0.752 mmol) 
dissolved in 5 ml THF was added to it. The reaction was allowed to stir at 40 0C for 12 h 
and then vacuum filtered through celite with subsequent concentration of the filtrate. The 
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product was purified by column chromatography using ethyl acetate: hexane (1:2) to 
afford 11a (120 mg, yield =62%) as a yellow viscous liquid. 
2.5.6.1 Ethyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-2’-cyclopenten-1’-yl)-2-nitroacetate 
(11a). viscous yellow liquid; 1H-NMR (CDCl3, 400 MHz) δ: 1.25 (t, 3H, J=7.2 Hz), 1.57 
(m, 1H), 1.92 (bs, 1H), 2.50 (m, 1H), 3.46 (t, 1H, J=2.4 Hz), 4.23 (q, 2H, J=6.8 Hz), 4.79 
(bs, 1H), 5.06 (t, 1H, J=8.0 Hz), 5.74-5.83 (dd, 1H, J=6.0, 4.8 Hz), 5.95-5.97 (m, 1H). 
13C-NMR (CDCl3, 100 MHz) δ: 14.0, 36.2, 36.8, 45.4, 45.1, 63.3, 76.0, 76.3, 91.0, 91.4, 
131.6, 132.0, 137.7, 137.9, 163.8, 163.9 ppm.  HRESIMS calcd for C9H14NO5  ([M+H]+): 
216.0872; found: 216.0875.  
2.5.6.2 Ethyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-4-methyl-2’-cyclopenten-1’-yl)-2-
nitroacetate (11b). viscous yellow liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.21 (t, 3H, 
J=7.5 Hz), 1.34 (s, 3H), 1.79 (dt, 1H, J=14.2, 5.0 Hz), 1.95 (bs, 1H), 2.19 (dd, 1H, 
J=14.2, 8.2 Hz), 3.50 (m, 1H), 4.19 (q, 2H, J=7.5 Hz), 5.03 (t, 1H, J=8.2 Hz), 5.59 (2 dd, 
1H, J=5.5, 2.0 Hz), 5.82 (dt, 1H, J=5.5, 2.0 Hz) ppm; 13C-NMR (CDCl3, 62.5 MHz) δ: 
13.9, 27.5,27.6, 42.2, 42.8, 45.1, 45.5, 63.1, 82.1, 82.4, 90.6, 91.0, 129.1, 129.6, 141.8, 
142.1, 163.7 ppm. HRESIMS calcd for C10H16NO5  ([M+H]+): 230.1029; found: 
230.1034.  
2.5.6.3 Ethyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-4-phenylethynyl-2’-cyclopenten-1’-yl)-
2-nitroacetate (11c). viscous yellow liquid; 1H-NMR (CDCl3, 250 MHz ) δ: 1.24 (dt, 3H, 
J=6.7, 1.0 Hz), 2.1 (m, 1H), 2.53 (d, 1H, J=2.7 Hz, OH), 2.74 (m, 1H), 3.65 (m, 1H), 
4.19 (q, 2H, J=6.7 Hz), 5.06 (dd, 1H, J=9.0, 1.0 Hz), 5.79, 5.87 (2 dd, 1H, J=5.5, 2.0 Hz) 
6.00 (dt, 1H, J=5.5, 1.7 Hz), 7.22-7.36 (m, 5H) ppm; 13C-NMR (CDCl3, 62.5 MHz) 
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δ:13.9, 43.7, 44.4, 44.9, 45.2, 63.21, 63.26, 76.5, 77.5, 85.2, 89.8, 90.6, 90.8, 122.1, 
128.3, 128.7, 131.5, 131.6, 132.0, 138.8, 138.9, 163.5 ppm. HRESIMS calcd for 
C17H18NO5  ([M+H]+): 316.1185; found: 316.1180.  
2.5.6.4 Ethyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-2’-cyclopenten-1’-yl)-3-oxobutanoate 
(11d). viscous yellow liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.18 (t, 3H, J=7.2 Hz), 1.28 
(t, 1H, J=7.0 Hz), 2.18 (s, 3H), 2.37 (p, 1H, J=7.2 Hz), 3.19 (m, 1H), 3.45 (m, 1H), 4.14 
(q, 2H, J=7.2 Hz), 4.6 (m, 1H), 5.67-5.83 (m, 2H) ppm; 13C-NMR (CDCl3, 62.5 MHz) δ: 
14.2, 29.7, 29.9, 37.2, 37.8, 43.1, 43.2, 61.0, 64.7, 65.1, 76.22, 76.28, 134.2, 134.6, 135.2, 
135.5, 168.7, 169.0, 202.61, 202.66 ppm. . HRESIMS calcd for C11H17O4 ([M+H]+): 
213.1127; found: 213.1134. 
2.5.6.5  Ethyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-4-methyl-2’-cyclopenten-1’-yl)-3-
oxobutanoate (11e). viscous yellow liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.20 (t, 3H, 
J=7.0 Hz), 1.29 (s, 3H), 1.50-1.71 (2 dd, 1H, J=14.0, 5.2 Hz), 2.16 (m, CH3+H-5), 2.55 
(bs, 1H, OH), 3.24 (m, 1H), 3.47 (dd, 1H, J=8.7, 3.0 Hz), 4.13 (q, 2H, J=7.0 Hz), 5.52-
5.62 (2 dd, 1H, J=5.2, 2.5 Hz), 5.7 (dd, 1H, J=5.5, 2.0 Hz) ppm; 13C-NMR (CDCl3, 62.5 
MHz) δ: 14.0, 27.5, 29.6, 30.0, 43.3, 43.5, 43.6, 44.2, 61.4, 64.1, 64.2, 82.2, 82.3, 131.8, 
132.3, 139.7, 140.0, 168.8, 169.1, 202.3 ppm. HRESIMS calcd for C12H19O4 ([M+H]+): 
227.1283; found: 227.1280. 
2.5.6.6 2-Phenylsulfonyl (2R/S, 1’R, 4’S)-2-(4’-hydroxy-2’-cyclopenten-1’-yl)-1-
phenyl-ethanone (11f). viscous yellow liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.26-2.2 
(dt, 1H, J=14.0, 4.5 Hz), 2.52 (m, 2H), 3.32 (m, 1H), 4.67-4.80 (m, 1H), 5.05 (dd, 1H, 
J=21.2, 9.5 Hz), 5.45-5.49 (ddd, 1H, J=5.7, 2.5, 1.0 Hz), 5.8-5.9 (dt, 1H, J= 5.7, 2.5 Hz), 
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7.3-7.7 (m, 10H) ppm; 13C-NMR (CDCl3, 62.5 MHz) δ: 38.2, 38.4, 43.5, 44.0, 74.0, 74.3, 
75.7, 128.7, 128.8, 128.9, 129.7, 129.8, 133.7, 134.0, 134.2, 134.6, 136.2, 137.1, 137.17, 
192.9, 193.3 ppm. HRESIMS calcd for C19H19O4S ([M+H]+): 343.1094; found: 
343.1097. 
2.5.6.7 2-Phenylsulfonyl (2R/S, 1’R, 4’S)-2-(4’-hydroxy-4-methyl-2’-cyclopenten-1’-
yl)-1-phenyl-ethanone (11g). viscous yellow liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.36 
(s, 3H), 1.49 (dd, 1H, J=14.0, 5.0 Hz), 2.05 (m, 1H), 2.29 (s, 1H, OH), 3.16-3.39 (m, 1H), 
5.14 (dd, 1H, J=9.7, 2.5 Hz), 5.53, 5.78 (from 2 diastereomers) (2 dd, 1H, J=5.5, 2.5 Hz), 
6.14 (dd, 1H, J=5.2, 1.7 Hz), 7.29-7.86 (m, 10H). 13C-NMR (CDCl3, 62.5 MHz) δ: 27.5, 
29.6, 43.3, 43.5, 43.6, 44.2, 64.1, 64.2, 82.2, 82.3, 127.9, 128.4, 128.5, 128.74, 128.76, 
130.1, 130.4, 131.8, 132.3, 132.6, 133.8, 180.9, 190.4 ppm. HRESIMS calcd for 
C20H21O4S ([M+H]+): 357.1161; found: 357.1158. 
2.5.6.8  2-Phenylsulfonyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-4-phenylethynyl-2’-
cyclopenten-1’-yl)-1-phenyl-ethanone (11h). viscous yellow liquid; 1H-NMR (CDCl3, 
250 MHz) δ: 1.72 (dd, .5H, J=14.2, 4.0 Hz), 2.47 (dd, .5H, J=14.2, 7.2 Hz), 2.73 (m, 2H), 
3.47 (m, 1H), 5.15 (dd, .5H, J=15.0, 10.0 Hz), 5.49 (dd, .5H, J=5.2, 2.0 Hz), 5.84 (dd, 
1H, J=5.2, 1.5 Hz), 5.99 (dd, .5H, J=5.2, 1.0  Hz), 6.47 (dd, .5H, J=5.2, 2.2 Hz), 7.15-
7.86 (m, 15H) ppm; 13C-NMR (CDCl3, 62.5 MHz) δ: 43.5, 44.1, 45.4, 45.7, 73.5, 73.9, 
76.5, 77.4, 84.9, 85.0, 90.2, 90.4, 122.2, 122.3, 128.3, 128.3, 128.5, 128.8, 128.92, 
128.97, 129.7, 129.8, 131.6, 131.7, 133.9, 134.1, 134.2, 135.1, 136.9, 137.04, 137.08, 
137.2, 137.6, 192.8, 193.2 ppm. HRESIMS calcd for C27H23O4S ([M+H]+): 443.1317; 
found: 443.1321. 
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2.5.6.9  Ethyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-2’-cyclopenten-1’-yl)-2-cyanoacetate 
(11i). viscous yellow liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.27 (t, 3H, J=7.7 Hz), 1.5 
(tt, 1H, J=14.2, 4.0 Hz), 2.47 (s, 1H, OH), 2.56 (m, 1H), 3.23 (m, 1H), 3.53 (d, 1H, J=6.7 
Hz), 4.2 (q, 2H, J=7.7 Hz), 4.76 (m, 1H), 5.73-5.83 (dt, 1H, J=5.5, 1.2 Hz), 5.99 (m, 1H) 
ppm; 13C-NMR (CDCl3, 62.5 MHz) δ: 13.9, 36.8, 43.0, 44.5, 44.8, 62.9, 76.0, 76.1, 
116.1, 116.2, 132.0, 132.4, 137.6, 137.7, 165.3, 165.4 ppm. HRESIMS calcd for 
C10H14NO3 ([M+H]+): 196.0974; found: 196.0977. 
2.5.6.10 Phenylsulfonyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-2’-cyclopenten-1’-yl)-2-
acetonitrile (11j). viscous yellow liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.6 (dq, 1H, 
J=14.0, 4.5 Hz), 2.2 (bs, 1H, OH), 2.58 (m, 1H), 3.43 (m, 1H), 3.99 (dd, 1H, J= 27.2, 4.5 
Hz), 4.76 (s, 1H), 5.76-6.02 (m, 2H), 7.55-7.71 (m, 5H) ppm; 13C-NMR (CDCl3, 62.5 
MHz) δ: 37.1, 38.8, 41.6, 42.2, 61.9, 62.1, 75.8, 76.2, 113.5, 113.7, 129.4, 129.8, 131.71, 
131.75, 135.43, 135.47, 136.2, 136.3, 138.32, 138.35 ppm. HRESIMS calcd for 
C13H14NO3S ([M+H]+): 264.0694; found: 264.0688. 
2.5.6.11  2-(4-Hydroxy-cyclopent-2-enyl)-malonic acid dimethyl ester (11k). viscous 
liquid; 1H-NMR (CDCl3, 400 MHz) δ: 1.33 (m, 1H, J=14.0, 4.5 Hz), 2.35 (p, 1H, J=7.6 
Hz), 3.05 (m, 2H), 3.30 (t, 1H, J=7.6 Hz), 3.58 (s, 6H), 4.63 (s, 1H), 5.67(d, 1H, J=5.2 
Hz), 5.74 (s, 1H) ppm; 13C-NMR (CDCl3, 100 MHz) δ: 37.6, 43.8, 52.6, 56.4, 76.3, 
134.1, 135.9, 169.0, 169.2 ppm. HRESIMS calcd for C10H15O5 ([M+H]+): 215.0919; 
found: 215.0922. 
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2.5.7 General procedure for preparation of compounds 12a-k (Scheme 2-11).  
To a solution of 11a (100 mg, 0.465   mmol) in dry THF (10 ml) at room temperature 
was added acetic anhydride (51 mg, 0.5 mmol), and catalytic amount of DMAP. The 
reaction was allowed to stir for 3 hours and then concentrated. The residue was taken up 
in ethyl acetate (40 ml) and extracted twice with saturated sodium bicarbonate solution 
(20 ml), followed by brine (10 ml). The organic layer was dried over sodium sulfate and 
the resulting product 12a (110 mg, yield= 92%) was obtained as light yellow liquid. 
2.5.7.1 Ethyl (2R/S, 1’R, 4’S)-2-(4’-Acetoxy-2’-cyclopenten-1’-yl)-2-nitroacetate 
(12a). viscous liquid; 1H-NMR (CDCl3, 400 MHz) δ: 1.25 (t, 3H, J=7.2 Hz), 1.54-1.69 
(m, 1H), 1.97 (s, 3H), 2.53-2.61 (m, 1H), 3.51 (bs, 1H), 4.25 (q, 2H, J=7.2 Hz), 4.96 (t, 
1H, J=8.8 Hz), 5.58 (bs, 1H), 5.89-5.98 (m, 2H) ppm; 13C-NMR (CDCl3, 100 MHz) δ: 
14.0, 21.3, 33.2, 33.7, 44.7, 44.8, 63.3, 78.1, 78.4, 91.1, 91.3, 133.8, 134.0, 134.3, 134.7, 
163.5, 170.8 ppm. HRESIMS calcd for C11H16NO6 ([M+H]+): 258.0977; found: 
258.0978. 
2.5.7.2 Ethyl (2R/S, 1’R, 4’S)-2-(4’-Acetoxy-4-methyl-2’-cyclopenten-1’-yl)-2-
nitroacetate (12b). viscous liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.21 (t, 3H, J=7.0 
Hz), 1.5(s, 3H), 1.91(s, 3H), 2.02 (dt, 1H, J=14.2, 4.5 Hz), 2.21 (m, 1H), 3.52 (m, 1H), 
4.2 (q, 2H, J=7.0 Hz), 4.99 (dd, 1H, J=9.2, 2.0 Hz), 5.71 (dd, .5H, J=5.5, 2.5 Hz), 5.76 
(dd, .5H, J=5.7, 2.5 Hz), 6.13 (dt, 1H, J=5.5, 2.0 Hz) ppm; 13C-NMR (CDCl3, 62.5 MHz) 
δ: 13.9, 22.0, 24.5, 24.6, 40.3, 41.0, 44.5, 45.0, 63.1, 90.1, 90.4, 90.8, 131.2, 131.6, 138.6, 
138.8, 163.5, 170.4 ppm. HRESIMS calcd for C12H18NO6 ([M+H]+): 272.1134; found: 
272.1131. 
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2.5.7.3 Ethyl (2R/S,1’R,4’S)-2-(4’-Acetoxy-4-phenylethynyl-2’-cyclopenten-1’-yl)-2-
nitroacetate (12c). viscous liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.14 (dt, 3H, J=7.2, 
2.0 Hz), 1.98(s, 3H), 2.24 (m, 1H), 2.83 (m, 1H), 3.68 (m, 1H), 4.18 (dq, 2H, J=7.0, 1.5 
Hz), 4.97 (dd, 1H, J=9.2, 5.5 Hz), 5.9 (m, 1H), 6.27 (dt, 1H, J=5.5, 2.0 Hz), 7.19-7.35(m, 
5H) ppm; 13C-NMR (CDCl3, 62.5 MHz) δ: 13.9, 21.6, 41.9, 42.4, 44.4, 44.8, 63.2, 63.3, 
81.9, 82.1, 86.3, 86.7, 90.5, 122.0, 128.2, 128.7, 131.8, 133.2, 133.7, 135.9, 136.2, 163.3, 
169.1 ppm. HRESIMS calcd for C19H20NO6 ([M+H]+): 358.1291; found: 358.1294. 
2.7.7.4 Ethyl (2R/S,1’R,4’S)-2-(4’-Acetoxy-2’-cyclopenten-1’-yl)-3-oxobutanoate 
(12d). viscous liquid; 1H-NMR (CDCl3, 250 MHz ) δ: 1.12 (t, 3H, J=7.2 Hz), 1.4 (t, 1H), 
1.96 (s, 3H), 2.18 (s, 3H), 2.9 (p, 1H, J=7.5 Hz), 3.33 (m, 2H),  4.03 (q, 2H, J=7.2 Hz), 
5.5 (m, 1H), 5.81-5.82 (m, 2H) ppm;  13C-NMR (CDCl3, 62.5 MHz) δ: 14.1, 21.2, 29.4, 
29.7, 34.6, 34.7, 42.9, 43.0, 61.5, 61.6, 65.2, 65.3, 78.8, 78.9, 131.2, 131.3, 137.5, 137.6, 
168.3, 170.7, 201.0, 201.9 ppm. HRESIMS calcd for C13H19O5 ([M+H]+): 255.1233; 
found: 255.1231. 
2.5.7.5 2-Phenylsulfonyl (2R/S,1’R,4’S)-2-(4’-Acetoxy-2’-cyclopenten-1’-yl)-1-
phenyl-ethanone (12f). viscous liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.85-1.97 (s, 3H), 
2.2-2.6 (m, 2H), 3.2-3.4 (m, 1H), 4.50 (dd, 1H, J=27.2, 10.2 Hz), 5.4-5.6 (m, 1H), 5.7-5.9 
(dt, 1H, J=5.5, 2.2 Hz), 6.5 (m, 1H),7.34-7.78 (m, 10H) ppm; 13C-NMR (CDCl3, 62.5 
MHz) δ: 21.1, 21.2, 34.8, 35.6, 43.1, 43.8, 60.4, 65.1, 74.0, 74.2, 76.6, 128.8, 128.83, 
128.89, 128.97, 129.92, 132.5, 134.1, 134.3, 134.4, 135.9, 136.6, 136.9, 137.1, 137.6, 
170.4, 170.6, 192.5, 192.9 ppm. HRESIMS calcd for C21H21O5S ([M+H]+): 385.1100; 
found: 385.1103. 
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2.5.7.6 Ethyl (2R/S,1’R,4’S)-2-(4’-Acetoxy-2’-cyclopenten-1’-yl)-2-cyanoacetate 
(12i). viscous liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.26 (t, 3H, J=7.0 Hz), 1.65 (m, 
1H), 1.9 (s, 3H), 2.57 (p, 1H, J=6.5 Hz), 3.25 (m, 1H), 3.4-3.58 (2 doublets, (0.5x2H), 
J=6.5 Hz), 4.23 (q, 2H, J=7.0 Hz), 5.59 (m, 1H), 5.89-5.99 (m, 2H) ppm; 13C-NMR 
(CDCl3, 62.5 MHz) δ: 14.0, 21.1, 33.8, 34.5, 42.7, 44.3, 62.9, 78.2, 78.3, 115.1, 133.5, 
134.73, 165.1, 170.7, 170.8 ppm. HRESIMS calcd for C12H16NO4 ([M+H]+): 238.1079; 
found: 238.1080. 
2.5.7.7 Phenylsulfonyl (2R/S,1’R,4’S)-2-( 4’-Acetoxy-2’-cyclopenten-1’-yl)-2-
acetonitrile (12j). viscous liquid; 1H-NMR (CDCl3, 250 MHz) δ:  1.76-1.9 (m, 1H), 2.0 
(s, 3H), 2.67 (m, 1H), 3.41 (m, 1H), 3.87-4.05 (2 doublets, 1H, J=6.25, 5.0 Hz), 5.55 (m, 
1H), 5.91-6.05 (m, 2H), 7.56-7.98 (m, 5H) ppm; 13C-NMR (CDCl3, 62.5 MHz) δ: 20.1, 
32.8, 34.5, 40.5, 40.6, 60.5, 60.8, 76.9, 77.0, 111.8, 128.4, 128.5, 132.8, 133.0, 133.2, 
133.5, 134.4, 134.9, 135.1, 169.7, 169.6 ppm. HRESIMS calcd for C15H16NO4S 
([M+H]+): 306.0800; found: 306.0814. 
2.5.7.8  2-(4-Acetoxy-cyclopent-2-enyl)-malonic acid dimethyl ester (12k). viscous 
liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.56 (dt, 1H, J=14.0, 4.5 Hz), 2.05 (s, 3H), 2.54 
(dt, 1H, J=14.0, 8.0 Hz), 3.33 (m, 2H), 3.77 (s, 6H), 5.6 (m, 1H), 5.88 (dt, 1H, J=5.7, 2.0 
Hz), 6.00 (dt, 1H, J= 5.7, 2.0 Hz) ppm; 13C-NMR (CDCl3,100 MHz) δ: 21.0, 34.5, 43.4, 
52.3, 52.4, 56.7, 78.7, 131.3, 137.2, 168.4(splits into 2), 170.6 ppm. HRESIMS calcd for 
C12H17O6 ([M+H]+): 257.1025; found: 257.1029. 
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2.5.8 General procedure for preparation of compounds 13a-h, 13k (Scheme 2-12) . 
To a solution of 12a (70 mg, 0.272 mmol) in dry THF (10 ml) at room temperature was 
added potassium carbonate (37.6 mg, 0.272 mmol), Pd(PPh3)4 (15 mg, 0.013 mmol).  The 
reaction was allowed to stir for 12 h at 60 0C and then vacuum filtered over celite with 
subsequent concentration of the filtrate. The product was purified by wet column 
chromatography using ethyl acetate: hexane (1:2) to afford 13a using column 
chromatography as a yellow viscous liquid (45 mg, yield =85%). 
2.5.8.1 (1S,5S)-3-Aza-4-(ethoxycarbonyl)-2-oxabicyclo[3.3.0]oct-3,7-diene-3-oxide 
(13a) : viscous liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.29 (t, 3H, J=5.8 Hz), 2.63-2.78 
(m, 2H), 4.17-4.28 (m, 3H, CH2+H-4),  5.56-5.62 (m, 1H), 5.75-5.78 (m, 1H), 6.09-6.12 
(m, 1H) ppm; 13C-NMR (CDCl3, 62.5 MHz) δ: 14.0, 38.2, 44.6, 61.4, 84.2, 111.3, 127.7, 
137.0, 158.9 ppm; HRESIMS calcd for C9H12NO4 ([M+H]+): 198.0766; found: 198.0762. 
2.5.8.2 (1S,5S)-3-Aza-4-(ethoxycarbonyl)-7-methyl-2-oxabicyclo[3.3.0]oct-3,7-diene-
3-oxide (13b) : viscous liquid; 1H-NMR (CDCl3, 400 MHz) δ: 1.31 (t, 3H, J=6.8 Hz), 
1.81 (s, 3H), 2.56 (d, 1H, J=17.6 Hz), 2.73 (dd, 1H, J=17.2, 8.0 Hz), 4.27 (m, 3H), 5.45 
(s, 1H), 5.56 (d, 1H, J=8.8 Hz) ppm; 13C-NMR (CDCl3, 100 MHz) δ: 14.4, 16.6, 42.6, 
45.6, 61.8, 85.1, 112.1, 122.6, 148.5, 160.0 ppm; HRESIMS calcd for C10H14NO4 
([M+H]+): 212.0923; found: 212.0918.    
2.5.8.3  (1S,5S)-3-Aza-4-(ethoxycarbonyl)-7-phenylethynyl-2-oxabicyclo[3.3.0]oct-
3,7-diene-3-oxide (13c) : white solid: mp=72-74 °C; 1H-NMR (CDCl3, 250 MHz) δ: 
1.26 (t, 3H, J=7.0 Hz), 2.81-3.04 (m, 2H), 4.27 (m,3H), 5.66 (d, 1H, J=9.0 Hz), 6.01 (d, 
1H, J=2.0 Hz), 7.25-7.40 (m, 5H, Ph) ppm; 13C-NMR (CDCl3, 62.5 MHz) δ: 14.2, 41.8, 
    102 
 
45.0, 61.8, 83.7, 83.9, 95.5, 110.9, 122.1, 128.4, 129.0, 131.0, 131.4, 131.7, 159.0 ppm; 
MS(ESI) m/z= 298.1[M+H]+. HRESIMS calcd for C17H16NO4 ([M+H]+): 298.1079; 
found: 298.1072. 
2.5.8.4  (1S,5S)-4-(ethoxycarbonyl)-3-methyl-2-oxabicyclo[3.3.0]oct-3,7-diene(13d): 
viscous liquid; 1H-NMR (CDCl3, 250 MHz) δ:  1.20 (t, 3H, J=7.2 Hz), 2.09 (s, 3H), 2.3 
(m, 1H), 2.6 (m, 1H), 3.7 (t, 1H, J=8.4 Hz), 4.10 (q, 2H, J=6.8 Hz), 5.53 (d, 1H, J=9.2 
Hz), 5.7 (bs, 1H), 5.9 (bs, 1H) ppm; 13C-NMR (CDCl3, 62.5 MHz) δ:  14.5, 14.6, 40.1, 
43.9, 59.5, 91.9, 106.6, 128.5, 137.0, 166.4, 167.1 ppm; HRESIMS calcd for C11H15O3 
([M+H]+): 195.1021; found: 195.1018. 
2.5.8.5 (1S,5S)-4-(ethoxycarbonyl)-3,7-dimethyl-2-oxabicyclo[3.3.0]oct-3,7-diene 
(13e): viscous liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.21 (t, 3H, J=7.0 Hz), 1.71 (m, 
3H), 2.09 (d, 3H,  J=1.2 Hz), 2.27-2.34 (m, 1H), 2.51-2.55 (m, 1H), 3.70 (dt, 1H, J=7.7, 
1.0 Hz), 4.1 (m, 2H), 5.34 (m, 1H), 5.46 (d, 1H, J=8.8 Hz) ppm; 13C-NMR (CDCl3, 62.5 
MHz) δ: 14.42, 14.48, 16.5, 44.1, 44.6, 59.2, 92.3, 106.5, 123.0, 147.8, 166.3, 167.2 ppm; 
HRESIMS calcd for C12H17O3 ([M+H]+): 209.1178; found: 209.1181. 
2.5.8.6 (1S,5S) -3-phenyl-4-(phenylsulfonyl)-2-oxabicyclo[3.3.0]oct-3,7-diene (13f): 
viscous liquid; 1H-NMR (CDCl3, 250 MHz) δ: 2.73 (dt, 1H, J=7.2, 2.2 Hz), 2.85 (p, 1H, 
J=2.2 Hz), 3.82 (dt, 1H, J=7.7, 5.2 Hz), 5.64 (doublet of p, 1H, J=7.2, 1.2 Hz), 5.74 (dq, 
1H, J=5.7, 2.2 Hz), 6.06 (dt, 1H, J=5.7, 1.2 Hz), 7.18-7.6 (m, 10H) ppm; 13C-NMR 
(CDCl3, 62.5 MHz) δ: 40.1, 46.4, 91.9, 114.4, 127.0, 127.4, 127.9, 128.7, 128.8, 129.4, 
130.7, 132.6, 137.2, 142.2, 163.9, 192.3 ppm; HRESIMS calcd for C19H17O3S ([M+H]+): 
325.0898; found: 325.0892. 
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2.5.8.7 (1S,5S)-7-methyl-3-phenyl-4-(phenylsulfonyl)-2-oxabicyclo[3.3.0]oct-3,7-
diene (13g): viscous liquid; 1H-NMR (CDCl3, 250 MHz) δ: 1.76 (s 3H), 2.58-2.90 (m, 
2H), 3.84 (dt, 1H, J=7.7, 2.2 Hz), 5.41 (t, 1H, J=2.0 Hz), 5.62 (d, 1H, J=9.0 Hz), 7.19-
7.60 (m, 10H, PhSO2+COPh) ppm; 13C-NMR (CDCl3, 62.5 MHz) δ: 15.5, 43.2, 46.2, 
91.6, 113.3, 121.5, 125.9, 126.6, 127.7, 128.0, 128.4, 129.6, 131.5, 141.3, 147.3, 163.1 
ppm; HRESIMS calcd for C20H19O3S ([M+H]+): 339.1055; found: 339.1050. 
 2.5.8.8 (1S,5S)-3-phenyl-7-phenylethynyl-4-(phenylsulfonyl)-2-oxabicyclo[3.3.0]oct-
3,7-diene (13h): viscous liquid; 1H-NMR (CDCl3, 250 MHz ) δ: 2.89-3.17 (m, 2H), 3.94 
(dt, 1H, J=8.2, 2.2 Hz), 5.70 (d, 1H, J=9.0 Hz), 6.00 (d, 1H, J=1.7 Hz), 7.26-7.61 (m, 
15H); 13C-NMR (CDCl3, 62.5 MHz) δ: 43.7, 46.6, 84.5, 91.4, 94.8, 114.3, 122.5, 127.0, 
127.7, 128.4, 128.6, 128.8, 129.4, 130.8, 131.0, 131.7, 131.9, 132.0, 132.7, 142.1, 164.2 
ppm; HRESIMS calcd for C27H21O3S ([M+H]+): 425.1211; found: 425.1203. 
2.5.8.9  2-Cyclopent-2-enylidene-malonic acid dimethyl ester (13k): viscous liquid;  
1H-NMR (CDCl3, 250 MHz) δ: 2.58 (m, 2H), 2.90 (m,2H), 3.70 (s, 3H), 3.73 (s, 3H), 
6.76 (s, 2H) ppm; 13C-NMR (CDCl3, 62.5 MHz) δ: 31.0, 32.9, 51.8, 52.0, 115.3, 132.4, 
152.4, 166.2, 166.6, 168.3 ppm; HRESIMS calcd for C10H13O4 ([M+H]+): 197.0814; 
found: 197.0812. 
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Chapter  3 
A NEW ROUTE TO γ-CARBONYL COMPOUNDS VIA ONE POT Pd(0) 
CATALYZED ISOMERIZATION-ALKYLATION 
3.1 General introduction 
 The last few decades of 20th century have witnessed the emergence of transition 
metal catalysis as an indispensable tool for carbon-carbon and carbon-heteroatom bond 
formation. Transition metal catalysts offer newer ways to form carbon–carbon bonds 
between or within functionalized and sensitive substrates which has not only helped in 
total synthesis of complex natural products but has also benefited fields such as process 
chemistry, as well as chemical biology and nanotechnology.1 Among all organometallic 
catalysts , palladium based catalysis has been extensively studied and applied in organic 
syntheses.2 The nucleophiles used in Pd catalyzed alkylation includes C-nucleophiles 
such as malonate esters, acetoacetates, N-nucleophiles such as primary and secondary 
amines, amides, azides and O-nucleophiles such as alcohols and phenols. Some of these 
nucleophiles such as nitro esters and alkanes exhibit ambident nature and can result in C 
as well as O alkylation. The ratio of C versus O alkylation can be easily controlled by 
changing the reaction conditions such as nature of ligand, solvent and alkyl groups on the 
substrate.  
                     Importantly, despite their utility in synthetic organic chemistry, 
nitroalkanes have received little attention in Pd catalyzed allylic alkylations as a 
nucleophile source. For example, nitro group can be easily converted to a ketone (Nef 
reaction), reduced to amine or transformed into carboxyl group, imines and  
hydroxylamines.3,4 Furthermore presence of some other functional groups such as 
carbonyl enhances the synthetic utility of  the nitro compounds. For example the γ-nitro 
ketones have been extensively used in synthesis of 2,3-dihydro-1H-
cyclopenta[b]quinolin-9-ylamine related compounds which act as fructose-1,6-
bisphosphatase inhibitors and prazosin analogs which act as α1-adrenoreceptors.5 The 
scarce utilization of nitroalkane in Pd (0) catalyzed allylic alkylations can presumably be 
attributed to their ambident nature (C vs O alkylation), low reactivity of bulky 
nitroalkanes and formation of side products.6  
OCO2RRO2CO Pd(0), PR3 RO2CO
NO2
R
R
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Fig 3-1  Pd catalyzed allylic alkylation of nitroalkanes 
 
Pd catalyzed alkylation of nitroalkanes has been reported on different  allylic  substrates 
as carbonates, esters and allylic alcohols resulting in a simple γ,δ- unsaturated nitro 
alkane (Fig 3-1). The survey of literature7 reveals that the new carbon-carbon is formed 
invariably at the allylic carbon of the electrophile, i.e., γ-unsaturated nitro compounds are 
formed (Fig 3-1). Recently, Shibasaki et al7f conducted allylic alkylation of various 20 
nitroalkanes using Pd(0) catalysis giving β,γ-unsaturated nitro compounds. Trost et al7b 
has also Pd catalyzed asymmetric alkylation of nitroalkanes using cyclic esters. Deardorff 
et al7e has shown that in compounds containing both allylic acetate and carbonate, only 
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the carbonate undergoes substitution giving allylic acetate as the product. Based on all 
these reports and the need of more allylic alkylations involving nitroalkane, Pd catalyzed 
alkylation of acetates using various 10, 20 , 30 nitroalkanes was conducted. Instead of the 
expected alkylated products containing nitroalkane moiety, saturated γ -nitro carbonyl 
compounds were obtained. This intriguing result prompted us to further investigate this 
reaction for not only mechanistic details but also for substrate generality. In this chapter 
the studies conducted on this new Pd catalyzed reaction of various nitroalkanes are 
presented. This Pd catalyzed alkylation of nitroalkanes is believed to involve an 
isomerization-alkylation and is the first report of syntheses of γ -nitro carbonyl 
compounds using a Pd catalyzed allylic alkylation. 
3.2 Importance of nitro compounds 
3.2.1 Nitro group in synthetic organic chemistry 
The nitro group is one of the most versatile functional group as it can be transformed into 
various other synthetically important functional groups, viz.; amines, carboxylic acid, 
imines, oximes  and aldehydes. Historically, aromatic nitro compounds have been 
important precursors to dyes and explosives.8 
 Fig 3-2  Various transformations of nitro group 
Nitro compounds provide important intermediates for synthesis of complex 
molecules and natural products. The importance of nitro compounds is further enhanced 
by their easy availability and ease of transformation to other functional groups (Figure 3-
2). Nitro group is also involved in a large number of named reactions such as Nef 
reaction which involves conversion of nitro group to an aldehyde and ketone. Henry 
reaction or nitro-aldol reaction is kknown for over 100 years is an extremely important 
carbon-carbon bond formation process and has been extensively used in natural product 
syntheses.3,4 
3.2.2 Nitro group in natural products  
Nitro group is also found in a number of important bioactive peptides and natural 
products (fig 3-3).9 For example Psychrophilin A9a, a fungal metabolite isolated from the 
psychrotolerant  fungus  Penicillium ribeu and Nitropeptin, a dipeptide antibiotic isolated 
from the culture broth of Streptomyces xanthochromogenus 6257-MC1 both possess nitro 
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group.9b Similarly, another nitro containing natural product, Kijanimicin is a 
spirotetronate antibiotic isolated from Actinomadura kijaniata, a soil actinomycete. It has 
a broad spectrum of antimicrobial activity against gram-positive bacteria, anaerobes, and 
the malaria parasite Plasmodium falciparum, and it has also shown antitumor  activity.9c 
The structure of kijanimicin consists of a pentacyclic core, which is equipped with four 
L-digitoxose units and a rare nitrosugar, 2,3,4,6-tetradeoxy-4-(methylcarbamyl)-3-C-
methyl-3-nitro-D-xylo-hexopyranose, commonly known as D-kijanose.9f More than 60 
kijanimicin-related spirotetronate-type compounds have been reported.9e-g 
 
 
 
 
 
 
 
 
Psychrophilin A 
 
 
 
                                      Kijanimicin 
N
O NO2
N
HN
O
O
  
       Tetrocarcin A 
 
Fig 3-3 Peptides and natural products containing NO2 group 
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Nitroalkanes such as nitromethane, nitroethane, 1-nitropropane and 2-nitropropane act as 
versatile and inexpensive feedstocks. A large number of pharmaceutical products such as 
ranitidine, methyldopa and ethambutol are based on nitro-chemistry( fig 3-4).10 
 
Fig 3-4  Important drugs containing NO2 group 
Apart from being an important part of common drugs (fig 3-4) nitro group also offer 
valuable synthons and intermediates for synthesis of various drugs and bioactive 
compounds. Scheme 3-1 shows how nitro chemistry plays an important role in synthesis 
of various drugs and bioactive compounds using reactions such as Michael addition, 
Knoevenagel reaction and Henry reaction. 
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 Scheme 3-1 Use of nitroalkanes in syntheses of bioactive compounds and important drug 
molecules. 
 3.2.3 Palladium catalyzed reactions of nitroalkanes  
Pd catalyzed allylic alkylation, also known as Tsuji-Trost reaction has been extensively 
used in organic syntheses.2  A large number of nucleophiles, including active methylene 
and methine compounds, and various heteroatom (N, O, S) nucleophiles have been 
employed in this reaction. In case of N nucleophiles, amines have been extensively 
utilized as the alkylation proceeds smoothly in the presence of various ligands. 
Interestingly, the other N-nucleophile, nitroalkanes have received little attention in Pd 
catalyzed allylic alkylations as a nucleophile source even though nitro group can be 
easily converted to other functional groups.4  Wade et al studied the alkylation of various 
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nitro compounds including primary and secondary nitroalkanes and observed the 
formation of both C as well as O alkylation products.7a The survey of literature 4 reveals 
that the new carbon-carbon bond is formed invariably at the allylic carbon of the 
electrophile, i.e., unsaturated nitro compounds are formed (Scheme 3-2).  The scarce 
utilization of nitroalkane in Pd (0) catalyzed allylic alkylations can presumably be 
attributed to their ambident nature (C vs O alkylation), low reactivity of bulky 
nitroalkanes and formation of side products.5  
 3.2.3.1 Previous work on Pd catalyzed alkylation of nitroalkanes 
Aleksandrowicz et al 11 conducted a detailed study on Pd catalyzed alkylation of 
nitro alkanes. 2-nitropropane was used as the model compound to obtain the optimal 
alkylation conditions. The reaction was carried out using 
dichlorobis(triphenylphosphine)palladium ,  PPh3 , 2-nitropropane in MeOH with 
MeONa as the  base. Aleksandrowicz et al also obtained higher yields of the alkylated 
products  in protic solvents as MeOH rather than in  THF or DMSO due to low solubility 
of  nitroalkane salts in aprotic solvents (scheme 3-2). 
 
Scheme 3-2  Pd catalyzed alkylation of nitroalkanes using allylic substrates 
Wade et al7a also studied Pd catalyzed C-alkylation of cinnamyl acetate and 2-butenyl 
acetate using monoanions of primary nitroalkanes. Interestingly it was also pointed out 
that these reactions do not require extensive dry conditions and in fact water is necessary 
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in the reaction of nitroalkanes with allylic substrates.Also the authors reported the 
formation of allylic rearrangement products(scheme 3-3) which can be explained on the 
basis of competitive attack on the two sites of π−allyl complex. 
 
Scheme 3-3  Pd catalyzed alkylation of nitroalkanes giving isomerization products 
Recently, Shibasaki et al 7f reported the allylic alkylation of secondary nitroalkanes and 
observed that: 
1. The nucleophiles were limited to nitromethane, other primary nitroalkanes and  2-
nitropropane. However, bulkier nitroalkanes are not that reactive, i.e.  2-
nitrobutane and 2-nitro pentane are less reactive than 2-nitropropane.      
2. A large amount of base was required to generate the carbanionand when catalytic 
or no external base was used, a large amount of Pd catalyst or high temperature is 
required.                                
3. Nitroalkanes did suffer from competition between C versus O alkylation. 
4. Enantioinduction at α position of the NO2 group was also tedious and only few 
reports of this type of enantioinduction are known. 
5.  Shibasaki et al also optimized the reaction by examining various Pd ligands and 
catalysts.7f Also the Pd catalyzed allylic alkylation of nitroalkanes was highly 
dependent on the nature of the solvent and base used. For example, the reaction 
did not proceed in polar protic solvents as MeOH, tBuOH. Polar protic solvent 
solvents such as DMF and DMSO did favor the reaction.  
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6.  Several bases were also screened for Pd catalyzed allylic alkylation of 
nitroalkanes using DMSO as the solvent. As the basicity increased, the yield of 
the alkylation products also increased (table 3-1).   
Table 3-1 Optimization of reaction conditions for Pd catalyzed alkylation of nitroalkanes 
Entry Base Solvent Yielda (%) 
1 DABCO Toluene 6 
2 DABCO CH2Cl2 4 
3 DABCO THF 8 
4 DABCO DMF 35 
5 DABCO DMSO 50 
6 DABCO t-BuOH 0 
7 DABCO MeOH/CH2Cl2 0 
8 None DMSO 8 
9 La(Oi-Pr)3 DMSO/THF(1:1) 14 
10 i-Pr2NEt DMSO 15 
11 TMG DMSO 75 
12 TBD DMSO 71 
13 DBU DMSO 86 
                                              a NMR analysis 
The proposed catalytic cycle by Shibasaki et al is shown in scheme 3-4. Initially formed 
Pd-complex II undergoes decarboxylation of the allylic carbonate to generate complex 
III which reacts with the nitronate generated by deprotonation using an external base. 
The last step involves reductive elimination of palladium (0) from complex  IV to 
generate the product V. Also, the protonated form of the base (DBU in the catalytic 
cycle) is neutralized by the tert-butoxide ion  to regenerate the base and the 
corresponding alcohol. 
 
Scheme 3-4  Mechanism for Pd catalyzed alkylation of nitroalkanes.  
 Diastereo- and enantioselective allylation of substituted nitroalkanes has also been 
reported by Trost  et al.  Allylic carbonate 2a was treated with nitroethane, chiral ligand 
3, Pd(0) complex 4 and tetra-n-butylammonium chloride in CH2Cl2 resulted in 
monoalkylated product (83% yield, 98%brsm) in 22%ee after 48 hours. 
 
Scheme 3-5  Asymmetric alkylation of nitroalkanes via Pd catalysis 
The catalyst loading had a dramatic influence on the ee, i.e lowering catalyst loading 
from 0.5mol% to 0.25mol% resulted in an increase in ee from 86 to 91% for compound 
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5c. Use of nitroethane as the nucleophile source resulted in more interesting results (table 
3-2, scheme 3-6).When cesium carbonate was used as base in DMSO the product 6a was 
obtained as 1:1 mixture of diatereomers in 45% ee. Changing the base to O,N-
bis(trimethylsilyl)-acetamide (BSA) in CH2Cl2 in the absence or presence of tetra-n-
butylammonium chloride resulted in good diatereoselectivity but moderate ee’s (table 3-
2, entry 2,3). As discussed earlier lowering the catalyst loading resulted in an increase in 
both the diatereoselectivity and enantioselectivity. Also changing the allylic carbonate to 
2b gave the resultant product 6b in 55% yield (% brsm) in 5:1 diastereomeric ratio, 
wherein the major diasteremer was obtained in 96% ee. 
 
Scheme 3-6 Pd catalyzed asymmetric alkylation of nitroethane  
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Table 3-2 Asymmetric alkylation of nitroalkanes via Pd catalysis 
Entrya mol% 3 mol% 4 Time(h) Isolated 
yield 
drf %eef,g 
1d 6 2.0 16 84 1:1 45 
2c 6 2.0 6 99 5:1 36 
3 6 2.0 6 96 6:1 53 
4 1.5 0.5 24 95 10:1 92 
5b 1.5 0.5 36 85(98)e 8:1 97 
6 1.5 0.5 72 65(99) e 11:1 96 
7 0.75 0.25 48 71(99) e 11:1 97 
a All reaction were carried out in CH2Cl2 with 0.5M allyl substrate and 5-8 equivalents 
of nitromethane and (C4H9)4NCl as an additive and BSA as base b1.2 eq of 
nitromethane was used. c No additive was used. d Cs2CO3 was used as the base in 
DMSO. e Yields based on recovered starting material. f Base on chiral GC analyses. g 
enantiomeric excess was determined for the major diastereomer except for entry 1, 
where it represents the ee for both isomers. 
 
Deardorff et al 7e reported a two step conversion of allylic alcohols into homoallylic nitro 
compounds via a Pd(0) catalyzed alkylation of ethyl carbonates (scheme 3-7). 
 
Scheme 3-7 Pd catalyzed alkylation of allylic acetates bearing an allylic carbonate 
 This reaction was effective for both primary and secondary allylic substrates and 
tertiary substrates were not studied. This allylation provided the corresponding nitro 
compounds in high regio- and stereoselectivities. In case of palladium catalyzed 
alkylation it is usually observed that allylic carbonates react at a faster rate than allylic 
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acetates. Hence when the allylic acetoxy carbonate (table 3-3, entry 7) was subjected to 
allylic alkylation using nitromethane, only the allylic carbonate reacted with the 
nucleophile.  
Table 3-3  Pd catalyzed alkylation of allylic acetates bearing an allylic carbonate 
entry Alcohola T (oC)b Product % yieldc 
 
1 
 
rt 
 
62d 
2 
 
rt 
 
74 
3 
 
rt 
 
71 
4  
65 
 
70e 
5 
 
65 
 
71f 
 
6 
 
50 
 
60 
7 0 
 
63 
a Alcohols were converted to corresponding carbonates using pyridine and ethylchlorooformate at 00C.b 
fragmentation temperature. c isolated yields. d E/Z ratio 10:1. e ratio of regioisomers 3:1. f ratio of 
regioisomers 3.4:1 
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The authors proposed palladium induced ionization-fragmentation sequence for  Pd(0) 
catalyzed nitromethylation (scheme 3-8) via simultaneous generation of transient Pd 
complex and alkoxide base in equal proportions. Evolution of CO2 after addition of the 
Pd(0) catalyst indicated towards an initial decarboxylation step which also prevented any 
reversibility of the Pd complex back to the allylic carbonate. This decarboxylation step 
also generated ethoxide ion deprotonates nitromethane (pKa = 10.2), generating the 
stabilized nitronate ion. 
 
Scheme 3-8 Proposed mechanism for Pd catalyzed alkylation of allylic acetates bearing 
an allylic carbonate 
The stereochemistry of the major products obtained was independent of the 
stereochemistry of the starting allylic carbonates. All the allylic carbonates employed in 
this study resulted in the formation of E and Z products in a diastereomeric ratio of 10:1. 
Since, nucleophilic additions to the Pd-allyl systems results in Z-product in case of Z-
substrates and E-product in case of E-substrates, the formation of the E isomer from both 
E and Z substrates suggests an isomerization to be involved.  The authors proposed a 
    124 
 
π−σ−π rearrangement between the syn and anti complexes to occur at a faster rate than 
attack by the nitronate ion (scheme 3-9).7e 
 
Scheme 3-9 Isomerization of π-allyl complexes in a Pd catalyzed alkylation 
Also the regiochemical outcome of the reaction was also influenced by the steric 
parameters of the π-allyl intermediate. In case of substrates 6 and 7 (table 3-3) the allylic 
polar heteratoms greatly influence the regiochemistry of the product by directing the 
attack of the incoming nucleophile towards less sterically hindered distal end of the π-
allyl system. In case of substrates lacking a directing heteratom (entry 2,3 table 3-3) a 
mixture of both regioisomers were obtained. 
3.2.3.2  Synthesis of bioactive compounds via Pd catalyzed alkylation of nitroalkanes 
Palladium catalyzed asymmetric allylic alkylation has also been extended to synthesize 
new bioactive molecules. Hamada et al utilized Pd catalyzed allylic alkylation of 
nitromethane to synthesize (R)- preclamol and (R)- Baclofen (Fig 3-5).12-14 
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 Fig 3-5  Structure of R-isomers of Baclofen and Preclamol HCl 
1,3-diphenyl ethyl propyl carbonates (scheme 3-10) were chosen as the substrates for  
asymmetric allylic alkylation and were treated with nitromethane (3 equiv) in the 
presence of [(η3-C3H5PdCl)2](2.5mol%), (S, Rp)-Ph-DIAPHOX (10 mol%), BSA (3 
equiv) in CH2Cl2 at room temperature for 24 hours. The authors made some key 
observations while optimizing the reaction conditions like even though the chemical yield 
was low when nitromethane was used as solvent but it improved the enantioselectivity of 
the reaction. Also increasing the reaction time resulted in low yields and 
enantioselectivities. It has also been reported that silyl nitronates can be generated in the 
presence of BSA and an amine.  
 
Fig 3-6  Chiral ligand used in synthesis of R-isomers of Baclofen and Preclamol HCl 
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Scheme 3-10  Synthesis of Baclofen and Preclamol HCl via Pd catalyzed alkylation  
3.2.3.3  Miscellaneous reactions involving Pd catalyzed alkylation of nitroalkanes 
Apart from utilization of Pd catalyzed alkylation of nitroalkanes in synthesis of new 
bioactive and NO2 containing compounds, this method is also utilized for other reactions 
as oxidation of allylic esters. Recently Trost et al utilized nitronates as nucleophilic 
oxidants for allylic carbonates and esters to the corresponding enones (scheme 3-11, table 
3-4).15 A bulky nitroalkane was chosen  to overcome the problem of C-alkylation in case 
of nitroalkane. Nitroalkane A was deprotonated using KHMDS which was generated in 
situ using KH and freshly distilled HMDS. 
 
Scheme 3-11: Pd catalyzed oxidation of allylic esters and carbonates 
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Table 3-4  Pd catalyzed oxidation of allylic esters and carbonates 
Entry Substrate Time Product Yield 
(brsm) 
1 
O
O
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NO2
NO2
SPh
(±)
 
 
 
<1 h O
SPh
 
96% 
2 
O
O
NO2
NO2
N
O
(±)
 
 
 
1h 
O
N
O
 
92% 
3 
O
O
NO2
NO2
OH
(±)
 
 
 
2 h O
OH
 
82% 
4 
O
O
NO2
NO2
O
O
NO2O2N
(±)
 
 
<1 h 
O
O
O
NO2O2N
 
88% 
5 
O
O
NO2
NO2
OTBS
(±)
 
 
 
2 h O
OTBS
 
95% 
6a OBzBzO
 
0.6h OBzO
 
61%(73%)b 
7 
OBz
BzO
 
 
12 h O
BzO
 
45%(95%) c 
8a BzO
OBz 
 
2 h 
BzO
O 
75% b 
a Absolute stereochemistry confirmed by comparing the optical rotation of known compound. 
b 99%ee based on chiral GC or HPLC analyses  c 98%ee  
The authors proposed that the reaction is believed to proceed via an initial O-alkylation 
followed by a fragmention sequence to result in the enone and the oxime (scheme 3-12). 
 
Scheme 3-12 Proposed mechanism for Pd catalyzed oxidation of allylic esters and 
carbonates 
3.3  Present Work-New route to γ-nitro carbonyl compounds via Pd catalyzed 
alkylation-isomerization  
3.3.1  Pd catalyzed alkylation-isomerization of allylic acetates using nitroalkanes 
In our quest of synthesizing new amino acids and amino alcohols , Pd catalyzed allylic 
alkylation was extended to nitroalkanes. As discussed in the previous sections of this 
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chapter palladium catalyzed allylic alkylation of nitroalkanes has always resulted in the 
formation of a γ,δ-unsaturated nitroalkane. Surprisingly, when the same Pd catalyzed 
strategy was applied to hydroxy allylic acetates 1-3 using  10 and 20 nitroalkanes γ- nitro 
carbonyl compounds were obtained instead of the usual unsaturated nitroalkanes (Scheme 
3-13).  
 
Scheme 3-13: Pd-catalyzed alkylations of nitroalkanes 
Another interesting feature of this reaction was the change in the position of new C-C 
bond formation from expected C-4 to C-3 (Scheme 3-13) suggesting an isomerization to 
be involved in the reaction pathway.  This reaction adds a new tool to the arsenal of Pd 
mediated C-C bond forming methodologies. Interestingly, as detailed above, nitroalkanes 
have received little attention in Pd catalyzed allylic alkylations as a nucleophile source 
even though nitro group can be easily converted to other functional groups.3 The scarce 
utilization of nitroalkane in Pd (0) catalyzed allylic alkylations can presumably be 
attributed to their ambident nature (C vs O alkylation), low reactivity of bulky 
nitroalkanes and formation of side products.6  Also, the survey of literature7 reveals that in 
Pd catalyzed alkylation of nitroalkanes the new carbon-carbon bond is formed invariably 
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at the allylic carbon of the electrophile, i.e., unsaturated nitro compounds are formed 
(Scheme 3-13). 
3.3.2  Optimization of reaction conditions for Pd catalyzed alkylation-isomerization 
of allylic acetates using nitroalkanes 
To understand the mode of the reaction various solvents, bases, catalyst-ligand systems 
were evaluated (Table 3-5). The reaction was highly dependent on the nature of the 
solvent.  No reaction was observed in protic solvents (t-butanol, t-BuOH+THF) or in 
nonpolar solvents (toluene, CHCl3), i.e., starting material was recovered.  In polar aprotic 
solvents (DMF, DMSO, THF), however, the reaction resulted in the γ-nitro carbonyl 
compound 10c in 10-12 hours. Owing to its relative ease of handling, THF was selected 
as the solvent of choice for subsequent investigations. The rate and outcome of the 
reaction also depended on the base used. Although K OtBu and DABCO led to the 
product formation, K2CO3 proved to be the most efficient base for this reaction.  When 
bulkier and stronger bases such as Cs2CO3 were used in THF no product formation was 
observed and the starting material was obtained along with the corresponding diol. It was 
also found that Pd(OAc)2 and PdCl2 did not catalyze the reaction, the reaction was only 
catalyzed by Pd(0).  
In order to study the substrate generality and scope of the reaction, cyclic and 
acyclic allylic acetates and primary and secondary nitroalkanes were subjected to the 
alkylation (Table 3-7).  The five and six membered allylic monoacetates were 
synthesized by enzymatic hydrolysis of the corresponding diacetates (scheme 3-14). The 
diacetates were synthesized from the dienes via two different routes both involving Pd 
catalysis. 
Table 3-5  Optimizaton of reaction conditions for Pd catalyzed alkylation-isomerization 
 
 
Entry Base Solvent Yielda drd 
1 K2CO3 THF 60 1:1 
2 K2CO3 DMF 54 1:1.1 
3 K2CO3 DMSO 53 1:1 
4 K2CO3 CHCl3 -b - 
5 K2CO3 Toluene - b - 
6 K2CO3 t-BuOH - b - 
7 K2CO3 t-BuOH+THF(1:1) - b - 
8 Cs2CO3 THF -c - 
9 KOtBu THF 40c 1.7:1 
10 DIPA THF -b - 
11 DABCO THF 52 1.1:1 
aIsolated yields. bStarting material was recovered. cmeso-cyclopent-2-en-1,4-
diol was also formed (20%). dDiastereomeric ratio (dr) based on GC analyses. 
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 Scheme 3-14  Synthesis of five and six membered mono acetates  
Cyclic acetates 7 and 14 resulted in formation of corresponding γ-nitro ketones 10 
and 11, respectively.  The acyclic acetate 15 which was synthesized by monacetylation of 
butene1,4-diol led to γ-nitro aldehydes  12. 10 and 20 nitroalkanes reacted with equal ease 
under these reaction conditions; even bulky nitroalkanes such as nitrocyclohexane reacted 
with both acyclic and cyclic hydroxyl allylic substrates.  The reaction required 5-8 mol % 
Pd(0) catalyst and was completed in 10-12 hours.  The structures of the γ-nitro carbonyl 
compounds were established unambiguously from analysis of the 1H- and 13C- NMR 
spectral data and its comparison with the literature data, when available.16 The reaction 
conversions were determined using GC chromatography and the products were isolated 
by column chromatography over silica gel. As shown in table 3-7 cyclic and acyclic 
substrates reacted with different nitroalkanes to yield the corresponding nitro-ketone or 
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aldehyde. The products obtained were quite stable and could be purified by column 
chromatography. Apart from alkenes, alkynes like 4-acetoxy-2-butyn-1-ol were also 
subjected to this Pd catalyzed methodology  but did not show any reactivity. Efforts to 
conduct the alkylation using Pd (II) catalysts as PdCl2, Pd(OAc)2 also proved to be futile.   
Table 3-6 Pd catalyzed alkylation-isomerization in the presence of chiral ligands 
 
Entry Ligand Pd catalyst Base de 
1 R-BINAP Pd(PPh3)4 K2CO3 1:1.15 
2 R-BINAP Pd[(π-allyl)2Cl]2 K2CO3 1.08:1 
3 S-ToL BINAP Pd2(dba)3 K2CO3 1:1.3 
4 dppp Pd2(dba)3 K2CO3 1:1 
5 S-ToL BINAP Pd[(π-allyl)2Cl]2 NaH 1:1.2 
 
 
 
 
 
 
The stereochemical analyses of the products identified these to be a mixture of 
diastereomers and enantiomers, e.g., starting from the optically pure (1S, 4R)- 4-
acetoxylcylcopent-2-en-1-ol (7)7e a racemic mixture of the respective products 10a-e was 
obtained. Products 10b and 10c were separated into its corresponding diastereomers by 
column chromatography and were identified to be racemic mixture of enantiomers.  The 
loss of optical purity was somewhat intriguing as the Pd (0) catalyzed reactions are 
known to proceed with stereochemical retention via a double inversion.2b,i,7 the use of 
different bases gave identical results with a diastereomeric ratio of almost 1:1 except in 
case of KOtBu (table 3-5,entry 9) which resulted in a diastereomeric ratio of 1.7:1. 
Importantly, reactions performed in the presence of chiral ligands such as R-BINAP and 
S-TolBINAP did not lead to optically pure products; only marginal  influence on 
diastereomeric ratio was observed.  Also trying different Pd(0) catalysts in the presence 
    134 
 
of both chiral as well as achiral (dppp, PPh3) ligands did not improve the diastereomeric 
ratio of the products (10 b,c) (table 3-7) . Compounds 10a, d, e, 14, 15 were obtained as a 
racemic mixture of the enantiomers. Based on these results it is evident that the 
mechanistic pathway of the reaction involved loss of stereochemistry possibly through 
racemization of the reaction intermediates. 
Table 3-7  Pd catalyzed isomerization-alkylation of allylic acetates 
Entry Acetate Nitroalkane Product Conv.a 
isolatedb 
1  
 
 
(> 99% ee) 
(7) 
 
CH3NO2 O
NO2
10a
88 (65) 
2 C2H5NO2 O NO2
10b
85 (59) 
3 C3H7NO2 O
NO210c
83 (60) 
4 
 
O
NO210d    
88 (58) 
5 
 
O NO2
10e
90 (62) 
 
6 
 
    (±) 
(14) 
 
 
O
NO211a  
75b 
 
7 
 
 
 
O
NO2
11b
85b 
 
8 
 
 
   
    (15) 
 
C3H7NO2 
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H NO2
O 12a
82 (58) 
 
9 
 
 
H
O
NO2
12b  
 
 
77 (53) 
 
10 
  
 
 
H
O
NO2
12c   
 
76 (60) 
a Based on GC analyses of the reaction mixture. bIsolated yield after 
column chromatography. 
 
 
The acyclic substrates were further modified by replacing one of the allylic-H by a 
methyl group. The secondary acyclic acetates 19, 20 were synthesized starting from 
propargylic alcohol as shown in scheme 3-15. Propargylic alcohol was protected as a 
THP ether followed by treatment with 1 equivalent of BuLi to generate the carbanion at 
the terminal alkyne carbon  followed by a nucleophilic attack on acetaldehyde to obtain 
the substituted alkyne. The reduction of the alkyne to the alkene required careful 
monitoring of the reaction. Extended reaction times resulted in a mixture of the 
corresponding alkene and alkanes. 
Ac2O, DMAP
    THF
H
OH
OH
OTHP
OAc
OTHP
1N HCl
 MeOH
1. DHP, pTSA
2.BuLi, CH3CHO (-780C)
3.Pd/ BaSO4, Quinoline
OAc
OH
16 17 18 19  
Scheme 3-15 Synthesis of substituted acyclic substrates 17, 18, 19.  
Pd catalyzed  reaction of allylic acetate 19 did not yield the desired nitro-aldehyde, albeit 
resulted in tranesterification and the two acetates were obtained in a ratio of 3:7 which 
was confirmed by NMR and GC analyses (scheme 3-16). In order to remove the 
possibility of transesterification the primary hydroxyl group in 19 was protected as THP 
ether and was subjected to Pd catalysis. The THP ether 18 did not yield the alkylation 
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product but resulted in 2,4-diene system 21. These experiments show that in acyclic 
substrates the presence of substitution at allylic carbon slows the formation of π-allyl 
complex, hence allowing transesterification to compete with the Pd catalyzed alkylation 
step. When THP protected acetate was subjected to Pd catalyzed alkylation, the π-allyl 
complex thus formed underwent β-hydride elimination to give diene 21. Two important 
conclusions can be derived from these set of experiments. First, any substitution at the 
allylic center specially in acyclic substrates slows the formation of  π-allyl complex hence 
favoring any other competing reactions such as transesterification to proceed. Secondly, 
the presence of a free allylic-hydroxy group is pivotal for this novel isomerization-
alkylation to work.  
 
Scheme 3-16 Reaction of substituted acyclic substrates 18, 19 with 2-nitropropane in the 
presence of Pd(0) catalyst  
 
3.3.3 Mechanistic studies for Pd catalyzed alkylation-isomerization 
 
Since the products obtained during these Pd catalyzed alkylation are different from the 
conventional products obtained, hence a survey of the Pd literature was done to 
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understand this new Pd catalyzed C-C bond forming process. The first example of the 
nucleophilic attack at the center carbon of a π-allyl system in a Pd catalyzed process was 
reported by Hegedus et al during cyclopropanation of ester enolates(scheme 3-17).18 A 
mechanism involving palladacyclobutane formed by a direct nucleophilic attack on the 
central carbon of the π-allyl system was therefore considered (scheme 3-18).    
 
Scheme 3-17  Mechanism involving formation of a palladacyclobutane intermediate 
The possibility of a direct nucleophilic attack on the C-3 carbon leading to a 
palladacyclobutane intermediate, followed by β−H elimination to produce the enol which 
tautomerizes to the give γ-nitro carbonyl compound as the final product is shown in 
scheme 3-18.   The initial steps involve the oxidative addition of Pd to allylic acetate 
followed by the attack of the nucleophile. This mechanism differs from a normal Pd 
catalyzed allylic alkylation because of the fact that the nucleophile attacks the central 
carbon of the allyl system followed by a formation of 4-membered  palladacycle B. The 
palladacycle undergoes β-elimination to give enol intermediate C which undergoes 
reductive elimination to give the final product E. According to the mechanism shown in 
scheme 3-18 the product obtained should be optically pure but Pd catalyzed alkylation of  
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nitroalkanes resulted in complete loss of optical purity and a racemic mixture was 
obtained.  
 
Scheme 3-18  Plausible mechanism involving formation of a palladacycle intermediate 
Hegedus also reported that the palladacycle formation is only observed when HMPA and 
/or Et3N is used (instead of PPh3) which coordinates to the metal forming [π-allyl 
PdL3]+.18a  Also, in the cyclopentane and cylcohexane monoacetate susbtrates, low kinetic 
stability of such a palladacyclobutane bearing a γ-OH substituent is certainly a cause for 
concern.19 Szabό et al  studied the effect of polar substituents on the stability of 
palladacyclobutane complexes and proposed that palladacyclobutanes bearing single 
bonded electronegative substituents such as OH have low kinetic stability of such 
species.19-20 Also, Backvall et al recently conducted an extensive study on central versus 
terminal attack in nucleophilic addition to (π-allyl) palladium complexes and concluded 
that π-acceptor complexes such as PPh3, dppf direct the attack to the terminal carbon 
whereas σ-donor ligands such as TMEDA direct the attack to terminal carbon, based on 
13C shifts. 19b In case of π-acceptor ligands, the Pd-complex has more cationic character 
and the positive charge is located on the terminal carbon of the allyl system.  Based on 
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above comments and observations the Pd catalyzed alkylation of nitroalkanes presented 
here is less likely to follow this pathway. 
Another plausible mechanism involving an initial isomerization of the allylic 
acetate to α,β-unsaturated ketone followed by a Michael addition using nitroalkane as a 
nucleophile was also considered  and investigated. The formation of the α,β-unsaturated 
ketone was not observed and considering the fact that no C-3 alkylation was observed in 
alkylation with other nucleophile (active methylene compounds), a different mechanism 
is suggested.  Attempts at isolating the Pd complex were unsuccessful. Also in order to 
rule out the possibility of an initial isomerization of the allylic acetate to α,β-unsaturated 
ketone, allylic monoacetaes were subjected  however, 3-cyclopentenone23 was isolated as 
the only product upon treatment of the monoacetate 7 with PPh3 and Pd(PPh3)4 in 
absence of the nitroalkane (fig 3-7, scheme 3-19). The formation of 3-cyclopentenone can 
be easily explained from both π-allyl complexes II, III via a β-hydride elimination and 
tautomerization (scheme 3-19). 
HO OAc
Pd(0)
HO
PdL2
HO
L2Pd
β-hydride
 elimination
HO O
3-cyclopentenone7
III
HO
L2Pd
HO
PdL2
II-σ
III-σ
II
 
 
Scheme 3-19  Mechanism for isomerization of allylic acetate 7 to 3-cyclopentenone. 
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Fig 3-7  1H-NMR study of the reaction of the monoacetate 7 with PPh3 and Pd(PPh3)4 in 
THF-d8 using 1H-NMR. A: Monoacetate B: Monoacetate + PPh3 C: 
Monoacetate+PPh3+Pd(PPh3)4 D: reaction mixture after 2.5 h at room temperature 
 
 
    142 
 
ore stabilized complex III. 
somerization of π-allyl palladium complexes has been put forward to explain loss of 
stereospecificity in some Pd catalyzed allylic alkylations.21 
 
Based on the above mentioned facts and the following observations, i) carbonyl group 
instead of an allylic alcohol is formed, ii) the new C-C bond formation at C-3 instead of 
C-4 of the allylic system, and iii) the loss of stereochemistry, we herein propose a 
catalytic cycle for the isomerization-alkylation reaction (Scheme 3-20).  The catalytic 
cycle involves oxidative addition of Pd(0) to the allylic acetate resulting in formation of 
the Pd-allyl complex (I) which upon ligand exchange generates the complex II. Complex 
II is a key intermediate as it can isomerize to a m
I
 
Scheme 3-20 Proposed Mechanism for Pd catalyzed isomerization-alkylation 
Complex III is attacked by the nitroalkane carbanion at the sterically favorable C-3 
position to yield IV which undergoes reductive elimination to give the enol V and 
regenerates Pd(0). Enol V tautomerizes to give the γ−nitro carbonyl compound. The 
isomerization of II to III is manifested in the formation of the new C-C bond at the C-3 
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rbonyl compounds.  Importantly, the hydroxyl 
be
ination will yield dienol complex B. Complex B can be represented as η4 complex C 
which upon regioselective re-addition (D) and σ−π interconversion can yield complex 
III. 
and not at the carbon bearing the leaving acetoxy group (C-4). The involvement of III 
also is supported by stereochemical scrambling observed in 1, an optically pure substrate, 
resulting in optically inactive γ-nitro ca
aring carbon in III is sp2 hybridized which makes the complex racemic and explains 
the loss of optical purity in the products. 
The isomerization of complex II can be explained as shown in scheme 3-21. Initially 
formed π-allyl complex II can undergo π−σ interconversion to A which upon syn 
elim
 
Scheme 3-21 Isomerization of π-allyl complex II to III 
The formation of III via an isomerization of II is dependent on two very important 
factors, 1) The availability of the free hydroxyl group to stabilize the resulting 
carbocation through nonbonding electron pair donation; 2) The slow generation of the 
carbanion from the nitroalkane. The large degree of charge buildup on the carbon atom 
during deprotonation of the α-hydrogen in nitroalkanes along with inductive effects of 
the alkyl groups makes the whole process extremely slow.22 This unusual property of the 
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nitroalkane combined with the availability of the allylic hydroxyl group results in this 
unusual isomerization-alkylation reaction resulting in γ-nitro carbonyl compounds. 
 
Scheme 3-22  The competing alkylation: C-3 vs C-4 
A schematic of the competing processes in an allylic alkylation of the nucleophiles 
generated from a diester and nitroalkane is depicted in Scheme 3-22.2b,i,7  The diethyl 
malonate (fast deprotonation) results in formation of the allylic alcohols with the new C-
 the C-4, while in nitroalkanes (slow deprotonation), the new C-C bond 
is f
solvent. Careful optimization of reaction conditions proved potassium carbonate and THF 
C bond formed at
ormed at the C-3 resulting in γ-nitro carbonyl compounds. 
3.4 Conclusion  
In conclusion, isomerization-alkylation process has been discovered which provides an 
easy route to synthetically important γ-nitro-ketones and aldehydes and a mechanistic 
explanation for the 'isomerization-alkylation' is also proposed. The reaction requires 
easily obtainable allylic monoacetates and works with a variety of 1°, 2° nitroalkanes. 
This new Pd(0)-catalyzed alkylation of nitroalkanes can be carried out under mild 
conditions and the outcome of the reaction is highly dependent on the nature of the 
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thetically important analogs should be valuable 
al product synthesis. 
logies). GC studies were carried out on Shimadzu gas chromatograph (Model 
3.5.2 Preparation of starting materials (1-3): 
to be the best base and solvent, respectively. The resultant γ-nitro carbonyl compounds 
that can easily be converted to other syn
as synthons in natur
3.5 Experimental 
3.5.1. General experimental information: 
Lipase PS-30 was generous gifts from Amano Enzymes. 1H-NMR and 13C-NMR spectra 
were recorded on a Bruker 250 MHz spectrometer MHz and 62.5 MHz respectively in 
CDCl3 with TMS as the standard. Chemical shifts are reported in ppm, multiplicities are 
indicated by s (singlet), d (doublet), t (triplet), q (quartet), p (quintet), h (sextet), m 
(multiplet) and bs (broad singlet). Optical rotations were measured with a Rudolph 
Research Analytical AutoPol IV Automatic polarimeter. Thin-Layer chromatography 
(TLC) was performed on glass plates coated with 0.25 mm thickness of silica-gel. All 
solvents were dried and distilled prior to use and organic solvent extracts dried over 
Na2SO4. Mass calculations were carried out on an ESI LC MS system (Agilent 
Techno
17A).  
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mmetrization of 
3.5.3 General Procedure for Pd catalyzed alkylation of nitroalkane: 
temperature was added Pd(PPh3)4 (40 mg, 0.035 mmol), PPh3 (184 mg, 0.704 mmol) 
2 3
atography using 
hed those found in the 
1 13
viscous liquid; H-NMR 
3 , 8H), 2.60-2.69 (m, 1H),4.23 
viscous liquid; H-NMR 
3 =7.5Hz ), 1.42-2.50 (m, 8H), 2.63-2.68 (m, 1H),4.23 
Optically pure 7 was prepared by lipase catalyzed enzymatic desy
corresponding meso-diacetates.24 Compound 14 and 15 were prepared following the 
known literature procedures.25   
To a solution of allylic acetate 7 (100 mg, 0.704 mmol) in dry THF (10 mL) at room 
under a nitrogen atmosphere.  The reaction was allowed to stir for 5 minutes and then 
nitropropane (63 mg, 0.704 mmol) and K CO  (97 mg, 0.704 mmol) were added.  The 
reaction was refluxed for 12 h and then vacuum filtered through celite with subsequent 
concentration of the filtrate.  The product was purified by column chrom
ethyl acetate: hexane (1:2) to afford 10c (72 mg, yield =60%) as a viscous liquid. 
3.5.3.1 3-(Nitromethyl) cyclopentanone (10a)16 : NMR data matc
literature and H- and C- spectra is presented in the later section. 
3.5.3.2 3-(1-Nitroethyl) cyclopentanone (10b)16: NMR data matched those found in the 
literature and 1H- and 13C- spectra is presented in the later section. 
3.5.3.3 3-(1-Nitropropyl) cyclopentanone (10c) (less polar):   1
(CDCl , 250 MHz) δ: 0.92 (t, 3H, J=7.5Hz ), 1.56-2.56 (m
(dt, 1H, J=10.5, 3.25 Hz) ppm; 13C-NMR (CDCl3, 62.5 MHz) δ:10.22, 25.99, 26.54, 
37.97, 40.26, 41.35, 94.20, 215.50 ppm. HRESIMS calcd for C8H13NO3 Exact Mass: 
172.0968 ([M+H]+); found: 172.0964 ([M+H]+). 
3.5.3.4 3-(1-Nitropropyl) cyclopentanone (10c) (more polar):   1
(CDCl , 250 MHz) δ: 0.90 (t, 3H, J
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 172.0968 
+ +
 matched those 
1 13
ose found 
1 13
 matched those 
1 13  the la
3
6H), 1.55-2.55 (m, 2H),  2.32-2.40 (m,1H), 2.49- 2.66 (m, 1H), 4.26-4.34 (m, 2H), 9.67 
3
2.23-2.28 (m, 1H) , 2.37-2.39(m, 1H), 2.79 (m, 
(dt, 1H, J=9.75, 4.0 Hz) ppm; 13C-NMR (CDCl3, 62.5 MHz) δ:10.14, 25.91, 26.46, 37.91, 
40.18, 41.27, 94.12, 215.42 ppm. HRESIMS calcd for C8H13NO3 Exact Mass:
([M+H] ); found: 172.0964 ([M+H] ). 
3.5.3.5  3-(2-Nitropropane-2-yl) cyclopentanone (10d)16: NMR data
found in the literature and H- and C- spectra is presented in the later section. 
3.5.3.6  3-(1-Nitrocyclohexyl) cyclopentanone (10e)16 : NMR data matched th
in the literature and H- and C- spectra is presented in the later section. 
 3.5.3.7 3-(2-Nitropropane-2-yl) cyclohexanone (11a)16: NMR data
found in the literature and H- and C- spectra is presented in ter section. 
3.5.3.8  3-(1-Nitrocyclohexyl) cyclohexanone (11b)16: NMR data matched those found 
in the literature and 1H- and 13C- spectra is presented in the later section. 
3.5.3.9  3-Methyl-4-nitrohexanal (12a): 1H- NMR (CDCl , 250 MHz) δ: 0.8-1.1 (m, 
(d, 0.5H, J=1.25Hz), 9.69 (s, 1H). 13C- NMR (CDCl3, 62.5 MHz) δ: 10.35, 10.52, 15.48, 
16.62, 24.0, 24.22, 31.0, 31.22, 46.45, 47.03, 93.37, 94.24, 199.93, 200.0. HRESIMS 
calcd for C7H17N2O3 ([M+NH4]+): 177.1233; found: 177.1231([M+NH4]+). 
3.5.3.10 3,4-Dimethyl-4-nitropentanal (12b) : 1H- NMR (CDCl , 250 MHz) δ: 0.90 (d, 
3H, J=7.0 Hz ), 1.47 (s, 3H), 1.49 (s, 3H), 
1H), 9.66 (d, 1H, J=2.25 Hz) ppm; 13C- NMR (CDCl3, 62.5 MHz) δ:15.36, 22.50, 23.84, 
35.87, 46.14, 91.24, 199.91 ppm. HRESIMS calcd for C7H17N2O3 ([M+NH4]+): 
177.1233; found: 177.1234 ([M+NH4]+). 
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H), 2.138 (m, 1H) , 2.36-2.55 (m, 3H), 9.66 (d, 
J=1.75 Hz) ppm;13C- NMR (CDCl3, 62.5 MHz) δ:15.05, 22.17, 22.26, 24.60, 31.21, 
21N2O3 ([M+NH4]+): 
 
flon tape and was 
m temperature. The spectra D corresponds to the reaction mixture after 2.5h. 
 two new peaks at 2.89 ppm and 6.1ppm start developing which 
ly of 3-cyclopentenone (fiq S1).23 
3.5.3.11 3-(1-Nitrocyclohexyl)butyraldehyde (12c) : 1H- NMR (CDCl3, 250 MHz) δ: 
0.88 (d, 3H, J=6.75Hz ), 1.11-1.66 (m, 9
1H, 
32.15, 36.16, 45.82, 94.17, 200.26 ppm. HRESIMS calcd for C10H
217.1586; found: 217.1582 ([M+NH4]+). 
3.5.4 Procedure for the time study using 1H-NMR spectroscopy 
Allylic monoacetate 7 (10 mg, 0.07 mmoles) was dissolved in THF-d8 (in a NMR-tube) 
and the spectral data was collected. Spectrum A corresponds to the 1H-NMR spectra of 
pure monoacetate 7. PPh3 (4 mg, 0.015 mmoles, 20 mol %) was added to the solution of 
monoacetate in THF-d8 and the 1H-NMR data was again collected (Spectrum B). This 
was followed by addition of Pd(PPh3)4 (4 mg, 0.003 mmoles, 5 mol %) (Spectrum C). 
Also after the addition of the catalyst the NMR tube was sealed using te
kept at roo
As the reaction proceeds,
correspond to H-6 and H-7 respective
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3.6  References: 
1.  (a) Metal-Catalyzed Cross-Coupling Reactions, 2nd ed.; deMeijere, A.; Diederich, 
F.; Ed.; Wiley-VCH: Weinheim, 2004. (b) Hegedus, L. S.; Transition Metals in the 
Synthesis of Complex Organic Molecules, 2nd ed., University Science Books: 
Sausalito, 1999. (c) Handbook of Organopalladium Chemistry for Organic Synthesis; 
Negishi, E
A Practical Guide; Miyaura, N.; Ed.; Springer: Berlin, 2002. (e) Organometallics in 
Synthesis; Schlosser, M., Ed.; John Wiley and Sons: New York, 1994; Chapter 5, pp 
383-461. 
2. (a) Maitlis, P. M. The Organic Chemistry of Palladium; Academic Press: New York, 
1971; Vols. 1 and 2. (b) Tsuji, J. Organic Synthesis with Palladium Compounds; 
Springer-Verlag: New York, 1980. (c) Heck, R. F. Palladium Reagents in Organic 
Synthesis; Academic Press: New York, 1985. (d) Larock, R. C. In Advances in 
Metal-Organic Chemistry; Liebeskind, L. S., Ed.; JAI Press: London, 1994; Vol. V, 
Chapter 3. (e) Tsuji, J. Palladium Reagents and Catalysts: Innovations in Organic 
Synthesis; Wiley and Sons: New York, 1995. (f) Li, J. J.; Gribble, G. W. Palladium 
in Heterocyclic Chemistry; Pergamon: New York, 2000. (g) Negishi, E. Handbook 
of Organopalladium Chemistry for Organic Synthesis; Wiley and Sons: New York, 
2002; Vols. 1 and 2. (h) Tsuji, J. Palladium Reagents and Catalysts: New 
Perspectives for the 21st Century; Wiley and Sons: New York, 2003. (i) Palladium 
in Organic Synthesis; Tsuji, J., Ed.; Springer: Berlin, 2005.(j) Heumann, A.; Jens, 
K.-J.; Reglier, M. Progress in Inorganic Chemistry; Karlin, K. D., Ed.; Wiley and 
Sons: New York, 1994; Vol. 42, pp 483-576. (k) Tsuji, J. J. Organomet. Chem. 
    150 
 
illaizeau, I.; 
 York, 2001. 
on. 
esi, M. L.; 
1986, 300, 281. (l) Kalinin, V. N. Russ. Chem. Rev. 1991, 60, 339. (m) Hegedus, L. 
S. Coord. Chem. Rev. 1996, 161, 129. (n) Hegedus, L. S. Coord. Chem. Rev. 1997, 
147, 443. (o) Larock, R. C. Pure Appl. Chem. 1999, 71, 1435. (p) Bäckvall, J.-E. 
Pure Appl. Chem. 1999, 71, 1065. (q) Tsuji, J. Pure Appl. Chem. 1999, 71, 1539. (r) 
Beletskaya, I. P.; Cheprakov, A. V. Chem. Rev. 2000, 100, 3009. (i) Amatore, C.; 
Jutand, A. Acc. Chem. Res. 2000, 33, 314. (s) Cacchi, S.; Fabrizi, G.; Goggiomani, 
A. Heterocycles 2000, 56, 613. (t) Zimmer, R.; Dinesh. C. U.; Nandanan, E.; Khan, 
F. A. Chem. Rev. 2000, 100, 3067. (u) Special issue “30 Years of the Cross-coupling 
Reaction”. J. Organomet. Chem. 2002, 653, 1. (v) Agrofoglio, L. A.; G
Saito, Y. Chem. Rev. 2003, 103, 1875. (w) Negishi, E.; Anastasia, L. Chem. Rev. 
2003, 103, 1979.(x) Zeni, G.; Larock, R. C. Chem. Rev. 2004, 104, 2285. (y) Ziegert, 
R. E.; Torang, J.; Knepper, K.; Brase, S. J. Comb. Chem. 2005, 7, 147.  
3.  (a) Ono, N. The Nitro Group in Organic Synthesis; Wiley-VCH: New
(b) Brown, B. R. The Organic Chemistry of Aliphatic Nitrogen Compounds; Oxford 
University: Oxford, 1994; pp 443–469. (c) The Chemistry of Amino, Nitro and 
Related Groups; Patai, S., Ed.; John Wiley & Sons: Chichester, 1996. 
4.  (a) Luzzio, F. A. Tetrahedron 2001, 57, 915. (b) Ballini, R.; Petrini, M. Tetrahedr
2004, 60, 1017. (c) Barrett, A. G. M.; Grabowski, G. G. Chem. Rev. 1986, 86, 751.  
(d) Berner, O. M.; Tedeschi, L.; Enders, D. Eur. J. Org. Chem. 2002, 1877; (e) 
Seebach, D.; Colvin, E.W.; Lehr, F.; Weller, T. Helv. Chim. Acta. 1985, 68, 1592. 
5. (a) Rosini, M.; Mancini, F.; Tarozzi, A.; Colizzi, F.; Andrisano, V.; Bologn
Hrelia, P.; Melchiorre, C. Bioorganic & Medicinal Chemistry. 2006,  14, 7846. (b) 
    151 
 
Chem. 2003, 46, 4895.   
 1978, 19, 565. (d) Tsuji, J.; Shimizu, I.; 
.; Kanai, M.; 
t. 1980, 33, 946. (e) 
Morimoto, M.; Fukui, M.; Ohkubo, S.; Tamaoki, T.; Tomita, F. J. Antibiot. 1982, 35, 
Rosini, M.; Antonello, A.; Cavalli, A.; Bolognesi, L. M.; Minarini, A.; Marucci, G.; 
Poggesi, E.; Leonardi, A.; Melchiorre, C. J. Med. 
6. a) Aleksandrowicz, P.; Piotrowska, H.; Sas, W. Tetrahedron 1982, 38, 1321. (b) 
Aleksandrowicz, P.; Piotrowska, H.; Sas, W. Monatsh. Chem. 1982, 113, 1221. (c) 
Genet, J. P.; Grisoni, S. Tetrahedron Lett. 1988, 29, 4543. (d) Rieck, H.; Helmchen, 
G. Angew. Chem. Int. Ed. Engl. 1995, 34, 2687.  
7. (a) Wade, P. A.; Morrow, S. D.; Hardinger, S. A. J. Org. Chem. 1982, 47, 365. (b) 
Trost, B. M.; Surivet, J.-P. J. Am. Chem. Soc. 2000, 122, 6291. (c) Tsuji, J.; 
Yamakawa, T.; Mandai, T. Tetrahedron Lett.
Minami, I.; Ohashi, Y.; Sugiura, T.; Takahashi, K. J. Org. Chem. 1985, 50, 1523. (e) 
Deardorff, D. R.; Savin, K. A.; Justman, C. J.; Karanjawala, Z. E.; Sheppeck, J. E.; 
Harger, D. C.; Aydin, N. J. Org. Chem. 1996, 61, 3616. (f) Maki, K
Shibasaki, M. Tetrahedron, 2007, 63, 4250.  
8.D. S. Moore, Rev. Sci. Instrum., 2004, 75, 2499. 12 W. C. Trogler, in NATO ASI 
Workshop, Electronic Noses & Sensors for the Detection of Explosives, ed. J. W. 
Gardner and J. Yinon, Kluwer Academic Publishers, Netherlands, 2004 
9. (a) Dalsgaard, P. W.; Larsen,T. O.; Frydenvang, K.; Christophersen, C.; J. Nat. Prod. 
2004, 67, 878. (b) Ohba, K.; Nakayama, H.; Furihata, K.; Shimazu, A.; Endo, T.; 
Seto, H.; Otake, N. J. Antibiot. 1987, 403, 709. (c) Tomita, F.; Tamaoki, T.; 
Shirahata, K.; Kasai, M.; Morimoto, M.; Ohkubo, S.; Mineura, K.; Ishii, S. J. 
Antibiot. 1980, 33, 668. (d) Tamaoki, T.; Kasai, M.; Shirahata, K.; Ohkubo, S.; 
Morimoto, M.; Mineura, K.; Ishii, S.; Tomita, F. J. Antibio
    152 
 
 Antibiot. 1981, 34, 1101. (g) Bradner, W. 
s, 
etrahedron 1982, 38, 1321. 
. L. G. Life Sci. 1981, 28, 1225. (b) 
ohansson, 
84, 27, 1030. 
. 
. 
1033. (f) Waitz, J. A.; Horan, A. C.; Kalyanpur, M.; Lee, B. K.; Loebenberg, D.; 
Marquez, J. A.; Miller, G.; Patel, M. G. J.
T.; Claridge, C. A.; Huftalen, J. B. J. Antibiot. 1983, 36, 1078. 
10. (a) Danneberg, P.; Weber, K. H.; Br.  J. Clin. Pharmacol. 1983, 16, 231. (b) Rickel
K.; Acta. Psychiatr. Scand. 2007, 74, 132. 
11. Aleksandrowicz, P.; Piotrowska, H.; Sas, W. T
12. Nemoto,T.; Jin, L.; Nakamura, H.; Hamada, Y. Tetrahedron. Lett. 2006, 47, 6577.  
13. Olpe, H. R.; Demiéville, H.; Baltzer, V.; Bencze, W. L.; Koella, W. P.; Wolf, P.; 
Haas, H. L. Eur. J. Pharmacol. 1978, 52, 133 
14. (a) Hjorth, S.; Carlsson, A.; Wikström, H.; Lindberg, P.; Sanchez, D.; Hacksell, U.; 
Arvidsson, L.-E.; Svensson, U.; Nilsson, J
Wikström, H.; Sanshez, D.; Lindberg, P.; Hacksell, U.; Arvidsson, L.-E.; J
A. M.; Thorberg, S.-O.; Nilsson, J. L. G.; Svensson, K.; Hjorth, S.; Clark, D.; 
Carlsson, A. J. Med. Chem. 19
15.  Trost, B. M.; Richardson, J.; Yong, K. J. Am. Chem. Soc. 2006, 128, 2540. 
16. Hanessian, S.; Pham, V. Org. Lett. 2000, 2, 2975. (b) Hanessian, S.; Shao, Z.; Warrier 
J. S. Org. Lett. 2006, 8, 4787
17. (a) Deardorff, D. R.; Matthews, A. J.; McMeekin, D. S.; Craney, C. L. Tetrahedron 
Lett. 1986, 27, 1255. (b) Siddiqi, S. M.; Chen, X.; Schneller, S. W. Nucleosides & 
Nucleotides. 1993, 12, 267. 
18. (a) Hegedus, L. S.; Darlington, W. H.; Russell, C. E. J. Org. Chem. 1980, 45, 5193. 
(b) Hoffmann, H. M. R.; Otte, A. R.; Wilde, A.; Menzer, S.; Williams, D. J. Angew. 
Chem., Int. Ed. Engl. 1995, 34, 100
    153 
 
 K. J.; Bäckvall, J. E. Angew. Chem., Int. Ed. 
102, 4730. (b) K. L. 
 (c) J. M. Brunel, M. 
R. J.; Arrington, J. P. J. 
, 1255. (c) Siddiqi, S. M.; Chen, X.; 
Schneller, S. W. Nucleosides & Nucleotides. 1993, 12, 267. 
25. Baeckvall, J. E.; Nordberg, R. E. J. Am. Chem. Soc. 1981, 103, 4959.  Johnson, C. R.; 
Bis, S. J. Tetrahedron Lett. 1992, 33, 7287.  
 
 
19. (a) Castanõ, A. M.; Aranyos, A.; Szabó,
Engl. 1995, 34, 2551. (b) Aranyos, A.; Szabó, K. J.; Castanõ, A. M.; Bäckvall, J. E. 
Organometallics. 1997, 16, 1058. 
20. Szabó, K. J. Theochem. 1998, 455, 205. 
21.  (a) Trost, B. M.; Verhoeven, T. R. J. Am. Chem. Soc. 1980, 
Granberg, J. E. Bäckvall, J. Am.Chem. Soc. 1992, 114, 6858.
Maffei, G. Muchow, G. Buono, Eur. J. Org. Chem. 2000, 1799. (d) J. M. Brunel, M. 
Maffei, G. Muchow, G. Buono, Eur. J. Org. Chem. 2001, 1009. 
22. Green, D.; Johnson, T. Innovations Pharm. Technol. 2000, 79. 
23. Buckley, S. L. J.; Harwood, L. M.; Macias-Sanchez, A. J. ARKIVOC , 2002, 8, 46. 
Tsuda, T.; Tokai, M.; Ishida, T.; Saegusa, T. J. Org. Chem. 1986, 51, 5216. 
24. (a) Crandall, J. K.; Banks, D. B.; Colyer, R. A.; Watkins, 
Org. Chem. 1968,  33, 423. (b)  Deardorff, D. R.; Matthews, A. J.; McMeekin, D. S.; 
Craney, C. L. Tetrahedron Lett. 1986, 27
 
 
 
 
    154 
 
Chapter  4 
 research. Out of all the peptidomimetics and related compounds, 
unnatural amino acids such as bicyclic and carbocyclic amino acids are of valuable  
interest as they have provided new building blocks for large number of potential drug 
candidates (fig 4-1).3 
CHEMOENZYMATIC SYNTHESIS OF L-CARBAFURANOMYCIN AND 
RELATED CYCLOPENTANE AMINO ACID ANALOGS 
4.1 Introduction 
The last three chapters focused on Pd (0) catalyzed alkylations involving various soft 
nucleophiles such as nitroesters, diesters and nitroalkanes. A review on the importance of 
these Pd catalyzed reactions in synthesis of O,N heterocycles is presented in chapter 1. 
This chapter focuses on the application of the Pd catalyzed methodologies studied and 
discussed in the prior two chapters.  Pd catalyzed alkylation was utilized to synthesize 
new carbocyclic amino acid analogs which not only provide valuable synthons for a large 
number of bioactive compounds and drug candidates but also show immense bioactivity 
on their own.The last few decades have seen the emergence of new therapeutics based on 
bioactive peptides and peptidomimetics.1-3 This class of compounds have not only 
attracted organic and medicinal chemists due to their novel structure but have also 
influenced biomedical
 
Fig 4-1 Biologically important carbocyclic amino acid analogs 
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 receptor 
comple
4.2 Biological importance of carbocyclic amino acid and its analogs  
Carbocyclic-amino acids offer diverse biological properties.4-6 For example, they can act 
as agonists and/or antagonists at both ionotropic and metabotropic glutamate receptors7,8 
and are involved in plant growth and fruit ripening9. They are also known to modify the 
biological properties of a protein or peptide when incorporated as a building block.10 
Compounds such as ACPD, MCCG (fig 4-1) have shown potential to act as N-methyl-D-
aspartate (NMDA) antagonists. Bicyclic amino acid LY 354740 was developed by Eli 
Lilly & Co as a highly potent and selective agonist of metabotropic glutamate (mGlu) 
receptor 2 and 3.11  Importantly, Ohfune et al showed that cyclic threonine analogues 
when incorporated as building blocks into peptides (e.g. Leu-enkephalin) can alter their 
biological effects.12  Also, 1-aminocyclopropane, 1-aminocyclobutane (ACBC), and 1-
aminocyclopentanecarboxylic acid are reported as partial agonists of the NMDA
x.13 Amino cyclopropane carboxylic acid analogs can also act concurrently as a 
glycine site partial agonist and as a glutamate site antagonist, thus protecting against 
neural cell death and has shown antipsychotic-like effects in animal models.13  
A large number of  β−amino acids also contain a carbocylic ring system. These 
β−amino acids form a new class of non-proteinogenic amino acids with cytotoxic, 
antibiotic and antifungal properties.14 The pharmacology and chemistry of these amino 
acids has been extensively reviewed.14 One of the first known β−amino acids include (1R, 
2S)-2-aminocyclopenatnecarboxylic acid (cispentacin) which is an antifungal metabolite 
isolated from Bacillus cereus and Streptomyces setonii.15 Cispentacin shows good 
therapeutic efficacy against a Candida infection in mice after either oral or parenteral 
administration. It also acts against systematic infection with Cryptococcus neoformans 
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gs showed that cyclohexane and norbornane analogs of 
cispentacin had no activity. Analogs of cispentacin like BAY 10-8888 with an exocyclic 
double bond showed better activity but introduction of double bond in the ring  results in 
loss of activity(fig 4-2).15b-d 
and also lung and vaginal infection due to Candida albicans in mice.15b-d. Also a SAR 
study for cispentacin analo
COOH
NH2
COOH
NH2
Cispentacin Bay 10-8888
antifungal activity Aspergillus spp.     : >500
Candida spp.         :<0.25->32
Aspergillus spp.     : not active 
Fig 4-2 Antifungal activities of cispentacin analogs 
Amipurimycin, a cyclopentane amino acid containing compound, is strongly active 
against Pyricularia oryzae both in vitro and in vivo(fig 4-3).16 Additionally, synthetic 
compounds containing a carbocyclic β-amino acid moiety have also shown potent 
bioactivity and applications. Tilidine ((±
In vitro Candida spp.         :  8-50
)-trans-2-(dimethyl-amino)-1-phenyl-3-
cyclohexene carboxylate hydrochloride) (fig 4-3) is used in therapy to control pain as an 
opioid analgesic.17 It is sold under various trade names as Findol, Grüntin, Tilidalor, 
Tiligetic, Tilitrate, Valomerck, Valoron, Valtran. 
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COOH
NH2
2-ACPC
Cispentacin
O
OH
HO
N
NN
N
NH2
HN
COOH
O
H2N
HO H
OH
N
Ph
COOEt
Amipurimycin
Tilidine  
Fig 4.3 Biologically important β-amino acids containing a carbocyclic system 
Specially, α,α-Disusbtituted cycloalkane amino acids play  an important role in the 
development of new peptides with enhanced properties(fig 4-4). 18-23 Incorporation of 
these cyclic structures in a peptide back-bone results in novel properties due to 
conformational restrictions present in these systems.  Incorporating these unnatural amino 
acids in naturally occurring peptides can have a pronounced effect on its bioactivity, the 
18-23  resultant peptides offer high stability due to resistance to enzymatic degradation.
 
OH
HO2C NH2
OH
HO2C NH2
OH
HO2C NH2
OH
HO2C NH2
(1S, 2S) (1R, 2R) (1S, 2R) (1R, 2S)
OH
HO2C NH2 HO2C NH2
H2N HO2C
CO2H
OH
NH2
OH
 
Fig 4-4 Structure of various five and six membered cycloalkane amino acids 
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The novel properties of cycloalkane amino acid analogs have attracted a large number of 
researchers. For example, several isomers of L-aspartyl-1-aminocylopropanecarboxylic 
acid methyl ester shown in figure 4.5 differ slightly in their structure but are found to 
have sweet to bitter taste properties when subjected to a taste  test .24 
H
N CO2CH3
AsP
H
H
N CO2CH3
AsP
H
H
N CO CH2 3
AsP
H
H
N CO CH2 3
AsP
H
sweet tasteless bitter bitter  
Fig 4-5 Taste properties of L-aspartyl-1-amino-cyclopropanecarboxylic acid 
Apart from offering various bioactive and pharmacological applications these novel 
amino acid and their analogs  offer building blocks for other modified peptides and 
biologically active compounds such as β-lactams and heterocycles  These unnatural 
amino acids are also finding their way in the field of combinatorial chemistry. Figure 4.6 
shows a schematic for combinatorial synthesis of 1,5-benzodiazepine-2-ones, 2-
thioxopyrimidinones, cyclic β-lactams.25 
COOH
NH2
COOH
NH2
COOH
NH2
CN CN
CN
CHO
CHO
CHO
Cl
O2N
N
O
O
N
H
R3
R2
n
n=0,1
COOH
NH2
CHO
R2
N R3
n
N
O
O
N
H
R3
R2
n
n=0,1  
Fig 4-6 Combinatorial synthesis based on Ugi reaction involving cyclic amino acids 
4.3 General methods for synthesis of cyclic amino acids 
A number of synthetic methods are  available for synthesis of cyclic amino acids. 
Depending on the type of reagent a racemic or an enantiopure poduct is obtained. Among 
the cyclic amino acids five and six membered analogs are most widely known due totheir 
easy availability from anthranilic acid. The following section describes various methods 
to synthesize cyclic amino acids. 
4.3.1 Selective reduction of anthranilic acid analogs26 
 2-Aminocyclohexanecarboxylic acids can be easily synthesized via selective reduction 
of anthranilic acid. This method is known for the last 100 years and is still used. 
Depending on the nature of the reducing agent the cis:trans ratio can be altered. 
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Anthranilic acid reduction using  Rh-Al catalyst or  Adam’s catalyst in acetic acid results 
in cis isomer exclusively. However, the use of colloidal ruthenium in a H2 atmosphere 
gives in a cis-trans ratio of 6:1 (scheme 4-1). 
NH2
COOH
NH2
COOH
NH2
COOH
NH2
COOH
NH2
COOH
6 :       1
Adams catalyst
   acetic acid
colloidal Ru
H2
 
Scheme 4-1 Synthesis of cyclohexane anino acids via selective reduction of anthranilic 
acid analogs 
4.3.2 Hofmann and Curtius degradation of 1,2-dicarboxylic anhydrides27 
A large number of cyclohexane amino acids can be synthesized via Hofmann and Curtius 
degradation. 1,2 cyclohexane-dicarboxylic anhydride synthesized via a Diels-Alder 
reaction of maleic anhydride and butadiene is converted to the corresponding 
monoamides and monoesters (scheme 4-2) which  are subjected  to Hofmann and Curtius 
degradation respectively. 
O
O
ONH4OH
COOR
COOH
COOH
CONH2
1.ROH
2.OH-
3.H+
Hofmann degradation
NaOH, Br2, 
DOWEX 50
Curtius degradation
1.SOCl2
2.NaN3
3.HCl
COOH
NH2  
Scheme 4-2  Synthesis of cyclohexane anino acids via Hofmann and Curtius Degradation  
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4.3.3 Hydrolysis of lactams28   
Cyclic amino acids can also be accessed from lactams via an acid hydrolysis (Scheme 4-
3). Cyclic beta lactams can be synthesized by 1,2 dipolar cycloaddition of chlorosulfonyl 
isocyanate (CSI) to different cycloalkenes. These additions always occur in a 
Markovnikov fashion in high regio- and stereoselectivity. 
CSI, DCM
N
H
O
NH3
COOH
aq HCl
room temp
Cl-
CSI, DCM
NH
O aq HCl
room temp COOH
NH3
Cl-
+
CSI, DCM
N
H
O
aq HCl
room temp COOH
NH3Cl
-
Cl
S
N
C
O
O
O
CSI  
Scheme 4-3 Synthesis of cycloalkane amino acids from β-lactams 
4.4 Furanomycin and its carba-analogs 
Furanomycin, an α-amino acid is a naturally occurring antibiotic isolated from 
metabolites of Streptomyces threomyceticus L-803 in 1967 by Katagiri et al.29 These 
metabolites inhibited  the growth of Coliphage T2. Further studies on these metabolites 
confirmed that they do also inhibit the growth of other organisms as Eschericihia coli, 
Bacillus subtilis, and several Salmonella strains. Furanomycin, the active compound in 
these fungal metabolites is an unusual amino acid, which bears resemblance to agaric  
toxin  muscarine whose  biosynthesis proceeds from pyruvate and glutamate. But labeling 
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experiments proved that furanomycin is formed via a polyketide pathway involving two 
acetate and one propionate unit (fig  4-7).30 The furan ring is formed by an intramolecular 
ring opening of epoxide.31 
O
O
COOH O
COOH
NH2
O NMe3
-O
GLUTAMATE AND PYRUVATE
 PATHWAY
Furanomycin
Muscarine  
Fig 4-7 Biosynthesis of Furanomycin and Muscarine involving two acetate and one 
propionate unit  
Incorporation of furanomycin in a bacterial protein instead of isoleucine results in its 
antibiotic activity.32 Also, the experiments conducted in E.coli indicated that furanomycin 
selectively inhibits the formation of isoleucyl-t-RNA without affecting aminoacyl-t-
RNA. The δ-methyl group in furanomycin plays a crucial role in substrate recognition 
and differentiation between Ile, Val and Leu. Since the mechanism of action for 
furanomycin is interesting from a pharmaceutical point of view hence a number of 
derivatives and analogs have been synthesized and studied for their bioactivity (figure 4-
8).33 
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Fig 4-8  Furanomycin and its analogs 
Norfuranomycin (2)  has exhibited antibiotic activity against E. coli and several species 
of Pseudomonas strains.33a A growth-inhibitory activity study of various furanomycin 
derivatives has been conducted. This study showed that modifying the structure of 
furanomycin and the position of methyl group had a profound effect on the biological 
activity. For example removal of methyl group did not effect the activity against S.aureus 
but altered the activity against against E.coli to large extent. Changing the position of 
methyl group from C-5 to any other carbon in the ring resulted in poor activity indicating 
the importance of the C-5 position of methyl group.33b Furanomycin has been synthesized 
by various methodologies using carbohydrates,34 tartaric acid,35 serine,36 or furans,37 as 
starting materials. Recently, Krause et al synthesized furanomycin using a Au catalyzed 
cycloisomerization of α-hydroxy allenes.38 There is a great deal of interest in the 
synthesis of the carbocyclic analogs of furanomycin because of their structural similarity 
and perceived biological activity. A series of racemic furanomycin analogs, 
cyclopentylglycine, and cyclopentenylglycine have been synthesized utilizing ring-
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closing metathesis, aldol additions, ester-enolate Claisen rearrangements and aldol 
reactions.34,35,39 
Importantly, carbocyclic nucleosides have also shown potent biological activity. 
An amino acid containing nucleoside, Sinefungin isolated from the cultures of 
Streptomyces griseolus and Streptomyces incarnatus has shown antiviral, antifungal, 
antiparasitical and amoebicidal activities in both in vivo and in vitro (fig 4.9).40 The 
primary amino group at C-6’ center in sinefungin makes it similar to S-Adenosyl 
methionine and explains the  antiviral, antifungal, antiparasitical and amoebicidal 
activities in both in vivo and in vitro.41 
N
NN
N
NH2
X
H2N
H2N
COOH
HO OH
N
NN
N
NH2
O
SMe
H2N
COOH
HO OH
X=O    (Sinefungin)
X=CH2(Carba-Sinefungin)
S-Adenosyl methionine
 
 
Fig 4-9 Structures of carbocyclic nucleosides containing amino acid moiety 
 Recently, Jäger et al synthesized carbafuranomycin in 16 steps (Scheme 4-4).34d 
The synthesis involved 1,3-dipolar cycloaddition of a chiral nitrile oxide with 
cyclopentadiene and the introduction of methyl group by by an SN2’ cuprate substitution. 
The cycloaddition was utilized to obtain a cyclopentaisoxazoline system which was 
further reduced to obtain amino alcohol. Installation of methyl group via organocuprate 
chemistry and later on series of oxidation and deprotections furnished carbafuranomycin. 
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Scheme 4-4 Retrosynthetic analyses for L-Carbafuranomycin by Jager et al  
4.5 Pd catalyzed synthesis of Carbafuranomycin and analogs 
As pointed out earlier, the last  two chapters have involved development of new 
methodologies based on Pd(0) catalysis. This chapter focuses on the application of Pd(0) 
catalysis towards synthesis of unnatural carbocyclic amino acids and their analogs. Pd 
catalyzed allylic alkylation using ethyl nitroesters as a nucleophile source can result in 
installation of nitro ester moiety on a cyclopentane ring (scheme 4-5). The nitro ester 
moiety provides an easy route to amino acid esters and  analogs. Also, as this reaction 
results in installation of a new stereocenter (C-6, scheme 4-5), the corresponding nitro 
esters were obtained as a 1:1 mixture of diastereomers in 67% isolated yield. 
Attempts to separate the two diastereomers were not successful and it was decided 
to answer the issue involving separation of diastereomers in the later stages of synthesis. 
The next step involved reduction of  the nitro group to  an amino group using Zn/HCl 
system in i-propanol to obtain the corresponding amino esters.42 The reduction required 
20 equivalents of Zn dust  and 10 equiv of HCl in i-propanol and furnished the 
corresponding amines in 85% yield as amixture of diatereomers. Fortunately, the two 
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diastereomers 13a,b were easily separated using conventional column chromatography (2 
% MeOH-CH2Cl2)with silica gel pretreated with Et3N.  
HO OAc O2N COOEt
K2CO3, Pd(PPh3)4
PPh3, THF
HO
COOEt
NO2
Zn/HCl
i-propanolHO
COOEt
NH2
HO
COOEt
NH2
11 12
13a 13b
1
2 3
4
5
6AcO OAc
PS-30
pH=7 phosphate buffer
acetone
13a:13b = 1.07:1
>99%ee
(based on GC analyses)
(90%)
67%
85%
meso-diacetate
10
 
Scheme 4-5 Synthesis of cyclopentane amino acids via Pd(0) catalysis 
After successful synthesis and separation of the cyclopentane amino esters the strategy 
was further applied towards synthesis of carba analogs of furanomycin (fig 4-8). As 
stated in the previous section Jäger et al43 recently synthesized an unnatural amino acid  
carbafuranomycin in 16 steps (Scheme 4-6). Even though this synthesis provided a route 
to carba analogs of furanomycin but had some shortcomings. The synthesis required 16 
steps involving a large number of oxidation, reduction steps and protection-deprotection 
protocols to yield the title compound. 
  Keeping all these facts in mind, two different Pd(0) catalyzed strategies involving 
less number of steps were designed towards synthesis of carbafuranomycin analogs. 
These new strategies also try to incorporate lipase catayzed enzymatic hydrolysis to 
obtain the carbafuranomycin analogs in high enantiopurity without the use of expensive 
chiral catalysts. 
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Scheme 4-6 Retrosynthetic analyses for analogs of Carbafuranomycin 
As shown in scheme 4-6 alkyl group (R) in carbafuranomycin analogs can be 
installed via a SN2’ cuprate addition to allylic acetate 15. The ring opening of isoxazoline 
18 will furnish the required acetate 15. These isoxazolines are easily obtainable from the 
nitroesters 12 in high enatiopurity via Pd(0) catalysis(chapter 2). Once again the 
stereochemical outcome of the whole process depends on the stereochemistry of the 
starting monoacetate 11 which can be easily modified by a simple protection-
deprotection strategy or by use of a different enzyme for the hydrolysis of the meso-
diacetate precursor.  
HO
COOEt
NO2
HO OAc
O2N COOEt
Pd(0),PPh3
11 12 Ac2O, DMAP
O
N O
COOEtH
H
SnCl2, 
CH3CN
O
N
COOEtH
HOH
COOEtH
H
NH2
16
1819
AcO
COOEt
NO2
Pd(0), K2CO3
K2CO3
17
AcO OAc
PS-30
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acetone
meso-diacetate
67%
95%
(quantitative) 90%
90%
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Scheme 4-7 Retrosynthetic analyses for analogs of Carbafuranomycin 
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The  synthesis of carbafuranomycin starts with enatiopure monoacetate 11, which 
is coupled with ethyl nitroacetate using Pd(0) catalysis to furnish compound 12 as a 1:1 
diatereomeric mixture and 67% yield. The allylic alcohol in compound 12 is esterified 
using acetic anhydride and DMAP to yield the corresponding acetate in 95% isolated 
yield. Allylic acetate 16 is a substrate for another intramolecular Pd catalyzed cyclization  
to an isoxazoline-2-oxide ring system 17. Isoxazoline-2-oxide 17 was easily 
deoxygenated using SnCl2 in acetonitrile in quantitative yields. The next step in the 
synthesis involved reduction of  the isoxazoline ring system to furnish the corresponding 
amino alcohol 19. Various reducing agents such as LAH, Na/Hg were tried but they led 
to decomposition of the starting material (isoxazoline 18). In the light of these difficulties 
the synthesis of carbafuranomycin analogs was further modified as shown in scheme 4-8. 
NH2
COOH
R
2120
11 22
NO2
COOEt
R
NO2
COOEtR OAcHO OAc
Pd(0) catalyzed 
     alkylation
RMgBr
CuCN
 
Scheme 4-8 Retrosynthetic analyses for  carba-analogs of Furanomycin 
This modified strategy involves initial installation of alkyl group via cuprate chemistry 
followed by Pd catalyzed alkylation. As shown in scheme 4-8 various carba analogs of 
furanomycin can be derived from reduction of the nitro ester 21 followed by the 
hydrolysis of the ester. Nitro esters 21 are the key compounds in the whole syntheses and 
can be easily obtained via a Pd(0) catalyzed allylic alkylation of acetates 22 using ethyl 
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nitroacetate as the nucleophile source. Allylic acetates 22 can be obtained by an 
SN2’substitution on enantiopure acetate 11 using organocuprate chemistry. The 
stereochemical outcome of the products again depends on the starting allylic monoacetate 
11 which can be easily obtained in high yields and optical purity via alipase catalyzed 
desymmetrization of the corresponding meso-diacetate. A simple protection/deprotection 
strategy or changing the enzyme used for enzymatic hydrolysis would enable access to 
the other enantiomer of the acetate 11. 
 
HO OAc AcO OAc
meso- 10
lipase PS-30
 pH=7 
phosphate buffer
8
11
(>99% ee)
O9(  )±
Ac2O, Pd(0)
THF
CH3CO3H
NaOAc, CH2Cl2
Cyclopentadiene
 
Scheme 4-9 Synthesis of enantiopure allylic acetates 11 using lipase catalyzed hydrolysis 
The synthesis begins with cyclopentadiene 8 which can be easily obtained from 
commercially available dicylopentadiene via a retro-Diels alder reaction. 
Cyclopentadiene 8 is oxidized to the racemic epoxide 9 using peracetic acid. 
Monoepoxide 9 can be ring opened under Pd(0) catalysis using acetic anhydride as the 
nucleophile source to yield the meso-diacetate 10. The desymmetrization of the 
mesodiacetate 10 with lipase to give the (+)-monoacetate 11 is the pivotal stereo-
differentiation reaction (Scheme 4-9). Unlike in resolution of a racemic substrate, in 
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which the yield per enantiomer is limited to 50%, the desymmetrization of the meso 
diacetate allowed conversion of higher than 97% to the enantiomerically pure single 
enantiomer.46 Enzymatic asymmetric induction is a powerful tool in developing elegant 
synthetic methodologies for natural products.44  Desymmetrization of meso compounds is 
an extremely important reaction and involves elimination of one or more symmetry 
elements in the substrate. Hydrolases are the enzymes which have shown immense 
potential in carrying out these desymmetrizations. Out of all the hydrolases, lipases have 
been extensively used.44e meso-2-Cycloalken-1,4-diols and diacetates have been 
subjected to enzymatic desymmetrizations utilizing lipase B from Candida antarctica 
(Novo SP-435) in organic and aqueous media.44e Of a number of different available 
lipases, the lipase from Pseudomonas cepacia (PS-30) was used to carry out hydrolytic 
desymmetrization of the diacetate.44d PS-30 catalyzed reaction of meso-diacetate 10 
produced monoacetate 11 in high enantiopurity (>99%) and 60% yield. So, the recovered 
diacetate was again subjected to hydrolysis with the recovered enzyme to obtain 
enantiopure monoacetate (11, αD20 (CHCl3) = +68.9; lit 44f αD20 (CHCl3) = +69.6) in total 
yield of 90%. The absolute stereochemistry of the monoacetate was established upon its 
comparison with the literature data 44f  as (+)-(1S, 4R)- 4-acetoxylcylcopent-2-en-1-ol. 
The enantiopurity of monoacetate 11 was confirmed by GC analyses upon injecting 
racemic and enzymatically prepared monoacetate through a cylcodexB (30mX0.25mm, 
J&W scientific) chiral capillary column.  
Installation of methyl group onto monoacetate 11 was done using dialkyl cuprates  
generated in situ by a reaction between CuCN and alkyl magnesium chloride.45 This 
reaction required few modifications from the reported literature reference by Kobayashi 
et al.45 The dialkyl magnesium cuprate was generated by adding two equivalents of 
methyl magnesium chloride to 1 equivalent of CuCN in dry THF at -180C (using an 
ethylene glycol-dry ice bath, instead of NaCl-water-ice bath as mentioned in the 
reference) (fig 4-10) . Also after the addition of Grignard reagent to a slurry of CuCN in 
THF, the reaction mixture has to be brought to room temperature to obtain a clear 
solution which indicates formation of the cuprate (case A). Failure to heat up the reaction 
mixture to room temperature resulted in extremely poor yields of the final product with 
the major product being the corresponding diol 26 due to nucleophilic attack on the 
acetate group by the the grignard reagent (case B). 
CuCN(3 eq)
MeMgCl(6 eq)
THF
OH
11 23(-180C)
MeMgCl (6 eq)
(250C) (-18
0C)(-180C)
CuCN
(3eq)
in THF
(-180C to 250C) ( 250C to-180C)Me2(CuCN)
(MgCl)2
Me2(CuCN)
(MgCl)2
HO OAc
4-5 hours HO
( 1eq)
stir for 30 min
Case A:
MeMgCl (6 eq)
(-180C)
CuCN
(3eq)
in THF
( 00C to-180C)CuCN+
MeMgCl
HO OAc
4-5 hours HO OH
( 1eq)
(-180C) (-180C)
CuCN+
MeMgCl
stir for 30 min
Case B:
OAcOH
23
26
75%
 
Fig 4-10 Steps involved in installation of methyl group on monoacetate 23 
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Scheme 4-10 Pd catalyzed alkylation of acetate 19 using ethyl nitroacetate 
After installation of the methyl group on the allylic monoacetate 11, the next step 
involved Pd catalyzed alkylation using ethyl nitroacetate as the nucleophile source 
(scheme 4-10). This alkylation step also posed some initial difficulty as the standard 
conditions involving the use of K2CO3 as base and ligands such as dppp, PPh3 did not 
furnish the desired product and the starting material was recovered back. It is also 
worthwile to mention that extended reaction time (>12h) also resulted in partial 
hydrolysis (~20%)of the starting allylic acetate to corresponding alcohol. Hence the 
reaction conditions were modified and use of NaH and PPh3 as the ligand did result in the 
desired product 25 (scheme 4-10). 
RO OR
OH
NO2
EtOOCn
OH
NH2
HOOC *
RO OR
OH
NO2
EtOOC
OH
NH2
HOOC *
OR= ester, carbonate
n=0,1,2,3
 
Scheme 4-11 Convenient  route to carbocyclic and acyclic amino esters and amino acid 
analogs 
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 This methodology can also be extended towards synthesis of other carba-furanomycin 
analogs by changing the alkyl cuprate used in the initial stages of synthesis. Also, 
diastereomeric mixtures of amino esters synthesized using this methodology were easily 
separated via column chromatography giving access to both the isomers, hence making 
the whole process more advantageous. The key feature of this methodology is reduction 
in the number of steps involved for synthesis of carbocyclic amino esters and amino acid 
analogs and use of lipases to obtain enantiopure products starting from a meso substrate. 
This methodology can also be extended to other ring systems as well as open chain 
compounds as shown in scheme 4-11. 
4.6 Conclusions 
As discussed in the first three sections of this chapter unnatural amino acids such 
as bicyclic and carbocyclic amino acids are of valuable  interest as they have provided 
new building blocks for large number of potential drug candidates. There are various 
methodologies to synthesize these class of compounds. The work presented in this 
chapter is another effort to provide a general synthesis for unnatural cyclopentane amino 
acid analogs. This methodology can also be extended to other ring systems as well as 
open chain compounds to obtain corresponding amino acid analogs. 
4.7 Experimental 
4.7.1 General experimental information 
Lipase PS-30 was generous gifts from Amano Enzymes. 1H-NMR and 13C-NMR spectra 
were recorded on a Bruker 250 MHz spectrometer MHz and 62.5 MHz respectively in 
CDCl3 with TMS as the standard. Chemical shifts are reported in ppm, multiplicities are 
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indicated by s (singlet), d (doublet), t (triplet), q (quartet), p (quintet), h (sextet), m 
(multiplet) and bs (broad singlet). Optical rotations were measured with a Rudolph 
Research Analytical AutoPol IV Automatic polarimeter. Thin-Layer chromatography 
(TLC) was performed on glass plates coated with 0.25 mm thickness of silica-gel. All 
solvents were dried and distilled prior to use and organic solvent extracts dried over 
Na2SO4. Mass calculations were carried out on an ESI LC MS system (Agilent 
Technologies). GC studies were carried out on Shimadzu gas chromatograph (Model 
17A).  
4.7.2 General Procedure for synthesis and spectral data for 11, 12, 16 and 17  
Compounds 11, 12, 16 and 17 are compounds 5, 11a, 12a, 13a discussed in chapter 2 and 
were synthesized using the same reaction conditions. 
4.7.3 General procedure for deoxygenation of isoxazoline-2-oxide (17) 
To a solution of isoxazoline-2-oxide 17 (100 mg, 0.507 mmol) in dry CH3CN (20 mL) at 
room temperature was added SnCl2. 2H2O (171 mg, 0.076 mmol).    The reaction was 
refluxed for 12 h and then vacuum filtered through celite with subsequent concentration 
of the filtrate.  The product was purified by column chromatography using ethyl acetate: 
hexane (1:2) to afford 18 (91 mg, yield =99%) as a viscous liquid.1H-NMR (250MHz, 
CDCl3) δ: 1.29 (t, 3H, J=5.8Hz), 2.63-2.78 (m, 2H), 4.17-4.28 (m, 2H,), 4.17-4.28 (m, 
4H), 5.56-5.62 (m, 1H,), 5.75-5.78 (m, 1H,), 6.09-6.12 (m, 1H,). 13C-NMR (62.5MHz, 
CDCl3) δ: 14.0, 38.2, 44.6, 61.4, 84.2, 111.3, 127.7, 137.0, 158.96. 
4.7.4 General procedure for preparation of compound 23  
To a slurry of CuCN (1.88g, 21 mmol) in dry THF was added  14 ml(42.0 mmol) of 3M 
solution of MeMgCl in THF at -180C. After complete addition of MeMgCl, the solution 
    175 
 
was warmed to room temperature. The solution was stirred at room temperature for 30 
min which also resulted in complete dissolution of CuCN (confirming formation of 
cuprate species). The reaction mixture was again cooled to -18oC and monoacetate 11(1g, 
7.0mmol) , dissolved in THF, was added to the reaction mixture. The reaction was 
allowed to come to room temperature overnight and then quenched by addition of 
distilled water and 5 drops of 28% NH4OH solution. The product was purified by column 
chromatography using ethyl acetate: hexane (1:2) to afford 23(510 mg, yield =75%) as a 
volatile liquid. 1H NMR (CDCl3, 250 MHz): δ 0.94(d, 3H, CH3, J=7 Hz), 1.54-2.0 (m, 
4H), 2.88 (m, 1H), 4.78 (m, 1H), 5.70 (m, 1H), 5.80 (dd, 1H, J=5.5, 2 Hz) ppm; 13C 
NMR (CDCl3, 62.5 MHz) δ: 20.9, 38.9, 42.4, 77.3, 131.9, 141.7 ppm.   
4.7.5 General procedure for preparation of compound 24  
To a solution of 23 (100 mg, 1.02 mmol) in dry THF (10 ml) at room temperature was 
added acetic anhydride (103 mg, 1.02 mmol), and catalytic amount of DMAP. The 
reaction was allowed to stir for 3 hours and then concentrated. The residue was taken up 
in ethyl acetate (40 ml) and extracted twice with saturated sodium bicarbonate solution 
(20 ml), followed by brine (10 ml). The organic layer was dried over sodium sulfate and 
the resulting product 24 (135 mg, yield= 96%) was obtained as colorless liquid. 1H NMR 
(CDCl3, 250 MHz): δ 0.96(d, 3H, CH3, J=7 Hz), 1.64-1.72 (m, 1H), 1.95 (s, 3H), 1.96 
(m, 1H), 2.86(m, 1H), 5.6-5.7 (m, 2H), 5.92 (m, 1H) ppm; 13C NMR (CDCl3, 62.5 MHz) 
δ: 20.68, 21.30, 38.58, 38.89, 80.48, 128.05, 144.21, 171.06 ppm.   
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4.7.6 General procedure for preparation of compound 25 
To a solution of ethyl nitroacetate (112 mg, 0.84 mmol) in dry THF (10 ml) at room 
temperature was added potassium carbonate (116 mg, 0.84 mmol) under a nitrogen 
atmosphere. The reaction was allowed to stir for 20 minutes and Pd(PPh3)4 (48 mg, 0.042 
mmol), PPh3 (220 mg, 0.84mmol), monoacetate 24 (120 mg, 0.84 mmol) dissolved in 5 
ml THF was added to it. The reaction was allowed to stir at 40 0C for 12 h and then 
vacuum filtered through celite with subsequent concentration of the filtrate. The product 
was purified by column chromatography using ethyl acetate: hexane (1:2) to afford 25 
(100 mg, yield =56%) as a yellow viscous liquid. 
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APPENDIX A 
Spectroscopic data for compounds of chapter 2 
Spectroscopic data for compounds of 
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Figure A-1 1H and 13C-NMR of spectra of (+)-(1S, 4R)- 4-acetoxylcylcopent-2-en-1-ol 
(5) 
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Figure A-2 1H and 13C-NMR of spectra of (R)-4-Acetoxy-2-cyclopenten-1-one (6) 
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Figure A-3 1H and 13C-NMR spectra of (1S, 4R)-1-Methylcyclopent-2-ene-1,4-diol (7) 
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Figure A-4 1H and 13C-NMR spectra of (1S, 4R)-1-Phenylethynyl-cyclopent-4-ene-1,4-
diol (8) 
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Figure A-5 1H and 13C-NMR spectra of (1R, 4S)-4-Hydroxy-4-methyl-2-cyclopenten-1-
yl Acetate (9) 
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Figure A-6 1H and 13C-NMR spectra of (1R,4S)-4-Hydroxy-4-phenylethynyl-2-
cyclopeneten-1-yl Acetate (10). 
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Figure A-7 1H and 13C-NMR of Ethyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-2’-cyclopenten-1’- 
yl)-2-nitroacetate (11a) 
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Figure A-8 1H and 13C-NMR of Ethyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-4-methyl-2’-
cyclopenten-1’-yl)-2-nitroacetate (11b). 
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Figure A-9 1H and 13C-NMR of Ethyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-4-phenylethynyl-
2’-cyclopenten-1’-yl)-2-nitroacetate (11c). 
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Figure A-10 1H and 13C-NMR of Ethyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-2’-cyclopenten-
1’-yl)-3- oxobutanoate (11d) 
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Figure A-11 1H and 13C-NMR of Ethyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-4-methyl-2’-
cyclopenten-1’-yl)-3-oxobutanoate (11e) 
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Figure A-12 1H and 13C-NMR of 2-Phenylsulfonyl (2R/S, 1’R, 4’S)-2-(4’-hydroxy-2’-
cyclopenten-1’-yl)-1-phenyl-ethanone (11f). 
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Figure A-13 1H and 13C-NMR of 2-Phenylsulfonyl (2R/S, 1’R, 4’S)-2-(4’-hydroxy-2’-
cyclopenten-1’-yl)-1-phenyl-ethanone (11g). 
    197 
 
 HO
11hPh
COPh
SO2Ph
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HO
11hPh
COPh
SO2Ph
Figure A-14 1H and 13C-NMR of 2-Phenylsulfonyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-4-
phenylethynyl-2’-cyclopenten-1’-yl)-1-phenyl-ethanone (11h). 
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Figure A-15 1H and 13C-NMR of Ethyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-2’-cyclopenten-
1’-yl)-2-cyanoacetate (11i) 
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Figure A-16 1H and 13C-NMR of Ethyl Phenylsulfonyl (2R/S, 1’R, 4’S)-2-(4’-Hydroxy-
2’-cyclopenten-1’-yl)-2-acetonitrile (11j). 
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Figure A-17 1H and 13C-NMR of Ethyl 2-(4-Hydroxy-cyclopent-2enyl)-malonic acid 
dimethyl ester (11k) 
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Figure A-18 1H and 13C-NMR of Ethyl (2R/S,1’R, 4’S)-2-(4’-Acetoxy-2’-cyclopenten-
’-yl)-2-nitroacetate (12a) 
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Figure A-19 1H and 13C-NMR of Ethyl (2R/S, 1’R, 4’S)-2-(4’-Acetoxy-4-methyl-2’-
ten-1’-yl)-2-nitroacetate (12b). 
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1H and 13C-NMR  of Ethyl (2R/S,1’R,4’S)-2-(4’-Acetoxy-4-phenylethynyl-
’-cyclopenten-1’-yl)-2-nitroacetate (12c). 
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igure A-21 1H and 13C-NMR of Ethyl (2R/S,1’R,4’S)-2-(4’-Acetoxy-2’-cyclopenten-1’-
 (12d). 
F
yl)-3-oxobutanoate
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Figure A-22 1H and 13C-NMR of 2-Phenylsulfonyl (2R/S,1’R,4’S)-2-(4’-Acetoxy-2’-
cyclopenten-1’-yl)-1-phenyl-ethanone (12f). 
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Figure A-23 1H and 13C-NMR of Ethyl (2R/S,1’R,4’S)-2-(4’-Acetoxy-2’-cyclopenten-1’-
l)-2-cyanoacetate (12i). 
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Figure A-24 1H and 13C-NMR of Phenylsulfonyl (2R/S,1’R,4’S)-2-( 4’-Acetoxy-2’-
cyclopenten-1’-yl)-2-acetonitrile (12j). 
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Figure A-25 1H and 13C-NMR of (1S,5S)-3-Aza-4-(ethoxycarbonyl)-2-
oxabicyclo[3.3.0]oct-3,7-diene-3-oxide (13a). 
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1H and 13C-NMR of (1S,5S)-3-Aza-4-(ethoxycarbonyl)-7-methyl-2-
xabicyclo[3.3.0]oct-3,7-diene-3-oxide (13b) 
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Figure A-26 1H and 13C-NMR of (1S,5S)-3-Aza-4-(ethoxycarbonyl)-7-phenylethynyl-2-
xabicyclo[3.3.0]oct-3,7-diene-3-oxide (13c) o
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13c
O
N
COOEt
O-
13c
Ph
    212 
 
 
 
 
O
COOEt
Me
13d
 
 
 
 
 
 
 
 
Figure A-27 1H and 13C-NMR of (1S,5S)-4-(ethoxycarbonyl)-3-methyl-2-
xabicyclo[3.3.0]oct-3,7-diene (13d) 
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Figure A-28 1H and 13C-NMR of (1S,5S)-4-(ethoxycarbonyl)-3,7-dimethyl-2-
xabicyclo[3.3.0]oct-3,7-diene (13e) 
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Figure A-29 1H and 13C-NMR of (1S,5S) -3-phenyl-4-(phenylsulfonyl)-2-
xabicyclo[3.3.0]oct-3,7-diene (13f) 
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Figure A-30 1H and 13C-NMR of (1S,5S)-7-methyl-3-phenyl-4-(phenylsulfonyl)-2-
oxabicyclo[3.3.0]oct-3,7-diene (13g) 
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Figure A-31 1H and 13C-NMR of (1S,5S)-3-phenyl-7-phenylethynyl-4-(phenylsulfonyl)-
2-oxabicyclo[3.3.0]oct-3,7-diene (13h) 
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2 1H and DEPT-135 of 2-Cyclopent-2-enylidene-malonic acid dimethyl ester 
3k) 
Figure A-3
(1
APPENDIX B 
Spectroscopic data for compounds of Chapter 3 
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1H and 13C-NMR of spectra of 3-(Nitromethyl) cyclopentanone (10a) 
 
 
Figure B-1 
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igure B-2 1H and 13C-NMR of spectra of 3-(1-Nitroethyl) cyclopentanone (10b-LP) 
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igure B-3 1H and 13C-NMR of spectra of 3-(1-Nitroethyl) cyclopentanone (10b-MP) 
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igure B-4 1H and 13C-NMR of spectra of 3-(1-Nitropropyl) cyclopentanone (10c-LP)  
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igure B-5 1H and 13C-NMR of spectra of 3-(1-Nitropropyl) cyclopentanone (10c-MP)  
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igure B-6 1H and 13C-NMR of spectra of 3-(1-Nitropropyl) cyclopentanone (10d)  
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igure B-7 1H and 13C-NMR of spectra of 3-(1-Nitrocyclohexyl) cyclopentanone(10e)  
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igure B-8 1H and 13C-NMR of spectra of 3-(2-Nitropropane-2-yl) cyclohexanone (11a) F
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igure B-9 1H and 13C-NMR of spectra of  3-(1-Nitrocyclohexyl) cyclohexanone (11b) 
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igure B-10 1H and 13C-NMR of spectra 3-Methyl-4-nitrohexanal (12a) 
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igure B-11 1H and 13C-NMR of spectra 3,4-Dimethyl-4-nitropentanal (12b) 
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igure B-12 1H and 13C-NMR of spectra 3-(1-Nitrocyclohexyl)butyraldehyde (12c) 
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igure B-13 1H and 13C-NMR of spectra 2-Buta-1,3-dienyloxy-tetrahydropyran(21) 
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Spectroscopic data for compounds of Chapter 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-1 1H and 13C-NMR of (+)ethyl-2- amino-2-{(1R, 4S)-4-hydroxycyclopent-2- 
nyl)}acetate (13a) e
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Figure C-2 1H and 13C-NMR of (-)ethyl-2- amino-2-{(1R, 4S)-4-hydroxycyclopent-2-
nyl)}acetate (13b) e
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igure C-3 1H and 13C-NMR of (1S,5S)-3-Aza-4-(ethoxycarbonyl)-2-
 (18) 
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oxabicyclo[3.3.0]oct-3,7-diene
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1H and 13C-NMR of (1S,4S)-4-methylcyclopent-2-enol (20) 
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Figure C-4 
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igure C-5 1H and 13C-NMR of (1S,4S)-1-acetoxy-4-methylcyclopent-2-ene (20) 
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igure C-6 1H and 13C-NMR of Ethyl (2R/S, 1’S, 4’S)-2-(4’-methyl-2’-cyclopenten-1’-
yl)-2-nitroacetate (24) 
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